



The Role of Regulatory T cells in  










Doctor of Philosophy 









 ii  
DECLARATION 
 
I declare that all work included in this thesis is my own, except where otherwise 




































School of Biomedical Sciences 






Infection with Epstein-Barr virus (EBV) during adolescence results in an immunopathological 
disease, Infectious Mononucleosis (IM), in around 25% of cases.  A role for Regulatory T cells 
(Treg) in IM has yet to be established.  These suppressiv  cells may affect the well-characterised 
cytotoxic T cell (CTL) response to EBV and thus thelevel of viral persistence and reactivation, 
potentially creating an environment conducive to the outgrowth of EBV-infected cells and 
tumour development.  The work in this thesis examines the frequency and functional capacity of 
Treg in primary EBV infection. 
 
The results show that the frequency of Treg within the CD4
+ T cell population of IM patients was 
reduced with borderline significance (p=0.05) compared with healthy controls as revealed by 
fluorescence activated cell sorting.  Treg function was confirmed using suppression assays on 
peripheral blood mononuclear cells (PBMC) from healthy controls but could not be assessed in 
IM patients due to low cell numbers.  EBV-specific Treg function was analysed using Interferon 
(IFN)-γ ELISPOT assays in which PBMC from IM patients and healthy controls were stimulated 
with phytohaemagglutinin (PHA) and EBV peptides in the presence or absence of Treg.  The 
IFN-γ response of PBMC to PHA stimulation was significantly reduced in IM patients compared 
to healthy controls (p=0.009) but the IFN-γ response to EBV peptides did not alter, irrespectiv  
of the presence or absence of Treg.  Investigation of FOXP3 expression by 
immunohistochemistry provided evidence of Treg presence and preliminary data indicated an 
increased expression in IM tonsil sections compared with healthy tonsil sections.  The 
proliferative responses and cytokine profiles of healthy controls, as measured by proliferation 
assays and ELISAs, in response to stimulation with the recall antigen PPD did not significantly 
alter upon the addition of latent membrane protein (LMP)-1 peptide.  In IM patients, the same 
treatment resulted in a significant reduction in IFN-γ (p=0.026) but no significant differences in 
IL-10 production or cell proliferation. 
 
The significantly reduced frequency of Treg in peripheral blood of IM patients and abundant 
FOXP3 expression in IM tonsils provides evidence for a Treg role in primary EBV infection.  
One plausible explanation is the recruitment of Treg to the site of primary infection by an as yet 
unidentified EBV-specific mechanism.  Clarification of Treg activity in IM may expose 
opportunities for immunomanipulation during early stages of infection. 
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Herpesviruses are one of the most successful virus families known to date, exemplified 
by their ability to infect species across the animal kingdom from mammals, such as 
wallabies (Callinan & Kefford, 1981), to reptiles, including a variety of species of 
tortoise (Une et al, 1999).  Currently 130 herpesviruses have been idetified and sub-
classified according to their biological properties.     
1.1.1 Structure & Classification  
Herpesviruses are identified by the architecture of the virus particle.  A herpesvirus 
virion consists of the core, capsid, tegument and envelope (Roizman & Baines, 1991).  
The core contains linear double-stranded DNA, the length and base composition of 
which varies depending on the virus.  The core is enclosed by the capsid, a 162-
capsomere icosadeltahedral structure of 100-110nm diameter.  This structure is 
surrounded by the protein-rich tegument, which is encased by a lipid bilayer membrane 
with external glycoprotein spikes, called the envelop  (Kieff & Rickinson, 2001).  The 
overall size of the virion varies between 120-300nm according to the thickness of both 
the tegument and envelope.  Figure 1.1 shows an example of a herpes virus particle.         
 
There are four main characteristics which can be ascribed to all herpesvirus species. The 
first is that all members of this family of viruses ncode genes for enzymes and factors 
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involved in DNA synthesis and protein-processing.  The number of these proteins varies 
between genera.  The second common characteristic is that synthesis of viral DNA and 
capsid assembly occurs in the nucleus and the capsid is enveloped as it transits through 
the nuclear membrane.  Thirdly, infected cells are ir versibly damaged with the 
production of infectious progeny during lytic replication.  The fourth characteristic is 
that all Herpesviruses have the capacity to remain latent in their natural host, during 
which the genome circularises and viral gene expression is reduced (Roizmann et al, 
1992). 
 
Figure 1.1: Human Cytomegalovirus structure.  Reprinted with permission 
from Dr Marko Reschke in Marburg, Germany, of the Human Cytomegalovirus 
Group. 
 
Despite these common themes, the herpesvirus family varies with respect to their 
biological properties.  For example, Herpes Simplex (HSV)-1 can infect a wide range of 
host cells whereas Epstein-Barr virus (EBV) has a more restricted cell host range, 
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Herpes Simplex (HSV)-2  multiplies rapidly (18-24 hours) whilst Human 
Cytomegalovirus (HCMV) has a slow replicative cycle (36-48 hours).  Factors such as 
these have allowed further sub-classification into Alpha-, Beta- or Gammaherpesviridae.  
Table 1.1 summarises the properties of these subfamilies. 
 




range replicative cycle site of latency virus 

















 lymphocytes EBV, KSHV 
 
 
1.1.2 Human Herpesviruses 
A viral aetiology had long been suspected for Kaposi’s arcoma (KS), a neoplasm 
associated with AIDS patients (Vogel t al, 1988;Bovenzi et al, 1993;Siddiqui, 1983).  
In an attempt to define the cause of this disease, for ign DNA was sought in KS tissue.  
The resulting sequences showed homology to the capsid and tegument proteins from 
gammaherpesviridae members, leading to the discovery of the eighth and newest 
member of human herpesviruses; human herpesvirus (HHV)-8 or Kaposi’s sarcoma 
herpesvirus (KSHV) (Chang et al, 1994). 
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Other members of the family include HHV1-7, the first 5 of which are alternatively 
named Herpes Simplex Virus (HSV)-1, Herpes Simplex Virus (HSV)-2, Varicella 
Zoster virus (VZV), Epstein-Barr virus (EBV), Cytomegalovirus (CMV) respectively.  
These viruses establish lifelong latent infection with periods of reactivation and are 
responsible for a variety of diseases, see table 1.2 for a summary. 
 
Table 1.2: Characteristics of Human Herpes viruses and their disease associations 
HHV 
type 
Name Subfamily Target cell 
type 










2 (HSV-2) alpha mucoepithelia neurons 
close contact 



































































unknown Blood, sexual 
Kaposi’s 
sarcoma 
Table created using http://pathmicro.med.sc.edu/virol/herpes.htm 
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1.2 Epstein-Barr Virus 
1.2.1 Introduction 
In 1957, a surgeon, Denis Burkitt, working in Kampala, Africa, was called for a 
consultation on a child with strange jaw lesions.  This was the first in a series of events 
leading to the discovery of what was to become known as Burkitt’s Lymphoma (BL).  In 
order to determine the underlying cause of this malign nt tumour, Burkitt and his 
colleagues collected clinical and epidemiological dta from all over Africa.  The 
resulting information pointed to a viral aetiology (Burkitt, 1983). 
 
A chance meeting with Dr Anthony Epstein in 1961 resulted in the exchange of ideas 
and Burkitt agreed to send biopsy samples from BL patients to the UK.  When Epstein 
and his colleagues at the Middlesex Hospital, London, examined cultured BL cell lines 
under electron microscopes, they discovered virus particles with a similar morphology to 
the herpes simplex virus (Epstein et al, 1965).  The new virus was identified as a 
member of the herpesviridae family and named Epstein-Barr Virus (EBV) (Epstein & 
Barr, 1964;Epstein et al, 1964).  In subsequent research, the distribution of BL was 
shown to be coincident with areas of intense malari infection.  Burkitt hypothesised that 
malaria, with the associated immunosuppression, someh w allowed EBV to act 
oncogenically. 
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The oncogenic potential of this virus is now evidenc d by a number of EBV-associated 
malignancies, including Nasopharyngeal Carcinoma (NPC) and Hodgkin’s Lymphoma 
(HL), as well as BL, as summarised in table 1.3.  Furthermore, immunosuppression of 
patients can cause the outgrowth of EBV-infected cells resulting in B 
Lymphoproliferative Disease (BLPD). 
 
EBV is a highly ubiquitous virus, infecting over 90% of the adult population worldwide 
(Crawford, 2001c).  EBV establishes latency in B lymphocytes and infection is life-long. 
Primary infection is usually asymptomatic during early childhood although a delay in 
EBV exposure infection results in Infectious Mononucleosis (IM) in approximately 25% 
of cases (Crawford et al, 2006b). 
1.2.2 Genome 
In 1984, Baer et al sequenced the B95-8 prototype laboratory strain of EBV (Baer et al, 
1984a), first isolated in 1973 (Miller et al, 1973), using a BamHI fragment library.  
Sequences of interest, such as genes, open-reading frames (ORFs) and promoters are 
therefore commonly referred to as the corresponding fra ment.  For example, the ORF 
(F) encoding an envelope glycoprotein gp110, is the BamHI A (BA) fragment, and its 
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Table 1.3: EBV-associated malignancies 
tumour cell of origin 
approximate EBV 
association cofactors/risk factors 









B Lymphoblast 90% 
immunosuppression, 
HIV 
Hodgkin’s Lymphoma centrocyte 40-80% 
Infectious Mononucleosis 
(IM) 







100% genetic & dietary factors  
Gastric carcinoma epithelial cell 10% unknown 
(Table from Crawford, 2001d) 
 
The EBV genome is approximately 172 kb in length and consists of tandem reiterated 
0.5 kbp direct repeats (TR) of the same sequence at both termini, 6-12 tandem 
reiterations of 3 kbp internal direct repeats (IR) and two unique sequencing domains, 
termed short (US) and long (UL) (Kieff & Rickinson, 2001). 
 
Two types of EBV exist; type 1 is the most commonly occurring whilst type 2 is equally 
as common as type 1 in equatorial Africa and New Guinea.  The difference between the 
two types comes from slight variation in the genes that encode EBV nuclear proteins 
(Adldinger et al, 1985;Dambaugh et al, 1984;Sample t al, 1986). 
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1.2.3 Structure  
The general structure of EBV is similar to other hepesviruses in that it consists of 
linear, double-stranded DNA wrapped around a core, a nucleocapsid, tegument and 
envelope.  Dolyniuk et al examined the similarities in structural polyprotein constituents 
between EBV and HSV (Dolyniuk et al, 1976a) and established that whilst parallels 
existed in nucleocapsid polypeptides, non-nucleocapsid olypeptides, predicted to be 
glycoproteins, varied considerably between the two viruses (Dolyniuk et al, 1976c).  
Further research revealed the existence of homology between some EBV glycoproteins 
and glycoproteins found in other HHV, two in particular, termed gp85 and gp110 
(Pellett et al, 1985;Gong et al, 1987;Balachandran et al, 1987;McGeoch & Davison, 
1986;Heineman et al, 1988).  However, the major envelope glycoprotein gp350/220, 
was not only established as exclusive to EBV (Dolyniuk et al, 1976b) but also as playing 
an important role in membrane adhesion allowing the virus entry to host cells. 
1.2.4 Latent replication 
The in vitro infection of resting human B lymphocytes with EBV, which results in the 
outgrowth of transformed cell lines, known as Lymphoblastoid cell lines (LCL), has 
been the main tool in understanding key events in EBV infection and replication.  Once 
EBV penetrates the cell, the linear DNA circularises to form an episome (see figure 1.2) 
and the virus switches to a latent state, expressing only a limited number of genes 
encoding 6 EBV nuclear antigens (EBNAs 1, 2, 3A, 3BC and leader protein), 3 latent 
membrane proteins (LMPs 1, 2A and 2B), and highly spliced Bam A rightward 
transcripts (BamH1A) (Kieff & Rickinson, 2001).  In addition, 2 small 
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nonpolyadenylated, nonencoding, EB small RNAs (EBERs) are expressed abundantly in 
LCL.  Figure 1.2 shows the episomal form of EBV DNA and the viral genes expressed 
by LCL and figure 1.3 shows the linear form of the EBV genome. 
 
One of two promoters positioned at the left-hand enof the EBV genome initiates 
transcription.  The usage of the promoters depends o  stage of infection; Cp usage occurs 
during established latency whereas Wp usage is only apparent at early stages of infection.  
The activity of the promoters is mutually exclusive (Woisetschlaeger et al, 
1990;Woisetschlaeger et al, 1989).  Recruitment of host-cell RNA polymerase II 
initiates transcription of the 6 EBNA genes as a major transcriptional unit from the left-
hand end of the genome, which is then spliced, resulting in mRNAs with common 5’ 
exons. 
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Figure 1.2: EBV episomal genome.  The origin of plasmid replication is oriP and shown in 
orange.  Latent genes are shown by purple arrows.  The promoters from which transcription is 
initiated are also shown, promoter C (Cp) or Wp andQp. Diagram from Murray and Young 
(2001). Adapted by permission from Cambridge Press Publishers Ltd  
 
 
Figure 1.3: BamHI restriction endonuclease map of prototype B95-8 EBV genome.  
Fragments are named alphabetically according to size, with A being the largest.  The origin of 
replication (oriP) is shown as are the two terminal repeats (TR) at both ends of the genome.  
Reprinted by permission from Macmillan Publishers Ltd [Oncogene] Young & Murray, 
copyright 2003.  
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After in vitro infection of B cells, EBNA-LP and EBNA-2 are the first EBV genes 
transcribed under the control of Wp.  EBNA-2 plays an important role in up-regulation 
of gene expression (Abbot e al, 1990c;Alfieri et al, 1991c) and viral promoter switching 
(Woisetschlaeger et al, 1991).  EBNA-2 expression causes the switch from Wp to Cp 
which is coincident with expression of EBNA-1 and EBNA-3A, -3B and 3C mRNAs.  
EBNA-1 expression causes a positive feedback loop resulting in increased EBNA 
transcription.  EBNA-2 and EBNA-LP also upregulate expression of LMP1, -2A and -
2B promoters (Alfieri et al, 1991b).  LMP-2A and -2B transcription is upregulated 
through EBNA-2 response elements upstream of their promoter (Zhang et al, 
1994;Zimberstrobl et al, 1993a).  By 32 hours post-infection, all EBNA and LMP 
mRNAs are expressed (Alfieri et al, 1991a).  By 48 hours after in vitro infection of B 
cells, all EBNAs and LMP-1 are near levels maintained consistently through latent 
infection (Kieff & Rickinson, 2001).  EBERs expression lags by 24 hours and does not 
reach substantial levels until 70 hours post-infection (Alfieri et al, 1991e). 
 
In addition to viral gene expression in vitro, EBV-infection induces LCL to express high 
levels of B-cell activation markers including cluster of differentiation (CD) 21, CD23, 
CD30, CD39 and CD40 and a number of cellular adhesion markers including 
Lymphocyte function-associated antigen (LFA)-1 (CD11a/CD18) and -3 (CD58) and 
intercellular adhesion molecule (ICAM)-1 (CD54) (Rowe et al, 1987).  The classic 
expression of all 9 latent viral antigens and EBERs, each of which are discussed in more 
detail below, observed in latently infected B lymphocytes in vitro is characteristic of the 
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latency III pattern.  In vivo, the expression pattern of the viral antigens and host proteins 
differs depending on the form of latency.  Table 1.4 summarises the gene expression 
pattern found in the 3 forms of latency. 
 
Table 1.4:  EBV latency patterns  
latency type EBV gene expression associated tumour type 
Latency I EBNA-1, EBER, BamH1A transcripts Burkitt’s lymphoma 
Latency II 
EBNA-1, LMP-1, LMP-2A, LMP-2B, 
EBER, BamH1A transcripts 
Hodgkin’s lymphoma,  
Nasopharyngeal carcinoma* 
Latency III 
EBNA-1, EBNA-2, EBNA-3A, 
EBNA-3B, EBNA-3C, EBNA-LP, 
LMP-1, LMP-2A, LMP-2B, EBER, 
BamH1A transcripts 
Lymphoproliferative disease 
Abbreviations: EBNA – Epstein-Barr viral nuclear antigen; EBER – Epstein-Barr virus 
encoded small RNAs; LP – leader protein; LMP – latent membrane protein.*LMP-1/-2 only 




EBNA-LP is one of the first viral antigens to be expressed, coincident with the 
expression of EBNA-2 (Alfieri et al, 1991d;Allday et al, 1989).  Although important in 
efficiency of transformation and cell growth post-infection, EBNA-LP is not essential 
for this process (Hammerschmidt & Sugden, 1989;Mannick et al, 1991;Allan et al, 
1992).  The most critical role for EBNA-LP is in stimulating EBNA-2-mediated 
transcriptional activation (Harada & Kieff, 1997;Nitsche et al, 1997). 
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EBNA-2 
Unlike EBNA-LP, EBNA-2 is absolutely essential for the transformation of primary B 
lymphocytes (Kieff & Rickinson, 2001).  EBNA-2 acts a  a transcriptional activator of 
both cellular genes such as CD23 (Wang et al, 1985a;Cordier et al, 1990a) and CD21 
(Cordier et al, 1990b;Wang et al, 1990a), and viral genes, including LMP-1 (Kieff & 
Rickinson, 2001;Abbot et al, 1990b;Fahraeus et al, 1990;Fahraeus et al, 1993;Ghosh & 
Kieff, 1990;Wang et al, 1990d) and LMP-2A and –B (Zimberstrobl et al, 1993b).  
EBNA-2 has 3 essential domains, an acidic domain involved in recruiting cellular 
proteins, a domain which associates with recombinatio  binding protein (RBP) Jκ, a 
sequence-specific DNA-binding protein involved in transcriptional activation (Grossman 
et al, 1994;Zimberstrobl et al, 1994), and a third domain that mediates homotypic 
associations (reviewed in Kieff & Rickinson, 2001).  
 
EBNA-3A,-3B,-3C 
The EBNA-3A,-3B and -3C genes encode hydrophilic nulear proteins that share the 
same gene structure, are tandemly placed in the genom  and compete with EBNA-2 
(Baer et al, 1984b;Bodescot et al, 1986;Bodescot & Perricaudet, 1987;Kieff & 
Rickinson, 2001).  Studies have demonstrated that EBNA-3A and EBNA-3C are 
essential for B cell transformation i  vitro whereas EBNA-3B is not.  All EBNA-3s have 
been postulated to act as transcriptional activators by virtue of their ability to bind 
RBPJκ (Marshall & Sample, 1995;Robertson et al, 1995;Robertson et al, 1996;Zhao et 
al, 1996). 




EBNA-1 binds the viral origin of replication and is absolutely essential for replication 
and maintenance of viral episome in proliferating cells (Yates et al, 1984).  In addition, 
it has also been shown to have transcriptional activ tor properties by studies which 
observed an upregulation of Cp and LMP-1 promoter (Kieff & Rickinson, 2001). 
 
LMP-1 
LMP-1 is an EBV oncogene and is essential for B cell transformation (Wang et al, 
1985b;Kaye et al, 1993).  This integral membrane protein, the expression of which 
depends on EBNA-2 (Abbot et al, 1990a;Wang et al, 1990c), alters the cell phenotype, 
inducing B cell activation and expression of a number of cellular proteins (Henderson et 
al, 1991b;Rowe et al, 1995;Wang et al, 1990b) via activation of the NF-κB transcription 
factor pathway (Huen et al, 1995).  It also induces expression of a cellular oncogene bcl-
2 which protects the B cell against programmed cell d ath (Henderson et al, 1991a). 
 
LMP-2A,-2B 
The expression of these 2 similar viral antigens is not essential for B cell transformation 
in vitro (Longnecker, 2000).  The main role of LMP-2A is to maintain latent infection in 
B cells (Raab-Traub, 2002a).  Evidence also indicates a role for LMP-2A in 
transformation of epithelial cells (Raab-Traub, 200b).  LMP-2B has been implicated in 
controlling LMP-2A function (Longnecker, 2000). 




It is likely that these nonpolyadenylated nonencoding RNAs are expressed in all forms 
of latency (Young & Murray, 2003a) although they are not essential for B cell 
transformation (Arrand & Rymo, 1982;Swaminathan et al, 1991).  Evidence from work 
on BL cell lines indicates EBERs are responsible for inducing the expression of human 
interleukin (IL)-10, suggesting they have a role in the pathogenesis of EBV-positive BL 
since blocking IL-10 with an antibody or antisense oligonucleotide resulted in abrogated 
cell growth (Kitagawa et al, 2000). 
1.2.5 Lytic Replication 
In a latently infected B cell, EBV lytic replication is initiated within the origin of 
replication, oriLyt, and reactivation is concomitant with the expression of 2 immediate-
early (IE) lytic genes BZLF1 and BRLF1, viral transctivators that activate promoters of 
both viral and cellular origin (Young & Murray, 2003b).  IE gene expression activates 
early (E) gene transcription which is followed by the lytic cascade of viral genome 
replication and late gene (L) expression.  During lytic replication EBV is amplified over 
100-fold.  Late genes encode a number of structural proteins, including the two major 
glycoproteins involved in cell binding and penetration, gp350 and gp85, and their 
expression is concordant with cell death and subsequent release of viral progeny. 
 
In the majority of LCL, EBV remains latent with only a small proportion of infected B 
cells supporting lytic replication.  The switch is most likely dependent upon B cell 
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differentiation into plasma cells (Crawford & Ando, 1986).  In vivo, there is also little 
evidence of virus replication (Rickinson et al, 1975), despite the fact that EBV has been 
demonstrated in saliva (Gerber t al, 1972;Sixbey et al, 1983a).  EBV has also been 
detected in genital secretions of both women (Sixbey et al, 1986) and men (Israele et al, 
1991) albeit at a low level (Thomas et al, 2006b).  The cellular origin of secreted EBV 
has been a matter of debate and the topic is still ho ly debated (Pegtel t al, 2004). 
1.2.6 EBV lifecycle 
Salivary transmission of EBV results in viral replication in a permissive cell type present 
in the oropharynx, and high levels of virus shedding.  The permissive cell type has yet to 
be confirmed.  However, EBV is known to infect mucosal B lymphocytes, transform 
them and enter latency.  The infected B cells proliferate in the extrafollicular regions of 
the tonsillar lymphoid tissue and circulate in the p ripheral blood.  The restricted 
expression of viral antigens in latently infected B cells allows these cells to evade the 
immune response.  Periodically, by a mechanism not yet fully understood, EBV 
reactivates and progeny virions are released.  Alterna ively, epithelial cells may be the 
primary source of lytic virus (Hislop et al, 2007). 
1.2.7 B lymphocyte Infection 
The main cell type permissive for infection with EBV in vitro is the human B 
lymphocyte (Henle et al, 1967) due to their abundant expression of the cell surface 
marker CD21, which acts as the EBV receptor (Altiok et al, 1989;Calender et al, 
1987;Hansson et al, 1983;Marchini et al, 1992;Marchini et al, 1993;Kieff & Rickinson, 
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2001).  Fully differentiated plasma cells lack CD21 expression and cannot be infected.  
NK and T cells can also be infected, both in vitro and in vivo, albeit with a reduced 
efficiency than B cells (Shapiro et al, 1982;Kanegane t al, 1996).   
 
EBV enters B lymphocytes by binding the complement receptor type 2 (CR2), also 
known as the C3d receptor or CD21, on the cell surface (Fingeroth et al, 1984;Frade et 
al, 1985).  The main EBV-encoded glycoprotein involved in attachment is gp350/220 
(Nemerow et al, 1987) as demonstrated in studies where monoclonal a tibodies 
neutralised virus infectivity (Thorley-Lawson & Geilinger, 1980).  After binding CD21, 
the virion fuses to the target cell membrane using a complex of glycoproteins, consisting 
of gp85, gp25 and gp42 (Li et al, 1995;Wang & Hutt-Fletcher, 1998).  An interaction is 
required between gp42 and HLA class II protein, HLA DR (Spriggs et al, 1996) which 
acts as an essential co-receptor in B cell infection in vitro (Li et al, 1997;Haan et al, 
2000a).  Expression of HLA DP and HLA DQ on B cell lines has been shown to confer 
susceptibility to EBV infection leading to the suggestion that they may act as substitutes 
for HLA DR (Haan & Longnecker, 2000;Haan et al, 2000b). 
1.2.8 Epithelial cell infection  
The demonstration of viral DNA in a tumour of epithelial cell origin, nasopharyngeal 
carcinoma (NPC), provided the first evidence that EBV could infect this cell lineage 
(Zur Hausen et al, 1970).  However, initial studies found epithelial cell lines refractory 
to infection in vitro and attributed this finding to lack of epithelial expression of CD21, 
the EBV receptor (Shapiro & Volsky, 1983;Glaser et al, 1980). 
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In 1980, researchers reported the in vitro fusion of EBV-infected lymphoblastoid cells 
with uninfected human T lymphoblastoid cells (Jurkat cells) and human embryo 
fibroblasts (HEF cells), both of which are devoid of EBV receptors, resulting in 
polykaryocytes containing EBV antigens.  They hypothesised that this would permit 
virus entry into cells devoid of CD21 expression, ad this might occur in vivo between 
infected B cells and epithelial cells since these two cell types are found in close 
proximity in Waldeyer’s ring (Bayliss & Wolf, 1980). 
 
Meanwhile, the body of evidence suggesting direct in vitro EBV infection of, and 
replication in, epithelial cells grew (Lemon et al, 1977;Sixbey et al, 1983b;Sixbey et al, 
1984;Wolf et al, 1984).  Further fuel for direct epithelial infection came with the 
discovery of a receptor similar to CR2 on undifferentiated uterine cervical (Sixbey et al, 
1987) and pharyngeal epithelia (Young et al, 1986).  Researchers debated whether 
epithelial cells might provide the major site for EBV replication and that infection of B 
lymphocytes may be a secondary event in primary EBV infection (Allday & Crawford, 
1988). 
 
To date, varied reports have been published on the entry of EBV to epithelial cells.  
Fingeroth et al demonstrated the expression of CD21, albeit at a low level, on an 
epithelial cell line (Fingeroth et al, 1999) providing yet more proof for the direct 
epithelial infection.  However, in support of a CD21-independent mechanism of viral 
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entry into epithelial cells, 3 theories have been postulated; direct cell-cell contact across 
the apical cells membranes of infected B lymphocytes and pharyngeal epithelia, 
basolateral infection with cell-free virions by virtue of interaction between the EBV-
encoded BMRF-2 glycoprotein and cell surface β1 or α5β1 integrins, or lateral spread 
across the membrane of adjacent cells (Tugizov et al, 2003b).  Release of progeny 
virions is thought to occur at both the basolateral and apical membranes (Tugizov et al, 
2003a). 
 
Reports on the EBV glycoproteins involved in epithel al cell penetration are also varied.  
A requirement for gp85, as well as gp350, has been d monstrated in a number of studies 
(Wu et al, 2005;Molesworth et al, 2000).  Borza and Hutt-Fletcher demonstrated 
enhanced infection of epithelial cells using a recombinant virus lacking gp150 (Borza & 
Hutt-Fletcher, 1998).  Furthermore, Wang and colleagu s established that gp42, an 
essential co-receptor involved in B cell infection, is nonessential, and they speculate that 
this is largely due to the lack of HLA DR expression n epithelial cells (Wang et al, 
1998b).  The broad spectrum of data on epithelial cel entry by EBV have led 
researchers to hypothesise that different glycoprotein complexes are required for entry 
into both cell types (Wang et al, 1998a;Borza & Hutt-Fletcher, 2002). 
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1.3 EBV Disease Associations & Immune Response 
1.3.1 Seroepidemiology 
Primary infection via salivary transmission of EBV normally occurs asymptomatically at 
a young age.  However, if exposure is delayed until adolescence, viral infection results 
in Infectious Mononucleosis (IM) in 25% of cases (Crawford et al, 2006a).  It is thought 
that virus dose may cause this age-related association, for example small children 
exposed to a low dose of EBV from family members or due to sucking saliva-
contaminated toys whereas high levels of virus willbe transmitted during adolescence 
through kissing (Crawford, 2001b).  In addition, EBV has been detected in sexual 
secretions possibly allowing transmission of the virus via this route (Thomas et al, 
2006a). 
1.3.2 Acute Infectious Mononucleosis 
The symptoms of IM, consisting of fatigue, pharyngitis, fever, lymphadenopathy, 
pharyngitis, with additional clinical findings including splenomegaly and hepatocellular 
dysfunction, develop after an incubation period of 30-50 days.  In addition, IM is 
accompanied by generalised immunosuppression, demonstrated by the reduced 
proliferation of PBMC from IM patients in response to stimulation by both PHA and 
anti-CD3 (Perezblas et al, 1992a). 
 
Both humoral and cell-mediated immune responses are induced by EBV infection; B 
cells produce antibodies with specificities for lytic and latent antigens as well as gp350, 
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and cytotoxic CD8+ T cells (CTLs) circulate in the blood and infiltrate lymphoid tissue, 
releasing a plethora of antiviral cytokines including tumour necrosis factor (TNF)-α and 
-β, IL-1β and IL-6 (Foss et al, 1994a).  The symptoms of IM are thought to arise a  a 
direct result of the vigorous CTL response to EBV (Williams et al, 2005;Foss et al, 
1994b), although the reason for this exaggerated reaction is unknown.  The importance 
of the CTL response in IM is demonstrated in immunocompromised individuals (see 
below).  However, in healthy individuals the majority of cases IM resolves within 6 
months (Crawford, 2001a). 
 
Chronic active EBV infection 
Chronic active EBV infection (CAEBV) is characterised by chronic or recurrent IM-like 
symptoms, resulting in a number of complications including development of lymphoma, 
myelodysplastic syndrome and virus-associated hemophagocytic lymphohistiocytosis 
(Rickinson, 1986;Straus, 1988;Kanegane et al, 2002).  Persistently high levels of EBV-
specific antibodies found in patients with CAEBV recognising lytic phase viral antigens 
suggests a poor control of viral replication.  The exact cause of this disease is unclear 
although it is likely to be a combination of host immune dysregulation and viral factors 
(Maia & Peace-Brewer, 2000). 
 
Fatal IM 
Severe or fatal IM (FIM) is the more aggressive butmost rare form of IM, involving 
early lymphocytosis followed by the invasion on vital organs with EBV-specific 
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lymphocytes and patients die of opportunistic infections or haemorrhage within a few 
weeks (Wick et al, 2002a).  The majority of FIM patients are immunocompromised 
either by drugs or genetically.  For example, patients with X-linked lymphoproliferative 
syndrome (XLP), caused by a genetic abnormality, fail to control primary EBV 
infection, resulting in tissue infiltration by CD8+ T cells and widespread damage to the 
host.  Children who survive this go on to develop complications including B cell 
lymphoma.  The gene defective in XLP encodes SLAM-associated protein (SAP), a 
protein expressed on activated T cells, important in cell proliferation induction 
(Crawford, 2001).  Rarely, FIM arises in a previously healthy individual, in which case 
it is termed sporadic FIM (SFIM) (Penman, 1970).  It is thought that the symptoms and 
disease progression occurs as a result of the exuberant T cell response, most particularly 
the cytokines released in response to EBV (Ohga et al, 1993). 
 
1.3.3 Immune response 
Natural Killer (NK) cells are an essential component of the innate immune response to 
most pathogens and whilst expansions of activated NK cells have been reported in IM 
patients (Williams et al, 2005), most evidence suggests that this cell type do s not 
feature highly in the response against EBV in vivo (Hislop et al, 2007).   
 
Due to the lack of symptoms, little is known about primary infection in individuals that 
undergo clinically silent seroconversion.  However, the adaptive immune response to 
EBV has been extensively researched in IM where the major role played by CD8+ T 
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cells is well characterised.  Clinical primary EBV infection results in a massive 
expansion of these T cells expressing a broad repertoire of T cell receptors (TCRs) 
specific for EBV epitopes (White t al, 1996b;Steven et al, 1996b;Steven et al, 1997a).  
Up to 40% of the total CD8+ T cell population recognise one specific viral epito e, 
namely from lytic EBV epitopes such as IE and E antigens, whereas the response to 
latent antigens is somewhat less and focuses on the EBNA 3 family (Hislop et al, 2007). 
 
Consistent with activated CD8+ T cells, these cells express perforin, a cytolytic molecule 
involved in apoptosis of target cells, and the activ tion markers CD38, and Ki-67 
(Callan et al, 1998b;Catalina et al, 2001b;Hislop et al, 2002;Hislop et al, 2005b;Dunne 
et al, 2002b).  Functional studies revealed that EBV-specific cytotoxic CD8+ T cells 
were capable of recognising and killing target cells loaded with the relevant peptide 
epitope ex vivo (Steven et al, 1996a;Steven et al, 1997b;Callan et al, 1998a).  In 
addition, a proportion of EBV-specific CD8+ T cells responded to the relevant peptide 
by producing IFN-γ (Hoshino et al, 1999;Catalina et al, 2001a;Woodberry et al, 
2005b;Hislop et al, 2005a;Callan et al, 2000b;Catalina et al, 2002;Precopio et al, 
2003a).  Another characteristic of these cells is the rapidity with which they die upon ex 
vivo culture unless restimulated with antigen (Callan et al, 2000a;Dunne et al, 
2002a;Tamaru et al, 1993). 
 
Once the primary CD8+ T cell response to EBV successfully reduces the numbers of 
circulating infected B cells, the EBV-specific CD8+ T cell population, responding to 
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both lytic and latent antigens, eventually subsides, concurrent with a downregulation in 
some activation markers including CD38 (Callan, 2004a).  Despite these changes in 
frequency and phenotype, EBV-specific CD8+ T cells responding to both lytic and latent 
epitopes can still be detected after the resolution of primary infection (Tan et al, 1999b) 
and account for a significant proportion of the antigen-experienced pool of cells in 
healthy seropositive individuals, with a frequency of between 0.1-1% in peripheral blood 
(Callan, 2004b). 
 
The response of CD4+ T cells to primary EBV infection is less well understood and the 
epitopes to which they respond are not as extensively characterised, partially due to the 
fact that EBV-specific CD4+ T cells do not expand to the extent of the EBV-specific 
CD8+ T cells in IM patients, making them more difficult to isolate and study.  However, 
CD4+ T cells responding to both lytic and latent epitopes have been described 
(Woodberry et al, 2005a;Precopio et al, 2003b).  Precopio et al’s study of primary 
infection in IM patients identified CD4+ T cell responses, by short in vitro stimulation 
followed by intracellular staining for IFN-γ, to lytic antigens BZLF1 and BMLF1 and 
latent antigen, EBNA-1, with a small minority of CD4+ T cells responding to EBNA-3A 
(Precopio et al, 2003c). 
 
When assayed directly ex vivo, Amyes et al detected IFN-γ release by CD4+ T cells from 
acute IM patients when stimulated with EBV-infected B cell lysate.  On assaying PBMC 
from the same patients 4 months post-infection, the response was found to be 
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significantly reduced (Amyes et al, 2003d), furthermore, in healthy EBV carriers, very 
little response was observed using the same experimental protocol.  So although their 
activity can be demonstrated, CD4+ T cells with EBV-specificity are found at a low 
frequency in peripheral blood of healthy seropositive individuals. 
 
In general, CD4+ T cells do not phenotypically alter from primary to persistent infection, 
continuing to express CD45RO, CD27 and CD28, with the exception of CD38, found to 
be expressed on CD4+ T cells in acute IM patients but not 4 months post-infection and 
not on healthy EBV carriers (Amyes t al, 2003c). 
 
At four months post-primary infection, the frequency of EBV-specific CD4+ T cells has 
declined to the level detected in the persistent phase of infection (Amyes et al, 2003b).  
The isolation of CD4+ T cells from healthy carriers recognising lytic cycle antigens, 
such as BZLF1-encoded IE epitopes (Adhikary et al, 2006a), BMFL1- and BHRF1-
encoded E proteins (White t al, 1996a;Amyes et al, 2003a;Landais et al, 2004) and 
epitopes from L proteins (Adhikary et al, 2006b;Wallace et al, 1991), indicates a clear 
memory response. 
 
To date the majority of EBV-specific T cell targets identified are in certain viral epitopes 
(Yewdell & Bennink, 1999), a phenomenon observed in most donors irrespective of 
HLA background, and this hierarchy differs between the CD4+ and CD8+ T cell response 
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(Hislop et al, 2007).  The likelihood is that many more epitopes exist and are yet to be 
discovered. 
 
The generation of EBNA-1 specific T cell lines after in vitro stimulation with EBNA-1 
peptides resulted in some IFN-γ-producing CD4+ T cell clones with regulatory 
properties, as evidenced by their inhibition of T cell proliferation in cocultures of naïve 
CD4+ and CD8+ T cells responding to anti-CD3 stimulation.  This, a  the authors imply, 
indicates that some epitopes may induce regulatory T cell (Treg) activity (Voo et al, 
2005d).  Studies have also demonstrated IL-10 releas  when PBMC are stimulated in 
vitro with LMP-1 protein (Dukers et al, 2000b) and a variety of LMP-1 peptides 
(Marshall et al, 2003i).  This adds to the concept that some epitopes may induce Treg.  
Whether this is a mechanism for EBV immune evasion has yet to be established. 
1.3.4 Hodgkin’s Lymphoma 
Hodgkin’s lymphoma (HL) is a cancer of the lymphatic system, characterised by the 
presence of malignant Hodgkin’s Reed-Sternberg (HRS) cells.  The origin of HRS cells 
has been identified as germinal centre B cells (Marafioti et al, 2000).  The frequency and 
type of non-neoplastic cell populations associated with the HRS cells allow for further 
sub-classification of HL into nodular sclerosis (NS), mixed cellularity (MS), lymphocyte 
depletion (LD), lymphocyte rich classical (LRC) and lymphocyte predominance (LP).  
The first 4 types are strongly associated with EBV and collectively known as classical 
HL; LP is non-EBV associated and considered a distinct form of lymphoma.  
 
Chapter 1                               Introduction: EBV disease associations & immune response 
 27 
A role for EBV in the development of HL was first suggested in 1966 (MacMahon, 
1966) and early evidence linking the virus with HL included the detection of elevated 
levels of antibodies specific for EBV antigens in HL patients when compared with 
patients with other lymphomas (Levine et al, 1971); this appeared to precede tumour 
development by a number of years (Mueller et al, 1989).  In addition it was determined 
that individuals with a history of IM had a higher risk of developing HL than silent 
seroconverters (Gutensohn & Cole, 1980).  Weiss t al detected EBV DNA in a subset 
of HL (Weiss et al, 1987) and Wu et al demonstrated the localisation of the EBV 
genome to the HRS cells (Wu et al, 1990).  EBV has since been associated with 
approximately 50% of HL in western societies with a higher incidence in developing 
countries (Crawford, 2001e). 
 
Where EBV is found in association with HL, HRS cells express a restricted pattern of 
EBV antigens, termed Latency II, which includes EBNA-1, LMP-1, LMP-2A proteins 
and EBER and BamH1A transcripts (Pallesen et al, 1991).  A link between EBV-
associated HL and HLA class I microsatellite markers has been established (Diepstra et 
al, 2005).  This, in addition to more recent findings that the same HLA class I alleles 
occur more frequently in IM patients when compared with healthy carriers (McAulay et 
al, 2007), has led researchers to propose that altered EBV peptide presentation to CD8+ 
T cells may affect the immune response to EBV and hence predispose these individuals 
to EBV-related diseases (Haque et al, 2007b). 
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1.4 Regulatory T cells 
1.4.1 Introduction 
Regulatory T cells are characterised by their ability to suppress proliferation of various 
cell types, including CD4+ and CD8+ T cells, and inhibit cytokine release.  Broadly 
speaking, Treg can be divided into two groups; ‘natural’ Treg and adaptive, or induced, 
Treg. 
 
Natural Treg are of thymic origin, developing from CD4
+CD8+CD3high T cells, and can be 
detected in the foetus at an early stage of gestation (Darrasse-Jeze et al, 2005;Cupedo et 
al, 2005).  They comprise 2-5% of CD4+ T cells in human PBMC (Bacchetta et al, 
2005c).  Phenotypically they are defined by their constitutive expression of the high 
affinity IL-2 receptor α chain CD25 (Shevach, 2002a;Sakaguchi, 2000) and the 
transcription factor, FOXP3. 
 
In contrast, adaptive Treg arise in the periphery, expressing FOXP3 only when activated 
by certain stimulatory conditions.  For example, type 1 regulatory Tr1 cells develop in 
an IL-10-rich background.  In addition, adaptive Treg can be induced from CD4
+ T cells 
lacking the CD25 activation marker.   
 
Other cell-surface markers associated with regulatory properties have been described 
including glucocorticoid-induced TNF receptor family-related gene (GITR) (Shimizu et 
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al, 2002d;McHugh et al, 2002a) and cytotoxic-T-lymphocyte-associated protein 
(CTLA)-4 (Read et al, 2000c). 
 
FOXP3 is a transcription factor first identified when scientists were investigating the 
genetic basis for the fatal autoimmune disease immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome (Bennett et al, 
2001b;Wildin et al, 2001;Chatila et al, 2000).  A similar autoimmune disease was 
observed in mice with the scurfy mutation in the FOXP3 gene (Brunkow et al, 2001b).  
It was determined that mutations in FOXP3 caused these diseases by resulting in the loss 
of Treg and, furthermore, scurfy mice could be rescued from the disease with transgene 
expression of wild-type FOXP3 (Brunkow et al, 2001a).  FOXP3 is now widely 
accepted as playing a crucial role in Treg development and function (Zheng & Rudensky, 
2007;Campbell & Ziegler, 2007b) and to date is the most specific marker for Treg (Hori 
& Sakaguchi, 2004;Khattri et al, 2003).  
 
However, a number of human non-regulatory T cell subsets have been shown to express 
FOXP3 upon activation under certain conditions, including human CD4+CD25- T cells 
and CD8 T cells (Bacchetta et al, 2005b).  For example, Sereti t al report that a high 
percentage of CD4+CD25- T cells from healthy humans will express high leves of 
FOXP3 and CD25bright when activated with anti-CD3 and anti-CD28 antibodies (Sereti 
et al, 2005).  In a review of the subject, Rouse et al suggest that ‘in humans, FOXP3 
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expression is a normal consequence of T cell activation’ (Rouse et al, 2006), hence an 
exclusive marker for Treg is still being sought. 
 
Numerous T cell subsets have been ascribed with regulatory activity with roles in 
suppressing autoimmune disease, controlling infection, allergy and immunopathology.  
Table 1.5 summarises the characteristics of known Treg subsets.  Unless otherwise stated, 
Treg refers to CD4
+CD25+FOXP3+ T cells in the following text.  Current research 
indicates a necessity for IL-2, in initiating regulatory activity (Shevach, 2002b;Setoguchi 
et al, 2005), and for survival in the periphery.  Treg suppress proliferation and IFN-γ 
production of both CD4+ and CD8+ T cells (Bacchetta et al, 2005a) although the 
mechanisms by which they achieve this is still the topic of intense research. 
 
A role for GITR has been postulated since antibodies against GITR abrogated 
suppression in cocultures of Treg and responder T cells (Shimizu et al, 2002c;McHugh et 
al, 2002b).  Stephens et al demonstrated that interaction of GITR ligand (GITR-L), 
expressed primarily on antigen-presenting cells (APCs), with GITR resulted in a raised 
suppression threshold on CD25- cells (Stephens et al, 2004).  Another marker, cytotoxic 
T lymphocyte-associated antigen (CTLA)-4, has also been implicated with a role in Treg 
function since antibodies against this marker result in abrogation of suppression 
(Perezblas et al, 1992b), enhanced antitumour immunity (Leach et al, 1996) and 
exacerbation of autoimmune disease (Karandikar et al, 1996;Luhder et al, 1998).  
Furthermore, Treg important in regulating murine colitis have been shown to require 
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Table 1.5: Characteristics & Properties of Treg types 
Abbreviations: APCs – antigen presenting cells; NKT – natural killer cells; TGF-β – 
transforming growth factor-β; IL-10 – interleukin-10; ILT – immunoglobulin-like transcripts; 
DCs – dendritic cells; IFN-γ – interferon-γ. (Table created using Rouse & Suvas, 2004a;Lan et 
al, 2005b;O'Garra & Vieira, 2004;Rouse et al, 2006). 
 
Natural Treg have been shown to regulate the proliferation, differentiation and effector 
function of a number of cell types, including CD4+CD25- T cells, CD8 T cells and B 
cells (Lim et al, 2005).  Determining the mechanisms by which Treg suppress target cell 
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activity has been a major focal point of research in th s field.  To date, these fall into one 
of three categories; cell-cell contact, release of immunomodulatory cytokines and local 
competition for growth factors.   
 
Roles for membrane TGF-β and CTLA-4 have been shown in cell-cell contact studies 
although results often conflict and it is likely tha  slight differences in methodology 
greatly effect data.  A role for cyclic adenosine monophosphate (cAMP), a molecule 
associated with inhibition of cell proliferation, differentiation and downregulation of 
genes encoding IL-2 and IFN-γ, has been demonstrated.  Minguet et al, (2005) showed 
that Treg increased cAMP levels in target cells, either directly by Treg themselves or 
indirectly via local generation of adenosine.   
 
Numerous studies have demonstrated that Treg can mediate their activity via secretion of 
immunomodulatory cytokines such as TGF-β and IL-10, produced either by Treg or Treg-
induced production from other cells such as antigen presenting cells (APC).  More 
recently, a novel cytokine, produced by Treg and designated IL-35, has been shown to 
have an inhibitory effect on T cell proliferation (Collison et al, 2007).  
 
The third mechanism of inhibition employed by Treg is competition for growth factors.  
In vitro studies have shown that Treg compete with naïve CD4 T cells for IL-2 (Barthlott 
et al, 2005).  In addition, Pandiyan et al, (2007) established both in vitro and in vivo that 
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the presence of Treg resulted in cytokine deprivation-induced apoptosis of CD4 effector 
T cells, whereas activation and proliferation were unaffected.    
 
A recent review on the subject of immunosuppressive mechanisms employed by Treg 
suggests that the Treg response is likely to be determined by the conditions under which 
the Treg encounters a target cell (Sojka et al, 2008).     
1.4.2 History 
The late immunologist Richard Gershon was the firstto propose that a group of T cells, 
termed suppressors, were responsible for the toleranc  he observed in a mouse model 
(Gershon, 1975).  He postulated that these cells mediated their suppressive role by 
producing soluble factors, specific for certain antigens and consisted of MHC-encoded I-
J determinants and, initially, a number of studies supported this finding (Tada et al, 
1976;Murphy et al, 1976;Okumura et al, 1976).  These cells were primarily associated 
with tolerance although Horohov et al extended the notion of suppressive cells to 
infectious disease scenarios (Horohov et al, 1985).  However, the concept fell into 
disrepute with the inability of researchers to verify eports of the secreted molecules 
(Shevach, 2000).  With the discovery of the Th1/Th2 lineage of T cells in the late 1980s, 
suppressive activity of T cells was attributed to counter-production of cytokines by these 
T cell subsets (Shevach, 2000) and interest in suppressors waned. 
 
Despite the lack of evidence for a regulatory subset of T cells, a minority of groups 
persisted in their research using murine models of autoimmune disease (Shevach, 2000).  
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The major break-though came with the discovery in a murine model of autoimmune 
disease, that CD4+ T cells with suppressive activity expressed the IL-2R α-chain, CD25 
(Sakaguchi et al, 1995b), finally providing a more definitive marke in this system. 
 
Key observations early in the Treg field were that T cells, distinguishable by high 
expression of CD25, existed to control the response of autoreactive T cells to self-
antigens (Sakaguchi et al, 1995a;Thornton & Shevach, 1998a).  Furthermore, 
autoimmune lesions could occur when Treg were absent (Maloy & Powrie, 2001).  When 
such cells were present, the inflammatory effects of autoreactive T cells could be 
modulated both in vitro and in vivo (Thornton & Shevach, 1998b;Sakaguchi, 2005). 
 
With the rebirth of Treg, questions were again raised concerning the role of similar T 
cells in infectious disease.  In 2002, the first proof that Treg played a role in infectious 
disease was provided by Belkaid et al in a model of parasitic infection with Leishmania 
major (Belkaid et al, 2002a).  Since then a number of publications have described a role 
for Treg in infection with various pathogens (Suvas et al, 2003b). 
1.4.3 Role of Regulatory T cells in autoimmune disease 
The vast number of microorganisms capable of causing disease demands a broad 
repertoire of TCRs in order for the host to mount a adaptive immune response.  
Immature T cells are checked for reactivity to self-peptides within the thymus and the 
majority of cells with high affinity for host-derived proteins are deleted.  Peripheral 
tolerance is maintained through a variety of mechanisms consisting of anergy, deletion 
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or suppression.  Despite these checkpoints, self-reactivity can occur by a variety of 
mechanisms, such as cross-reactivity or molecular mimicry, resulting in autoimmune 
disease.  
 
Evidence for a role for Treg in peripheral tolerance came originally from murine models 
where deletion of CD4+CD25+ Treg by thymectomy resulted in spontaneous multiorgan 
autoimmune disease; adoptive transfer of these regulatory cells prevented the 
development of the disease (Asano et al, 1996;Suri-Payer et al, 1999;Asseman et al, 
1999;Liu et al, 2005;Liu et al, 2003).  Since then Treg have been shown to play a role in 
many murine models of autoimmunity.  
 
The importance of Treg in human autoimmunity is evidenced by a genetic disor er, 
IPEX, that manifests as multiple autoimmune disease, severe allergy and inflammatory 
bowel disease.  The symptoms are caused by either a Treg deficiency or their 
dysfunctional regulation, both as a result of a defective gene encoding the transcription 
factor, FOXP3 (Bennett et al, 2001a).  Elucidating the role played by Treg in 
autoimmune diseases, such as type 1 diabetes and multiple sclerosis (MS), may allow 
scientists to manipulate or enhance Treg activity thereby having great clinical relevance.  
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Abbreviations: IFN-γ – Interferon-γ; TNF-α – tumour necrosis factor-α; IL-2 – interleukin-2; 
PHA – phytohaemagglutin; NA – not applicable; GITR – glucocorticoid-induced TNF receptor 
family-related gene; CTLA-4 – cytotoxic-T-lymphocyte-associated protein.  (Table adapted 
from Lan et al, 2005a). 
 
Experimental autoimmune encephalomyelitis (EAE) is the murine model used to 
investigate MS since they share many of the same featur s, in that myelin-specific T 
cells initiate inflammation of the central nervous system (CNS) resulting in the ultimate 
paralysis of the host.  McGeachy et al recovered IL-10 producing FOXP3+Treg from the 
CNS that were able to suppress the proliferation of CD4+CD25- T cells at ratios as low 
as 1:30 in vitro (McGeachy et al, 2005).  In an adapted model of EAE, they 
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demonstrated high rates of Treg proliferation within the CNS but not in the lymph nodes, 
an indication that the Treg were activated within the CNS rather than homing to the site 
of inflammation (O'Connor et al, 2007).  The specific antigen required to initiate Treg 
activity within the CNS has yet to be determined. 
1.4.4 Role of Regulatory T cells in Infection 
In autoimmune disease settings, Treg play an important role in controlling the immune 
response to self.  In microbial infection, a balance must be set between an excessive 
immune response to the infectious agent, resulting in immunopathological damage, and 
mounting an insufficient response allowing pathogen p rsistence.  The importance of 
achieving this balance is shown by a murine model in which mice are infected with 
Helicobacter pylori, a bacterium linked to stomach ulcers, gastritis and cancer in 
humans.  Adoptive transfer of lymph node cells, deplet d of CD4+CD25+ T cells, to T 
cell-deficient mice infected with H. pylori drives a more robust immune response to the 
bacterium than non-depleted lymph node cells but results in enhanced gastric 
inflammation (Raghavan et al, 2003) causing damage to the host.  In vitro evidence 
points to a similar role for natural Treg in humans infected with H. pylori (Lundgren et al, 
2003).  Similar situations are observed in other infectious diseases including parasitic 
infection with Leishmania major (Belkaid et al, 2002b) and viral infection with HSV-1 
(Suvas et al, 2004c).  Table 1.7 summarises the microbial infections with evidence of 
Treg activity.  The consequences of limiting collateral d mage are pathogen survival and 
in some cases persistence.  Belkaid & Rouse put it as ‘a compromise between the host 
and pathogen’ (Belkaid & Rouse, 2005a). 
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Table 1.7: Microbial infections in which a role for Natural Treg has been implicated 
Microbe species reference 
Parasites   
 Leishmania major mouse (Belkaid et al, 2002c) 
 Plasmodium yoelii mouse (Hisaeda et al, 2004) 
 Pneumocystis carinii mouse (Hori et al, 2002) 
Bacteria   
 Listeria monocytogenes mouse (Kursar et al, 2002) 
 Helicobacter hepaticus mouse & human (Maloy et al, 2003) 
 Helicobacter pylori mouse & human (Raghavan et al, 2003) 
 Bordetella pertussis  (McGuirk et al, 2002) 
Fungi   
 Candida albicans  (Montagnoli et al, 2002) 
Viruses   
Friend virus mouse (Dittmer et al, 2004b) 
Murine AIDS mouse (Beilharz et al, 2004) 
FIV cat (Vahlenkamp et al, 2004) 
HIV human (Aandahl et al, 2004a) 
CMV human (Aandahl et al, 2004b) 
HSV-1 mouse  (Suvas et al, 2003a;Suvas et al, 2004b) 
 
HCV human 
(Sugimoto et al, 2003a;Boyer et al, 
2004) 
Abbreviations: AIDS – acquired immunodeficiency syndrome; FIV – feline 
immunodeficiency virus; HIV – human immunodeficiency virus; CMV – cytomegalovirus; 
HSV – herpes simplex virus; HCV – hepatitis C virus.  Table created using (Rouse & Suvas, 
2004c;Belkaid & Rouse, 2005b) 
 
1.4.5 Role of Regulatory T cells in Persistent Viral infection 
The majority of viruses possess immune evasion mechanisms, particularly those that 
cause persistent infection (Rouse & Horohov, 1986;Tortorella et al, 2000).  In 2001, 
Iwashiro et al provided the first indication that a virus might subvert the immune 
response by inducing Treg activity (Iwashiro et al, 2001a).  The group were studying 
chronic Friend virus leukaemia infection of mice, characterised by increases in splenic 
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CD4+ T cells to almost double their normal frequency and loss of ability to reject tumour 
transplants.  Iwashiro et al established that the observed immunosuppression of anti-
tumour immunity was mediated by CD4+ T cells since adoptive transfer of these cells 
from infected mice to uninfected animals resulted in a similar effect.  Subsequently the 
group identified Treg as the cause of CD8
+ T cell response suppression (Iwashiro et al, 
2001b), an effect that was only detected in persistently infected animals (Dittmer et al, 
2004a).  Since then much evidence has been collected and several good reviews exist on 
the role of regulatory T cells in viral infection (Rouse & Suvas, 2004b;Belkaid & Rouse, 
2005c;Rouse t al, 2006).  A role for Treg in Hepatitis C virus (HCV) and HIV infection 
has been established.  Using these infections as the most well studied examples, the role 
of Treg in human persistent viral infections will be discused below. 
 
Hepatitis C virus 
HCV infects over 170 million people worldwide (Racanelli & Manigold, 2007) and is 
one of the major causes of chronic hepatitis and comm nest cause of liver transplants.  
The outcome of primary HCV infection is highly varible; ranging from complete 
erradication to viral persistence, liver cirrhosis and development of hepatocellular 
carcinoma (Rehermann et al, 1996).  Robust CD8+ and CD4+ T cell responses are 
associated with more favourable outcomes (Thimme et al, 2001).  In 2002, MacDonald 
et al isolated IL-10-producing Tr1 cells from chronically infected patients (MacDonald 
et al, 2002a) implying a role for induced Treg in HCV infection.   
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Evidence from numerous studies on HCV indicates that an expansion of Treg may 
account for the suppression of effector CD8+ T cell immunity observed ex vivo in 
chronically infected patients (Sugimoto et al, 2003b;Boettler et al, 2005g), Cabrera et al 
reported that the suppression observed was dependent on TGF-β and cell-cell contact 
(Cabrera et al, 2004g).  In addition, they and others demonstrated specificity by IL-10 
release from Treg in response to HCV antigens (Cabrera t al, 2004f;MacDonald et al, 
2002b).  However, the dependency on cytokines is disputed by two recent reports in 
which administration of antibodies to IL-10 or TGF-β did not abrogate suppression 
(Boettler et al, 2005f;Rushbrook et al, 2005a).  Of interest, both these studies 
demonstrated suppressed CD8+ T cell responses to other viruses, including Influenza 
and EBV in chronically infected HCV patients (Boettl r et al, 2005e;Rushbrook et al, 
2005g).  Currently the majority of studies have been conducted in vitro and as Rouse t 
al report in a recent review, preliminary findings of an ongoing chimpanzee model of 
HCV infection has provided evidence against a role f r Treg in viral pathogenesis (Rouse 
et al, 2006).  Studies are still required to establish what precise role Treg play in HCV 
infection if any.  
 
Human Immunodeficiency Virus 
Infection with human immunodeficiency virus (HIV) ultimately results in reduced CD4+ 
T cell numbers, excessive immune activation and eventually HIV patients develop 
Acquired Immunodeficiency Syndrome (AIDS) and succumb to opportunistic infections 
(Douek et al, 2003). 
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The investigation of Treg activity in HIV infection is difficult since the phenotype of 
human Treg is somewhat indistinguishable from highly activated T cells, such as those 
CD4+ T cells found in HIV+ patients.  In addition, the majority of studies have been 
undertaken on peripheral blood leukocytes (PBL) which is unlikely to have provided an 
accurate representation of the immunological events that occur in HIV infection since 
the critical interactions between HIV and Treg occur in the lymphoid tissue. 
 
An indication that Treg played a role in HIV infection was first demonstrated by Nixon’s 
group by depleting Treg from PBMC and enhancing the HIV-specific T cell response in 
vitro (Aandahl et al, 2004c).  Several other groups reported similar findings (Kinter et 
al, 2004b;Weiss et al, 2004a).  The suppression these groups observed appeared to be 
cell-contact dependent and cytokine independent, although the Weiss team reported that 
Treg  isolated from some HIV
+ patients responded specifically to the HIV antigen, p24, 
by producing TGF-β and IL-10 (Weiss et al, 2004b).  These studies indicate a negative 
role for Treg since they depress the anti-HIV T cell responses. 
 
The question of whether the role of Treg varied with disease progression was addressed 
by Kinter et al in a cohort of HIV-infected individuals at various stages of disease 
(Kinter et al, 2004a).  HIV-specific Treg activity was investigated in vitro and compared 
to viral load and the CD4+ T cell count.  The results showed that HIV patients with HIV-
specific Treg activity had lower viral loads in the plasma and icreased CD4
+ T cell 
counts than patients with reduced HIV-specific Treg activity (Kinter et al, 2004c).  These 
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findings led researchers to contemplate that Treg may play a beneficial role in HIV 
infection. 
 
Other research has indicated that Treg may play a positive role in HIV infection by 
limiting the characteristic immune activation observed with this disease.  Oswald-
Richter’s group observed that the frequency of FOXP3-expressing CD4+CD25hi T cells 
was reduced in HIV-infected individuals with low CD4+ T cell counts and high T cell 
activation in comparison to healthy HIV patients (Oswald-Richter et al, 2004b).  Eggena 
et al demonstrated a reduced frequency of Treg in HIV
+ patients when compared to 
uninfected individuals.  Furthermore, the reduction in Treg frequency was associated with 
CD4+ and CD8+ T cell activation (Eggena et al, 2005).  Both studies imply Treg depletion 
could hasten progression from HIV to AIDS. 
 
Currently the cause of Treg depletion in HIV infection is unknown although a number of 
plausible suggestions have been made.  HIV has been shown to directly infect Treg and 
transduction of conventional CD4+ T cells with FOXP3 generates cells that are more 
permissive to infection, although it is unclear whether this renders the Treg ineffective 
(Oswald-Richter et al, 2004a).  This suggests the possibility that Treg are targeted by 
HIV and infection specifically kills the cell. 
 
Underlying the interest in Treg depletion is the notion that although these cells are
reduced in frequency in the blood, they may be redistributed, possibly localising to 
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lymphoid tissue during in HIV infection, as has been r ported in non-HIV systems.  
Andersson et al provided data supporting the latter scenario in a longitudinal study of 
HIV infected subjects pre- and post-anti-retroviral therapy (Andersson et al, 2005b).  
During periods of HIV viremia, Treg moved from peripheral blood to lymphoid tissue. 
This was reversed when treated with anti-retroviral therapy.  Hence, the reduced 
frequency of Treg in HIV patients may reflect a redistribution of Treg rather than an 
overall decrease (Andersson et al, 2005a).  However, the group only identified Treg 
phenotypically and no functional studies were carried out. 
1.4.6 Evidence for a Role for Regulatory T cells in EBV infection 
In order to avoid the host’s immune response, persistent viruses have a number of 
immune evasion tactics.  One particular mechanism of i mune evasion adopted by EBV 
has been of interest recently since researchers have not determined a satisfactory answer 
to the lack of immunogenicity of LMP-1, a latent EBV antigen expressed by infected B 
cells and other EBV-associated malignancies such as HL and NPC.  In light of emerging 
evidence for Treg activity in persistent viral infections and previous research 
demonstrating the production of the immunosuppressiv  cytokine, IL-10, by CD4+ T 
cells stimulated in vitro with autologous LCL (Wilson et al, 2001), Vickers and 
colleagues hypothesised that LMP-1 induced Treg activity and set out to investigate this 
theory (Marshall et al, 2003h). 
 
PBMC isolated from EBV-seropositive donors were stimulated with purified LMP-1, 
resulting in high levels of IL-10 production by CD4+ T cells.  Additional experiments 
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established that addition of LMP-1 to donor PBMC resulted in the inhibition of both cell 
proliferation and IFN-γ release to non-EBV antigens, and suppression was depen ent on 
IL-10 since neutralisation of this cytokine abrogated suppressive activity (Marshall et al, 
2003g).  The same group assayed CD4+ T cell function from HL patients and reported 
high levels of IL-10 secreting regulatory T (Tr1) cells with suppressive activity in HL-
infiltrating lymphocytes (HLILs).  The Treg they describe were phenotypically identical 
to induced Tr1 cells, however, the mechanism by which Tr1 cells primarily mediate their 
suppressive activity is IL-10 alone, whereas this group describe regulatory activity being 
abrogated by prevention of cell-cell contact as well as by blocking CTLA-4 (Marshall et 
al, 2004a). 
 
Khanna’s group took this research one step further and investigated the ability of Treg to 
suppress responses to EBV latent antigens expressed in HL. They determined that a high 
level of lymphocyte activation gene (LAG)-3 expression, another marker affiliated with 
Treg (Huang et al, 2004b), on HLILs was associated with the loss of LMP-1/2-specific T 
cell function.  They also demonstrated that CD4+LAG-3+ T cells possessed regulatory 
properties (Gandhi et al, 2006a).  They showed an association between LAG-3 and EBV 
gene expression in tumour tissues and established tat LAG-3 was expressed more 
frequently on lymphocytes than FOXP3, and generally lymphocytes did not express both 
proteins.  No association was found between FOXP3 and LAG-3, histology or EBV 
status. LAG-3+CD4+ T cells in the peripheral blood were enriched for CTLA-4hi and 
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GITRhi but not FOXP3 and were present at higher frequency in patients with active than 
inactive disease (Gandhi et al, 2006c). 
 
In an attempt to understand the specificity of Treg in EBV infection, Voo et al undertook 
in vitro experiments in which they stimulated PBMC with EBNA-1 peptides.  They 
reported that the expanded T cell lines included CD4+ helper T cell clones but also CD4+ 
T cells with regulatory phenotypes and confirmed suppressive activity by functional 
assays (Voo et al, 2005c).  Both types of cell recognised the same EBNA-1 epitopes.  
The method of suppression was cell-contact dependent although some clones were still 
capable of suppression even in transwell coculture assays indicating a soluble inhibitory 
factor which was shown not to be IL-10 or TGF-β (Voo et al, 2005b). 
 
Because of the immunosuppressive nature of HL infiltrat ng lymphocytes and the ability 
of LMP-1 to stimulate Treg responses in healthy donors, Marshall et al hypothesised that 
LMP-1 was important in the generation of Treg responses in HL.  They compared Th1, 
Th2 and Treg responses to LMP-1 by PBMC and HLILs from EBV-positive and EBV-
negative HL patients.  EBV-positive HL patients had increased numbers of ex vivo IL-10 
secreting, CTLA-4-expressing cells compared to EBV-negative HL patients both in the 
periphery and lymph nodes.  PBMC/HLIL responses to LMP-1 in most patients were 
characterised by IL-10 secretion.  These results are consistent with the notion that LMP-
1 induces Tr1 cells as shown in previous publications (Dukers et al, 2000a;Marshall et 
al, 2003f), and these Treg cells infiltrate the HL tissue (Marshall et al, 2007b), but with 
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no clear evidence of a greater bias toward regulation in EBV-positive HL cases over 
EBV-negative cases, other mechanisms of Treg cell induction are also likely. 
 
The part played by Treg cells in EBV infection is of interest for two major reasons.  
Firstly, elucidating the role of Treg cells in primary EBV infection may expose 
opportunities for immunomanipulation at the initial stage of infection to ameliorate the 
symptoms of IM or prevent the subsequent risk of HL.  Secondly, EBV is an oncogenic 
virus and infection is associated with the development of a number of malignancies of 
lymphocytic and epithelial origin (reviewed in Young & Rickinson, 2004).  The Treg 
frequency and functional capacity may affect the level of viral persistence and therefore 
clarification of the Treg role could provide insight into the development of EBV-related 
tumours (Marshall et al, 2004b).  Voo et al have described the generation of a CD4+ T 
cell line via stimulation with EBV peptides.  Upon phenotypic analysis, the T cell line 
was found to contain Treg as well as helper T cells.  This highlights the ned to determine 
Treg specificity in EBV-related diseases since a cancer vaccine that causes the 
development of Treg, as opposed to CD4 helper T cells, could have serious consequences 
for the recipients (Voo et al, 2005a). 
 
An early publication demonstrated suppressor T cells cloned from two IM patients that 
demonstrated no cytotoxicity, reduced EBV-induced immunoglobulin production and 
delayed the outgrowth of immortalised cells (Wang et al, 1987).  Furthermore, the EBV 
lytic gene BCRF1, that encodes an IL-10 homologue, is thought to be expressed to 
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downregulate cytotoxic immune responses during viral replication (Suzuki et al, 1995).  
This may provide an environment conducive to Treg induction. 
 
1.5 Project Aims 
The aim of this project is to investigate the following hypothesis: 
‘Treg are specifically activated by EBV antigens during primary infection and 
contribute to the generalised immunosuppression’. 
In order to investigate the hypothesis the following questions need to be answered: 
In Healthy donors: 
1. Can EBV specific Treg be activated in PBMC from EBV seropositive donors? 
2. Do Treg inhibit EBV specific CTL activity? 
3. What is the antigenic specificity of Treg? 
In IM patients: 
1. Is Treg activity detectable in IM PBMCs? 
2. Are Treg raised or reduced in IM patients? 
3. Does the level of Treg activity correlate with:  
a) Level of generalised immunosuppression? 
b) Level of EBV specific CTL activity? 
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2 Materials and Methods 
2.1 Suppliers, equipment and solutions 
2.1.1 Suppliers 
AbD Serotec  Endeavour House, Langford Business Park, Langford 
Lane, Kidlington, Oxford, OX5 1GE, UK. 
 
ATi Atlas The Grange, Church Road, North Mundham, Chichester, 
West Sussex, PO20 1JQ, UK.  
 
Becton Dickinson  The Danby Building, Edmund Halley Road, Oxford 
Science Park, Oxford, OX4 4DQ, UK. 
      
Dako    Denmark House, Angel Drove, Ely, CB7 4ET, UK. 
 
Fisher Scientific  Bishop Meadow Road, Loughborough, LE11 5RG, UK.  
 
GE Healthcare  Amersham Place, Little Chalfont, HP7 9NA, UK.  
 
Invitrogen Inchinnan Business Park, 3 Fountain Drive, Paisley, PA4 
9RF, UK.  
 
Mast Diagnostics  Mast House, Derby Road, Bootle, L20 1EA, UK. 
 
Microgen Bioproducts Ltd 1 Admiralty Way, Camberley, Surrey, GU15 3DT, UK. 
 
Miltenyi Biotec Almac House, Church lane, Bisley, Surrey GU24 9DR, 
UK.  
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Nalgene  Nalge (Europe) Ltd, Unit 1a, Thorn Business Park, 
Hereford, HR2 6JT, UK. 
  
Novocastra Balliol Business Park, West Benton Lane, N wcastle 
Upon Tyne, NE12 8EW, UK.  
 
Nunc Brand Supplied by Fisher Scientific UK Ltd, Bishop Meadow   
Rd, Loughborough, Leicestershire LE11 5RG, UK.  
 
Perbio Unit 9, Atley Way, North Nelson Industrial Estate, 
Cramlington, NE23 1WA, UK.  
 
Promega   Delta House, Southampton Science Park, Southampton,  
SO16 7NS, UK.  
    
Roche Diagnostics Ltd Charles Avenue, Burgess Hill, West Sussex, RH15 9RY, 
UK. 
 
Sigma Aldrich The Old Brickyard, New Road, Gillingham, SP8 4XT, 
UK.  
 
Statens Serum Institut  5 Artillerivej DK-2300, Copenhagen S, Denmark. 
 
Thermo Scientific Thermo Fisher Scientific Inc. 81 Wyman Street, Waltham, 
MA 02454, US. 
 
Thistle Research  27 Westbourne Crescent, Glasgow G61 4HB, UK. 
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Thistle Scientific  DFDS House, Goldie Road, Uddingston, G71 6NZ, UK. 
 
Vector Laboratories 3 Accent Park, Bakewell Road, Peterborough PE2 6XS, 
UK.  
 
VWR Hunter Boulevard, Magna Park, Lutterworth, LE17 4XN, 
UK.   
 
2.1.2 Equipment 
Item      Model and supplier 
 
AID Elispot Reader version 3.2.3 Autoimmun Diagnostika 
 
Automatic pipette   ‘Pipetboy acu’, Integra Bioscienc s 
     ‘Powerpette plus’, Jencons 
 
Balances    fine: ‘AE163’, Mettler 
medium: ‘BP310P’, Sartorius 
gross: ‘EK-200G’, AND 
 
Centrifuges    ‘Falcon 6/300’, MSE 
‘Micro Centaur’ MSE 
‘Mistral 3000E’, MSE 
‘Mistral 3000i’, MSE 
‘Cytospin 2’, Shandon 
 
Flow cytometers   ‘FACScan’, Becton Dickinson  
‘FACSCalibur’, Becton Dickinson 
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Fume hood    Lynwood Installations 
 
Gamma counter   ‘1480 Wizard’, Perkin Elmer 
 
Haemocytometer   Scientific Laboratory Supplies 
     Improved Neubauer Bright 
 
Heating block    ‘DB.3’, Techne 
 
Histology Image Capture ‘BX51’ Olympus microscope with Polaroid 
‘PDMC-2’ camera and ‘DMC le’ software 
 
Humidity chamber   Sandrest 
 
Incubators    37°C: Windsor, Sandrest 
     37°C humidified: Leec, Forma Scientific  
 
Microbiological safety cabinets Medical Air Technology 
(Class II)    Envair 
     Arrowmight Biosciences 
 
Microscopes    ‘Laborlux K’, Leitz 
     ‘TMS’, Nikon 
 
Microwave    ‘SM18’, Proline 
 
pH meter    ‘HI 8521’, Hanna Instruments 
 
Pipettes    ‘Pipetman’, Gilson 
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Plate reader    ‘MRX II’, Dynex Technologies 
Refrigeration    4°C: Electrolux 
     -20°C: Labcold 
     -70°C: ‘Ultra 85’, Assab 
 
Stirrer     ‘Magnetic Stirrer Hotplate’, Stuart Scientific 
 
Waterbaths    Clifton 
     Grant Instruments 
 
2.1.3 Solutions 
Tissue Culture Medium 10% (TCM 10%) 
Roswell Park Memorial institute (RPMI) 1640  500ml 
L-glutamine      2mM 
Penicillin      100IU/ml 
Streptomycin      100IU/ml  
Foetal calf serum (Perbio)    10% v/v 
With the exception of foetal calf serum, all the above reagents were from Invitrogen  
 
Tissue Culture Medium 20% (TCM 20%) 
RPMI 1640      500ml 
L-glutamine      2mM 
Penicillin      100U/ml 
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Streptomycin      100µg/ml  
Foetal calf serum     20% v/v 
Wash Medium (Wash) 
Hank’s Balanced Salt Solution (HBSS, Invitrogen) 500ml  
Foetal calf serum     2% v/v 
 
Phosphate Buffered Saline (PBS) 
PBS tablet (Oxoid)     1 tablet 
Sterile distilled water     100ml 
 
Fluorescent Activated Cell Sorting (FACS) buffer 
Sterile PBS (pH 7.2)     500ml 
Bovine Serum Albumin (Sigma)   1%  
Sodium Azide (VWR)    0.1% 
Ethylenediamine tetraacetic acid (EDTA, Sigma) 0.02% 
 
Magnetic Activated Cell Sorting (MACS) buffer 
Sterile PBS (pH 7.2)     500ml 
Bovine Serum Albumin    0.5% 
EDTA       2mM 
 
FACS fix 
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BD CellFixTM 10% (Becton Dickinson)  1ml 
Sterile distilled water     9ml  
PBS/Tween 
Sterile PBS      1l 
Tween 20 (VWR)     0.02% 
 
Freezing Medium 
Foetal calf serum     45ml 
Dimethyl Sulfoxide (DMSO, Sigma)   4.5ml 
 
Antigen Retrieval Solution 
Tris (Thistle Scientific)    50mM  
EDTA       2mM 
pH 9 
 
Serotec Erythrolyse Buffer 
Serotec Erthrolyse buffer (AbD Serotec)  1ml 
Sterile distilled water     9ml 
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2.2 Tissue Culture Techniques 
2.2.1 Maintenance of cell lines 
All cells, with the exception of CTL, were grown in TCM 10%.  They were all incubated 
in a humidified 5% CO2 incubator at 37
oC.  CTL were grown TCM 20%.  See table 2.1 
for details of cell lines and references.  Plastics for cell culture were supplied by Sterilin, 
BD Falcon, Nunc and Greiner Bio-One. 
 
Table 2.1. Details of cell lines used. 
Cell lines Origin Reference 
B95-8 EBV transformed marmoset cell line (Miller et al, 1972)  
LCLs 
Human B-cell lines transformed in vitro 
with B95-8 
(Lam & Crawford, 1991) 
P3HR1 Burkitt’s Lymphoma (Hinuma et al, 1967) 
K562 Erythroleukaemia (Lozzio & Lozzio, 1975) 
  
2.2.2 Freezing and thawing cells 
To store cells long term, viable cells were centrifuged at 180g for 7 minutes and 
resuspended in freezing medium at between 5x106 and 2x107 cells/ml. Volumes of 1ml 
were aliquoted into cryovials and placed in a Mr. Fosty Control Freeze container 
(Nalgene) for overnight slow freezing at -70°C befor  being transferred to liquid 
nitrogen. Frozen cell lines were thawed quickly in a 37°C incubator and washed once by 
centrifugation in wash solution at 180g for 7 min.  Pelleted cells were resuspended at the 
appropriate concentration and media for the cell line
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2.2.3 Counting cells 
Cell viability and concentration were assessed using trypan blue incorporation. 10µl of 
0.4% w/v trypan blue was mixed with 10µl of cell suspension. 10µl of the mix was 
added to the chamber on a haemocytometer. The unstained viable cells were counted by 
light microscopy. 
2.3 Cell separation by centrifugation 
Buffy coat cells were obtained from the Scottish National Blood Transfusion Service 
(SNBTS).  Blood samples were provided by IM patients who were recruited from the 
Edinburgh University Health Centre.  Acute IM was confirmed by immunofluorescence 
staining for IgG and IgM anti-VCA.  Doctors provided further information regarding 
duration of symptoms.  PBMC were isolated from buffy coats or blood samples by 
density gradient centrifugation with Histopaque-1077 (Sigma).  Briefly, blood was over-
laid onto the same volume of Histopaque-1077.  Tubes w re centrifuged at 600g for 20 
minutes at 4oC.  Plasma was collected and stored either at -80oC or -20oC depending on 
its later use.  PBMC were harvested from the histopaque/plasma interface and washed 
twice in wash solution, centrifuged at 180g for 7 minutes and finally counted.  PBMC 
were either suspended in an appropriate volume according to use or frozen in freeze mix.  
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2.4 Virus Techniques 
2.4.1 Production of EBV 
B95-8 cells were grown up to a volume of 600ml in TCM 10%.  Flasks were sealed for 
7-10 days and then the contents were centrifuged at 490g for 10 min at 4oC.  The 
remaining suspension was poured into 0.8 micron filters.  The filtered suspension was 
aliquoted into 1ml cryovials and stored at -80oC until required. 
2.4.2 Establishing a Lymphoblastoid Cell Line (LCL) 
PBMCs were resuspended in an undiluted EBV preparation nd incubated at 37°C with 
occasional agitation.  After 1 hour the suspension was centrifuged at 180g for 7 minutes 
and the PBMC resuspended at 2x106 cells/ml in TCM 10%, supplemented with 1µg/ml 
cyclosporin A (CSA, Sigma).  PBMC were then seeded into a 48-well plate.  Culture 
plates were incubated at 37°C in 5% humidified CO2 and fed weekly by replacement of 
half the medium until outgrowth of immortalised cells signalled establishment of a LCL. 
2.5 Preparation of therapeutic Cytotoxic T Lymphocyte (CTL) lines 
2.5.1  T cell isolation and activation  
PBMC were isolated from buffy coats as described in section 1.3. On day zero the 
PBMC were counted and stimulated with γ-irradiated autologous LCL at a 40:1 ratio. 
On day 10 the PBMC were re-stimulated, again with γ-irradiated autologous LCL, at a 
ratio of 4:1. On day 14 and weekly for 8 weeks thereafter the CTL were re-stimulated 
with LCL at this ratio and IL-2 (Novartis) was adde to the culture to give a 
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concentration of 20U/ml.  CTL which were grown without regulatory T cells were 
depleted of this cells population on day zero (for the method see section 2.9). 
2.5.2 Cytotoxicity assay using Chromium 
Cytotoxic activity in vitro was measured using a standard chromium release assay.  Cells 
from each target cell line were labelled with 51Chromium (Chromium-51 supplied as 
sodium chromate in sterile sodium chloride solution at 1mCi/ml, GE Healthcare) for 1 
hour at 37°C. Target cells were then washed twice by centrifugation at 130g for 5 
minutes in wash buffer.  Target cells were then plated with effector cells at 
effector:target ratios of 20:1, 10:1 and 5:1.  After incubation at 37°C for 4 hours the 
release of 51Chromium from lysed cells was measured on a gamma counter.  
Spontaneous release was calculated by incubating target cells without effector cells, and 
maximum release calculated by incubating target cells with 1% Triton-X (Sigma).  
Percent specific lysis was calculated as follows; 
 
          % specific lysis   =  ___(test release – spontaneous release)___   x  100 
                     (maximum release – spontaneous release) 
 
2.6 Animal Model 
At the University of Edinburgh there is a breeding colony of CB.17 SCID mice.  The 
colony is kept in a specific pathogen-free environme t in microisolator (IVC) cages and 
handled in microbiological class 2 safety cabinets. The animals are fed autoclaved feed 
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and water without antibiotics.  The animal work in this study was carried out by Dr Ingo 
Johannessen, under relevant Home Office Project and Personal Licences in accordance 
with the Home Office ‘Animals’ (Scientific Procedures) Act 1986’, and was monitored 
by Home Office Inspectors and University Named Veterinary Surgeons. 
2.6.1 Inoculation of SCID mice 
Unmanipulated PBMC, PBMC with CD4+CD25+ T cells and PBMC depleted of 
CD4+CD25+ T cells, were washed with wash medium and resuspended at 5x107 cells per 
500µl in TCM 10%.  The cells were then inoculated via subcutaneous injection at 500 µl 
per animal into the mice.  Three mice were used for each cell fraction, and the 
experiment was repeated using PBMC from 5 healthy seropositive donors.  
2.6.2 Monitoring tumour growth 
Mice were monitored daily for signs of sickness and tumour development.  
Measurements were taken when the tumour was palpable using digital callipers.  Up to 
day 100 post-injection, mice were culled by cervical dislocation if they showed signs of 
illness in accordance with Home Office instructions and then submitted for necropsy.  
At necropsy, a macroscopic assessment was carried out and the following organs 
removed: lung, liver, spleen, and any tumour tissue.  All remaining animals were culled 
on day 100. 
2.7 Immunohistochemistry 
2.7.1 Cell Preparation 
PBMC, CD4-depleted cells, CD4+CD25- T cells or CD4+CD25+ T cells were separated 
as described later (see section 2.9) and resuspended i  1x106 cells per ml in sterile PBS.  
In some experiments, cell fractions were incubated for 3 days with the Dynabeads® 
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CD3/CD28 T cell expander kit (Invitrogen), at a ratio of 1 bead to 1 cell, and 500IU/ml 
IL-2 prior to suspension in sterile PBS and cytospin preparation. 
2.7.2 Cytospin Preparation 
Double cytofunnels (Thermo Scientific) were prepared by dampening the filters with the 
addition of 50µl PBS and centrifugation at 250g for 3 minutes at room temperature.  
PBMC (100µl) were added to double funnel chambers and centrifuged onto polysine 
slides (72-Polysine microscope slides, VWR) so each spot consisted of 1x105 cells.  
Slides were centrifuged as described above, left to air dry overnight and were not fixed. 
For long term storage slides were wrapped in silver foil and stored at -20oC. 
2.7.3 Immunohistochemistry for FOXP3 
Paraffin embedded sections were dewaxed by dipping serially into Xylene (VWR), 
100% Ethanol, 50% Ethanol and finally distilled water.  Slides were microwaved in 
50mM Tris/2mM EDTA pH 9 antigen retrieval solution for 4 minutes, then topped up 
and microwaved for a further 4 minutes.  The slides w re then transferred into PBS.  The 
slides were developed with the EnVision®+ System-HRP Kit (DakoCytomation) as per 
manufacturer’s instructions.  Briefly, the slides were removed from PBS, tissue sections 
were circumscribed with a hydrophobic barrier pen (ImmEdgeTM Pen, Vector 
Laboratories) and peroxidase block was added for 5 minutes.  The slides were then 
washed in PBS/T then the primary antibody, anti-FOXP3 E7 (kindly provided by Dr 
Alison Banham’s laboratory, Nuffield Department of Clinical Laboratory Sciences, 
University of Oxford, Level 4 Academic Block, John Radcliffe Hospital, Headington, 
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Oxford, Oxon, OX3 9DU, UK), was applied undiluted to cover the sections.  The slides 
were incubated with the primary antibody for 30 minutes, and then washed with PBS/T 
and a polymer anti-human mouse secondary antibody was added for a further 30 
minutes.  All incubations were carried out in a humid chamber.  Slides were developed 
using 3,3’-diaminobenzidine (DAB), counterstained with hematoxylin (Vector Labs) 
and mounted with Faramount aqueous mountant (Dako).  C ntrols performed using PBS 
as a primary antibody, then PBS or the polymer antibody as the secondary antibody 
ensured that positives seen were due to specific staining.  An antibody which binds the B 
cell membrane, L26, also kindly provided by Dr Alison Banham, was used as a positive 
control. 
2.7.4 Immunocytochemistry for FOXP3 
With the exception of increased incubation periods (40-50 minutes) with both the 
primary and secondary antibodies, cytospins were stained using the same method 
outlined in section 2.7.3, starting with the peroxidase block step. 
2.8 Enzyme-linked Immunosorbent Assays (ELISAs) 
2.8.1 Sample Collection 
Plasma from healthy controls and IM patients was obtained from whole blood after 
PBMC isolation and aliquots of 1ml were centrifuged at 1000g for 15 minutes.  Samples 
were then stored at -20oC until required.  Plasma collected in this manner was used to 
measure levels of cytokines in plasma ex vivo.  Cell culture supernatant from PBMC 
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stimulated with 15µg/ml LMP (PRG) peptide (Thistle Research), 10µg/ml Tuberculin 
PPD (Statens Serum Institut), 10µg/ml Phytohaemagglutinin (PHA, Sigma), or a 
combination of LMP peptide and PPD antigen, was colle ted after 5 days of incubation.  
Details of the LMP peptide can be found in table 2.2, section 2.10.3.  Samples were 
centrifuged at 11000g for 7 minutes to remove particulates.  These samples were used to 
determine levels of cytokines in cell culture supernatant after incubation of PBMC with 
a variety of stimulants. 
2.8.2 Interleukin (IL)-10 ELISA 
This ELISA was carried out as per manufacturer’s instructions (R&D Systems). Briefly, 
200µl of an IL-10 standard dilution, healthy seropositive plasma or IM plasma were 
incubated in duplicate wells for 2 hours at room tep rature.  The wells were washed 
and IL-10 conjugate was added and incubated for 2 hours at room temperature.  The 
wells were washed again and the substrate was added and incubated for 30 min at room 
temperature in the dark.  Finally stop solution was added.  The optical density for each 
well was read at 450nm with the reference wave length set to 540nm using a microplate 
reader.  IL-10 concentration was established using a standard curve. Since EBV is 
known to produce an IL-10 homologue (Hsu et al, 1990b), an ELISA was selected that 
recognised human IL-10 only. 
2.8.3 Transforming growth factor (TGF)-β1 ELISA 
This ELISA was carried out as per manufacturer’s instructions (R&D Systems).  TGF-β1 
is generally secreted in an inactive form.  The conjugate supplied in the kit only 
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recognises active TGF-β1; therefore an activation step was incorporated into the 
protocol.  Briefly, samples were incubated with 1 N HCl for 10 minutes at room 
temperature, followed by the addition of 1.2 N NaOH/0.5 M HEPES (Sigma).  Samples 
were then diluted 20-fold in Calibrator Diluent.  TGF-β1 standard dilutions, healthy 
seropositive plasma and IM plasma were added to duplicate wells (wherever possible) in 
50µl aliquots and then incubated for 2 hours at room te perature.  The wells were 
washed and TGF-β1 conjugate was added and incubated for 2 hours at room 
temperature.  The wells were washed again and the substrate was added and incubated 
for 30 min at room temperature in the dark.  Finally stop solution was added.  The 
optical density for each well was read at 450nm with the reference wave length set to 
540nm using a microplate reader.  TGF-β1 concentration was established using a 
standard curve.  
2.8.4 Interferon (IFN)-γ ELISA 
This ELISA was carried out as per manufacturer’s instructions (R&D Systems). Briefly, 
100µl of IFN-γ standard dilution, healthy seropositive plasma or IM plasma were 
incubated in duplicate wells for 2 hours at room tep rature.  The wells were washed 
and IFN-γ conjugate was added and incubated for 2 hours at room temperature.  The 
wells were washed again and the substrate was added and incubated for 30 min at room 
temperature in the dark.  Finally stop solution was added and the optical density for each 
well was read at 450nm with the reference wave length set to 540nm using a microplate 
reader. 
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2.9 Cell Separation 
Regulatory T cells were enriched by negative selection followed by positive selection as 
per manufacturer’s instructions (CD4+CD25+ T cell isolation Kit, Miltenyi Biotec).  
PBMC were isolated as previously described in section 2.3 and counted. Up to 1x108 
PBMC were centrifuged at 180g for 10 minutes with MACS buffer.  The supernatant 
was removed entirely and the cells were resuspended in 90µl of MACS buffer per 107 
cells.  Biotin-Antibody Cocktail (containing monoclnal anti-human antibodies against 
CD8. CD14, CD16, CD19, CD36, CD56, CD123, TCRγ/δ and glycophorin A) was 
added at 10µl per 107 cells and incubated at 4-8oC for 10 minutes.  Anti-biotin 
microbeads were then added at 20µl per 107 cells and incubated at 4-8oC for 15 minutes.  
The cells were then washed by centrifugation at 180g for 10 minutes in 2ml of MACS 
buffer, resuspended in 500µl buffer and applied to a prepared LD (designed particularly 
for stringent depletion of unwanted cells) column (Miltenyi Biotec).  Flow-through was 
collected (CD4+ enriched population) and the column was washed with MACS buffer 
twice.  The column was then removed from the magnet a d the remaining cells were 
eluted (CD4+ depleted population).  Both cell populations were counted.  The CD4+ 
enriched population was then washed by centrifugation at 180g for 10 minutes, 
resuspended in 90µl MACS buffer per 107 cells and 20µl of anti-CD25 microbeads 
added per 107 cells.  The cells were again incubated at 4-8oC for 15 minutes.  The cells 
were washed by centrifugation at 180g for 10 minutes, r suspended in 500µl MACS 
buffer and applied to a prepared MS (specifically designed for positive selection of cells) 
column (Miltenyi Biotec).  Flow-through was collectd (CD25 depleted population) and 
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the column was washed with MACS buffer twice.  The column was then removed from 
the magnet and the remaining cells eluted (CD25 enriched population).  Cell subsets 
were then counted as described in section 2.2.3.  
2.10 Enzyme-linked Immunosorbent Spot (ELISPOT) assays 
2.10.1 General Protocol 
The ELISPOT assay was carried out as per manufacturer’s instructions (R&D Systems). 
Briefly, PBMC were set up at a variety of densities and with various stimulants.  TCM 
10% was added to each well of an ELISPOT plate for 20 minutes.  The medium was 
then removed and the plate blotted dry.  Cells were added to appropriate wells according 
to the particular assay and incubated for 48 hours at 37oC.  Excess medium was removed 
by flicking and the plate was rinsed four times with wash solution.  Anti-IFN-γ detection 
antibody was then added and the plate was incubated ov rnight at 4oC.  The antibody 
was removed by flicking, the plate was rinsed four times with wash solution and 
Streptavidin AP was added and incubated for 2 hours at room temperature.  The plate 
was then washed four times and BCIP/NBT (5-Bromo-4-Chloro-3’Indolyphosphate p-
Toluidine salt/ Nitro blue Tetrazolium Chloride, IFN-γ ELISPOT kit, R&D Systems) 
was added for 1 hour at room temperature.  Finally the plate was washed with deionized 
water and allowed to dry at room temperature.  Initially spots per well were counted 
using a dissection microscope and then again using a  AID ELISPOT reader 
(Autoimmun Diagnostika).  A background level of IFN-γ was obtained from 
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unstimulated PBMC which was subtracted from the IFN-γ produced in response to 
stimulation. 
2.10.2 LCL Stimulation 
LCL were used to stimulate PBMC at the following ratios: 1:1, 1:2, 1:5 and 1:10. Cells 
were incubated for 48 hours before continuing with the ELISPOT protocol.  Stimulation 
with 5µg/ml PHA was used as a positive control, PBMC alone were used as negative 
controls. Tests were run in duplicate. 
2.10.3 Peptide Stimulation 
PBMC were resuspended in TCM 10% and added to wells of the ELISPOT plate at a 
density of 2x105 cells/well.  Peptides (see table 2.2 for details) were added individually 
at 10µg/ml to the PBMC and incubated for 48 hours before continuing with the 
ELISPOT protocol.  Stimulation with 5µg/ml PHA was used as a positive control, 
PBMC alone and PBMC stimulated with a non-A2 restricted peptide were used as 
negative controls.  Tests were run in triplicate. 










GLCTLVAML GLC A2 BMFL1 P1 
SVRDRLARL SVR A2 EBNA 3A P2 
LLDFVRFMGV LLD A2 EBNA 3C P3 
QAKWRLQTL QAK B8 EBNA 3A P4 
PRGPPLSSSLGLALLLLLLA PRG unknown LMP 1 LMP 
Abbreviations used: HLA, Human Leukocyte Antigen; EBNA, Epstein-Barr nuclear antigen; 
LMP, latent membrane protein. 
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2.11 Flow Cytometry 
2.11.1 Frequency of Regulatory T cells 
Cells were counted and centrifuged at 180g for 7 minutes then resuspended in FACS 
buffer at 5x106 cells/ml. FACS buffer was added to polystyrene round bottom tubes (BD 
Falcon) at 50µl/tube. Either no antibody, isotype control, CD4 FITC, CD25 PE or a 
combination thereof was applied to the appropriate FACS tube. Cell suspensions were 
added to give a density of 5x105 cells/tube.  The cells and antibodies were then 
incubated for 20 min at 4oC.  Cells were then washed twice with FACS buffer by 
centrifugation at 120g for 5 minutes. Cells were fixed with 200µl CellFixTM (Becton 
Dickinson) on a shaker for 10 minutes.  Finally 300µl FACS buffer was added. Cells 
were stored at 4°C in the dark for up to one week until analysed on either a FACScan 
(Becton Dickinson) or FACSCalibur (Becton Dickinson) flow cytometer in conjunction 
with CellQuest software. 
2.11.2 HLA A2 Typing 
Either unstained, isotype control or HLA A2 antibodies were added to 100µl of neat 
blood in polstyrene round bottom tubes (BD Falcon) a d incubated at room temperature 
for 30 minutes. Serotec Erythrolyse buffer (AbD Serot c) was then added and incubated 
at room temperature for 10 minutes.  The cells were washed by centrifugation at 120g 
for 5 minutes and the supernatant discarded. FACS buffer was added and the cells were 
washed by repeat centrifugation. Cells were then suspended in CellFixTM (Becton 
Dickinson) and incubated on a shaker for 10 minutes. Finally 300µl FACS buffer was 
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added to the cells. Cells were immediately analysed on FACScan in conjunction with 
CellQuest software (Becton Dickinson). 
2.12 Proliferation Assay 
2.12.1 MTT Proliferation Assay 
This proliferation assay works on the principle that proliferating cells reduce the 
tetrazolium compound, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
(MTT), so it forms insoluble purple formazan dye crystals. When a detergent is added, 
the crystals dissolve and the absorbance can be read using a plate reader. The 
absorbance, i.e. rate of tetrazolium reduction, is proportional to the rate of cell 
proliferation.  The MTT proliferation assay was carried out as per manufacturer’s 
instructions (TACSTM MTT assay, R&D Systems). Briefly, PBMC were suspended at a 
density of 5x106 cells/ml in TCM 10% with 1µg/ml PHA, 10µg/ml PHA or no stimulant.  
Doubling dilutions were made and plated out in a flt-bottomed 96-well plate at 
100µl/well and incubated overnight at 37oC, 5% CO2.  After 16 hours 10µl of MTT was 
added to each well and the plate was incubated for a further 2-4 hours until the 
appearance of intracellular precipitate. Detergent r agent was then added at 100µl per 
well and PBMC were incubated at 37oC, 5% CO2 overnight. The plate was read at 
540nm with the reference wave length set to 650nm. Cell proliferation assays were 
carried out in triplicate. 
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2.12.2 BrdU Proliferation Assay 
This proliferation assay works on the principle that 5-Bromo-2’deoxy-uridine (BrdU) is 
incorporated into freshly synthesized DNA.  Cells are then fixed and the DNA is 
partially digested which allows the binding of peroxidase-labelled anti-BrdU antibodies.  
Finally peroxidase substrate is added, which is cleaved by the peroxidase enzyme, the 
resulting product is coloured and hence absorbance of the sample can be established 
using a plate reader.  Absorbance is proportional to the amount of BrdU incorporated 
into cellular DNA.  The BrdU assay was carried out as per manufacturer’s instructions 
(BrdU Labelling and detection Kit, Roche Diagnostic).  Briefly, cells were set up in U-
bottomed 96-well plates at various densities and incubated for various time periods 
ranging from 24 to 120 hours with a variety of stimulants (see sections 2.10.2 and 
2.10.3).  The outermost wells were filled with PBS to humidify the cells.  BrdU was 
added at 10µg/ml and the plates were incubated overnight at 37oC and 5% CO2.  Plates 
were centrifuged at 180g for 7 min at 4oC and the supernatant removed by blotting.  The 
plates were then dried at 60oC for an hour.  Plates were kept for up to a week at 4oC.  
The DNA in the cells was denatured by incubation with FixDenat for 30 minutes at 15-
25oC.  FixDenat was removed and anti-BrdU-POD was added for 90 minutes and plates 
were incubated at 15-25oC.  The plates were then washed and incubated with substrate 
solution for 20 minutes at room temperature.  The reaction was stopped with the addition 
of 25µl/well 1M H2SO4 and the plates were read with an ELISA plate reader t 340nm 
with reference wavelength set at 370nm. 
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2.12.3 Stimulation using anti-CD3 
In some of the proliferation assays, plate-bound anti-CD3 (Clone UCHT1, BD 
Pharmingen) was used as a stimulant.  To optimize the concentration of antibody, anti-
CD3 was used at 0.5, 1, 2.5, 5, 10 or 20µg/ml.  The dilutions were made up in sterile 
PBS (sPBS).  The appropriate antibody dilution was added to wells of a 96-well U-
bottomed plate.  The plates were covered with parafilm and incubated at 37oC for 2 
hours.  Excess antibody was removed by tapping and the plates were washed twice with 
200µl sPBS before the cells were applied.  Cells were then incubated for 5 days and the 
BrdU proliferation was continued as described in section 2.12.2.  
2.12.4 Stimulation with Tuberculin PPD and peptide 
PBMC were counted and resuspended at 1.25x106 cells/ml in TCM 10% and 1ml 
aliquots were added to 15 wells of a 48-well plate. Either PRG peptide (15µg/ml, see 
table 2 in section 2.10.3 for peptide details), control recall Mycobacterium tuberculosis 
PPD antigen (RT50; Statens Seruminstitut, Copenhagen, D nmark) at 10µg/ml, PHA 
(10µg/ml) or PPD in combination with PRG peptide were us d to stimulate PBMC.  All 
stimulants were added to triplicate wells. PBMC were incubated for 5 days whereupon 
400µl tissue culture supernatant was carefully removed to avoid disturbing the cells and 
stored as described in section 2.8.  The remaining cells were resuspended and 400µl 
from each well was applied to a 96-well U-bottomed plate at 200µl per well. BrdU was 
added at 10µg/ml and the proliferation assay was continued as de cribed in section 
2.12.2.  
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2.12.5 Suppression Assay 
The ability of CD4+CD25+ cells to suppress proliferative responses of other cell 
populations was assessed in a suppression assay.  Un-separated PBMC, CD4+CD25- T 
cells, CD4+CD25+ T cells and recombined cocultures of CD4+CD25- T cells and 
CD4+CD25+ T cells were cultured at 1x105 cells per well in 200µl of TCM 10%.  The 
cell cultures were incubated for 5 days with 10µg/ml PHA, 5µg/ml plate-bound anti-
CD3 or no stimulation.  After 5 days proliferation was assessed with BrdU proliferation 
assay (details in section 2.12.2). 
2.13 Serology 
2.13.1 Monospot 
A Microgen Bioproducts IM kit was used as per manufcturer’s instructions to detect 
serum heterophile antibodies indicative of acute IM.  Heterophile antibodies comprise 
two types; Forssman and non-Forssman antibodies, IM causes the production of the 
latter which agglutinate horse red blood cells.  Briefly, 25µl of positive control or test 
serum was placed in each of two ovals of a white glass slide.  A drop of guinea pig 
antigen was added to one oval (binding and thus removing Forssman antibodies) and a 
drop of ox antigen (binding and thus removing nonForssman antibodies) was added to 
the other.  A drop of horse cell suspension was added to both ovals and the slide was 
rocked gently.  Agglutination occurring in an oval containing guinea pig antigen but not 
ox antigen was indicative of a positive result. 
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2.13.2 Immunofluorescence for EBV IgG and IgM anti-VCA 
Immunofluorescence for EBV antibodies was carried out f r diagnosis of acute IM. All 
sera were heat-treated prior to testing by incubating for 20 minutes at 56oC.  The test 
serum was diluted with PBS to give the following dilutions: 1:5, 1:10, 1:40, 1:160, 1:640 
and 1:2560.  Dilutions were added to IgG anti-VCA test slides comprising 12 wells of 
2x104 fixed P3HR1 cells.  In addition, 1:10 dilutions were applied to IgM anti-VCA 
slides (ATi Atlas).  The slides were incubated for 1 hour in a humidity chamber at 37oC.  
The slides were then washed twice with PBS for 5 minutes and then 15µl of FITC 
conjugated rabbit anti-human IgG (Dako), diluted 1:50 in PBS, was added per well.  The 
IgM slides were overlayed with 15µl of FITC conjugated rabbit anti-human IgM (Dako), 
diluted 1:50 in PBS.  The slides were then further incubated for 1 hour at room 
temperature in a humidity chamber.  The slides were then washed in PBS twice and 
mounted in PBS:Glycerol.  The slides were read using a  epifluorescent microscope.  
On the IgM anti-VCA a reading at 1:10 was a positive result.  On the IgG anti-VCA, the 
most dilute sample showing positive cells was taken to be the antibody titre. 
2.13.3 Rheumatoid Test 
Serum samples that tested positive for IgM antibody were tested for rheumatoid factor 
activity since this can cross-react with IgM antibodies leading to false positive results 
The MastalexTM RA80 kit was used as per manufacturer’s instructions (Mast 
Diagnostics).  One drop of undiluted serum was applied to the reaction card provided in 
the kit. One drop of latex reagent was added to the undiluted serum and the card was 
gently rocked until agglutination was observed in the positive control. Agglutination of 
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the undiluted serum sample indicated a positive rheumatoid factor reaction, indicating a 
possible false positive result in the IgM anti-VCA immunofluorescence test. 
2.14 Statistical Analysis 
The Mann-Whitney U test was used to test for differences in the medians of quantitative 
variables.  Survival analysis was carried out using the Logrank test for trend.  All tests 
were two-tailed and a P-values < 0.05 were considered significant.  All stati ical 
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3 Results 
3.1 Samples & Donors 
Details of the donors used in this study are shown in tables 3.1 and 3.2. 
3.1.1 Healthy donors 










* Donors recruited from SNBTS and anonymised 
3.1.2 IM Patients 
Table 3.2: IM patient information 
Donor Number Sex Age EBV status 
D1 F 37 seropositive 
D2 M 24 seropositive 
D3 M 27 seropositive 
D4 F 28 seropositive 
D5-53* unknown unknown seropositive 
Number Sex Age Monospot IgM anti VCA Symptom duration 
IM1 F 22 negative positive 2/52 
IM2 M 22 positive positive 2/52 
IM3 M 23 positive positive N/A 
IM4 M 21 positive positive N/A 
IM5 F 25 positive positive N/A 
IM6 F 25 positive positive 2/52 
IM7 M 26 positive positive N/A 
IM8 M 26 positive positive N/A 
IM9 F 24 positive positive 1/52 
IM10 M 24 positive positive 1/52 
IM11 M 23 positive positive 1/52 
IM12 M 23 positive positive 1/52 
IM13 F 21 negative positive N/A 
IM14 F 22 positive positive 1/7 
IM15 F 22 positive positive 3/52 
IM16 M 22 positive positive 1/52 
IM17 F 19 positive positive 3/7 
IM18 F 23 positive positive 3/52 
IM19 M 32 positive positive 2/52 
IM20 M 24 positive positive 1/52 
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Number Sex Age Monospot IgM anti VCA Symptom duration 
IM21 M 22 positive positive N/A* 
IM22 F 21 positive positive N/A* 
IM23 M 21 positive positive 1/52 
IM24 F 22 positive positive 1/52 
IM25 M 22 positive positive 4/7 
IM26 M 27 positive positive N/A* 
IM27 M 24 positive positive 2/52 
IM28 F 20 positive positive 1/52 
IM29 F 23 positive positive 2/52 
IM30 F 21 positive positive 4/7 
IM31 F 22 positive positive 3/52 
IM32 F 24 positive positive 1/12 
IM33 F 24 positive positive 1/52 
IM34 F 25 negative positive 1/52 
IM35 M 27 positive positive 1/52 
IM36 M 23 positive positive 5/7 
IM37 F N/A negative negative Non IM** 
IM38 M 25 positive positive N/A* 
IM39 M 22 positive positive N/A* 
IM40 M 21 positive positive 10/7 
IM41 M 20 positive positive 3/7 
IM42 F 26 positive positive 3/52 
IM43 M 20 negative weak positive N/A* 
IM44 F 17 positive positive 2/52 
IM45 M 23 weak positive negative Non IM** 
IM46 M 23 positive positive 2/7 
IM47 F 19 positive positive 2/52 
IM48 M 22 positive positive N/A* 
IM49 M 21 positive positive N/A* 
IM50 M 18 positive positive 4/7 
IM51 M 19 positive positive 1/12 
IM52 F 24 negative positive N/A* 
IM53 M 19 positive positive 2/52 
IM54 F 26 positive positive 1/52 
IM55 M 24 positive positive 1/52 
IM56 F 19 positive positive N/A* 
IM57 F 22 positive positive 1/52 
IM58 M 25 positive positive 5/7 
IM59† N/A N/A N/A N/A N/A* 
IM60† N/A N/A N/A N/A N/A* 
IM61 M 24 positive positive 5/7 
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Abbreviations: N/A – not available.  * Samples from IM patients with unknown symptom 
duration were not used in cytokine analysis.  ** Samples not used in experimental analysis.  
†only tonsil sections used from these patients.
 
3.2 Role of Regulatory T cells 
3.2.1 Enzyme-Linked Immunosorbent Assay (ELISA) 
Introduction 
Regulatory T cell subgroups have been shown to potentia  their activity via cytokine 
release, in particular IL-10 (Grazia Roncarolo et al, 2006;Battaglia et al, 2006a) and 
TGF-β (Weiner, 2001b).  Analysis of these cytokines has featured highly in Treg 
research, providing indirect evidence for the presence of various subsets of regulatory T 
cells. Assessing the levels of IL-10 and TGF-β1 in plasma collected from IM patients 
and normal healthy controls was the logical starting point for research investigating 
Number Sex Age Monospot IgM anti VCA Symptom duration 
IM62 F 21 positive positive 1/52 
IM63 F 24 positive positive 4/7 
IM64 M 32 positive positive 6/7 
IM65 M 22 positive positive 6/7 
IM66 M 24 positive positive 6/7 
IM67 F 22 positive positive 2/7 
IM68 M 20 positive positive 4/7 
IM69 M 19 positive positive 2/52 
IM70 M 20 positive positive 3/52 
IM71 F 21 positive positive 1/52 
IM72 M 22 positive weak positive 4/52 
IM73 F 23 positive positive 2/52 
IM74 F 21 negative weak positive 2/52 
IM75 M 20 positive positive 2/52 
IM76 F 21 positive positive 2/52 
IM77 F 22 positive positive 3/52 
IM78 F 21 negative positive 3/52 
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whether Treg cells played a role in primary infection with EBV.  Plasma samples were 
grouped as IM patients who had experienced symptoms f r 1 week or less, IM patients 
who had experienced symptoms for over a week and healthy seropositive controls. 
IL-10 and TGF-β1 levels in plasma from healthy controls and IM patients 
Median levels of IL-10 (shown in figure 3.1) were found to be significantly higher 
(p<0.001) in IM patients who had experienced symptos for one week or less (median 
IL-10 71.8pg/ml, range 0 to 290pg/ml) in comparison t  healthy seropositive controls 
(median IL-10 11.3pg/ml, range 0 to 50pg/ml) and IM patients who had experienced 
symptoms for over 1 week (p=0.0112).  IL-10 levels were lower when symptoms had 
been prolonged for over a week (median IL-10 48.43pg/ml, range 0 to 97.2pg/ml), 
although this was still significantly higher than IL-10 levels found in healthy 
seropositive controls (p=0.0028). 
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Figure 3.1: IL-10 concentration (pg/ml) in plasma from IM patients who 
had experienced symptoms for 1 week or less (closed squares), IM patients 
who had experienced symptoms for over 1 week (closed triangles) and 
healthy seropositive controls (open diamonds).  Median indicated by 
horizontal line. 
 
Levels of TGF-β1 (figure 3.2) were compared in the same groups of patients.  In the first 
week of IM symptoms median TGF-β1 levels (median 18.0ng/ml, range 4.4 to 
28.6ng/ml) were significantly higher (p=0.0185) than those found in healthy seropositive 
controls (median 9.3ng/ml, range 0 to 50.8ng/ml).  An even greater statistically 
significant increase in median TGF-β1 level was observed when symptoms had been 
endured for over a week (median 26.9ng/ml, range 9.8 to 41.1ng/ml) in comparison with 
both controls (p=0.0001) and IM patients with symptoms experienced for less than a 
week (p = 0.004).  
Chapter 3   Results: Role of Regulatory T cells 
 79 
























Figure 3.2: TGF-β1 concentration (ng/ml) in plasma from IM patients 
who had experienced symptoms for 1 week or less (clo ed squares), IM 
patients who had experienced symptoms for over 1 week (closed 
triangles) and healthy seropositive controls (open diamonds).  Median 
indicated by horizontal line. 
 
Conclusions 
The significantly higher median level of IL-10 seen in IM patients during the first week 
of symptoms, in comparison with healthy seropositive controls, suggests that Treg 
producing this cytokine as their mediator are present early in IM.  A significantly high 
median level of TGF-β1 is also observed early in IM, which increases further as the 
symptoms persist for over a week, suggesting a role for another subset of regulatory T 
cells, possibly with more emphasis later in infection. 
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3.2.2 FACS analysis 
Introduction 
A strict phenotype has yet to be established for regulatory T cells.  To date, the most 
widely accepted cell-surface markers distinguishing human Treg are CD4 and high levels 
of the IL-2β receptor, CD25 (Baecher-Allan et al, 2001a).  Previous studies looking at 
roles for human Treg in persistent viral infections have found differenc s in the frequency 
of these regulatory cells in the peripheral blood of infected individuals when compared 
with healthy, uninfected controls (Cabrera et al, 2004e;Weiss et al, 2004c;Boettler et al, 
2005d).  The frequency of Treg in the peripheral blood of IM patients was investiga ed 
and compared to healthy controls. 
Frequency of regulatory T cells in healthy controls and IM patients 
PBMC from IM patients and healthy seropositive contr ls were stained with a panel of 
antibodies, shown in table 3.3.  Tubes 1-5 were used as controls to set up the FACS 
analysis.   
Table 3.3: Antibody staining panel used to analyse frequency of regulatory T cells in PBMC 
Tube Number FITC-conjugated antibody PE-conjugated antibody 
1 unstained unstained 
2 IgG2a isotype control - 
3 - IgG2a isotype control 
4 - CD25 
5 CD4 - 
6 CD4 CD25 
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Representative plots from a healthy seropositive control and an IM patient are shown in 
figure 3.3 and figure 3.4, respectively.  Based on their size (forward scatter) and 
granularity (side scatter), PBMC were gated on the lymphocyte population (panel A).  
Dead cells were excluded since they exhibit lower forward and side scatter than live 
cells.  A further gating strategy was applied (panel B), to allow collection of data from 
three populations of T cells; CD4+CD25-, CD4+CD25low and CD4+CD25high.  Figure 3.5 
shows representative results for PBMC stained with CD4 FITC and CD25 PE from a 
healthy seropositive control (A) and an IM patient (B). 
 
Forward and side scatter plots of PBMC from the healt y seropositive control show that 
the PBMC are small with low levels of granularity (figure 3.3, panel A).  In contrast, 
PBMC from IM patients show an altered distribution f cells in the FACS plot with 
increased levels of forward scatter and side scatter (figure 3.4, panel A).  As a 


























































Figure 3.3: FACS analysis of PBMC from a representative healthy seropositive control. 
Lymphocyte gate (A). Further gating was based on expression of CD25 (B). PBMC were stained 
with a panel of antibodies; unstained (B), IgG2a FITC isotype (C), IgG2a PE isotype (D), CD4 
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Figure 3.4: FACS analysis of PBMC from a representative IM patient. Lymphocyte gate (A). 
































Figure 3.5: FACS analysis of representative PBMC from a healthy seropositive control (A) and 
an IM patient (B), stained with CD25 PE and CD4 FITC. 
 




























Figure 3.6: Frequency of CD4+CD25high T cells in acute IM patients (closed squares) and 
healthy seropositive controls (closed triangles) within both the lymphocyte and CD4+ T cell 
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The frequency of CD4+CD25high T cells in PBMC was investigated in 10 healthy 
seropositive controls and 9 IM patients (figure 3.6).  CD4+CD25high T cells were found 
at low frequency in the lymphocyte population of healthy controls (median 0.29%), 
ranging between 0.08-1.17%.  The frequency of these cells was significantly lower 
(p=0.0076) in PBMC from IM patients (median 0.04%) with a range of 0.01-1%.  
However, in acute IM there is a massive expansion of cyt toxic CD8-expressing T cells 
and since FACS measures the percentages of cells and the number of cells collected 
from each gate remains the same, the expanded CD8+ T cells would result in the 
apparent reduced frequency of CD4+ T cells.  Therefore the percentage of CD25high-
expressing cells within the CD4+ T cells was compared between IM and controls (figure 
3.6) since the CD4+ T cells have been shown not to expand in acute IM (Williams et al, 
2005). 
 
The frequency of CD25high-expressing cells within the CD4+ T cells in healthy 
seropositive controls (median 1.94%) ranged between 0.06 and 5.68%.  In IM patients, 
the frequency of CD25high-expressing cells was reduced compared to healthy controls 
(median 0.56%, range 0.24 to 2.18%) with borderline significance (p=0.05). 
Conclusions 
The reduced frequency of CD4+CD25high T cells in the CD4+ population of IM patients, 
when compared with healthy seropositive controls, suggests that these T cells might 
influence the outcome of primary infection with EBV, possibly by allowing the huge 
expansion of EBV-specific CD8+ T cells found in IM patients.  In order to establish 
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more precisely the role these cells play in IM, the function of CD4+CD25high T cells was 
addressed. 
3.2.3 Regulatory T cell enrichment 
Introduction 
CD4+CD25high T cells are found at low frequency in human peripheral blood, limiting 
the number of experiments that can be carried out.  To address this issue, a Treg 
enrichment kit was used to enrich for these particular cells. 
Summary of CD4+CD25high T cell enrichment from 5 healthy controls  
1x108 PBMC from 5 healthy seropositive donors were used to optimise the Treg 
enrichment procedure (see Materials and Methods, section 2.9).  The Miltenyi Biotec 
Treg Isolation kit uses a negative selection step, resulting in unmanipulated CD4
+ T cell 
enrichment, followed by a positive selection based on CD25high expression.  At each step 
a portion of cells were removed for FACS analysis and stained for CD4 and CD25 
expression, as previously described (see R sults, section 3.2.2).  This provided a set of 
data for each of the following; unseparated PBMC, CD4- cells, CD4+ T cells, 
CD4+CD25- T cells and CD4+CD25+ T cells.  A representative FACS plot for each cell















































Figure 3.7: Representative FACS analysis for CD4+CD25+ T cell frequency at each step of the 
Treg enrichment procedure from a healthy seropositive donor.  Unseparated PBMC (B), CD4-
depleted cells (C), CD4-enriched cells (D), CD4+CD25- T cells (E) and CD4+CD25+ T cells (F) 
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In addition, the CD4+CD25+-enriched T cell population of each donor was analysed for 
purity and percentage recovery (i.e. number of enriched Treg).  The mean percentage 
purity of CD4+CD25high T cells was 79.18% and the mean number of enriched ells was 
5.36x105 cells. Individual data are shown in table 3.4 for each of the 5 donors.  Due to 
restrictions in cell numbers this experiment could not be carried out on cells from IM 
patients. 
 




T cell purity % 
number of CD4+CD25high T 
cells enriched % recovery 
D14 69.61 4x105  0.40 
D15 94.15 4.2x105  0.42 
D16 68.13 2.8x105  0.28 
D17 87.25 7x105  0.70 
D18 76.77 8.8x105  0.88 
 
3.2.4 Proliferation Assays 
Introduction 
Proliferation assays were employed to measure the effect of enriched CD4+CD25+ T 
cells on cell populations activated by a variety of stimulants.  Thymidine incorporation 
is the most widely used assay to measure cell prolife at on.  However, the CMV 
laboratory does not support the equipment required for this procedure hence an 
alternative measure of proliferation was sought.  
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MTT proliferation 
In order to establish the best density of cells to use for this assay, doubling dilutions 
from 5x106 to 5x103/200µl well of 2 established lymphoblastoid cell lines (LCL) were 
used.  Figure 3.8 shows the mean absorbance for two LCL lines at different cell densities 
incubated for 24 hours.  Cell proliferation increasd as the cell density increased, as 
evidenced by the rise in mean absorbance.  The peak absorbance is 0.75 for both cell 
lines as stated.  



















Figure 3.8: Mean absorbance of established LCL 95 (closed squares) and LCL 28 (closed 
triangles) at different cell densities using MTT ass y.  
 
Serial dilutions of PBMC, ranging from 5x106 to 5x103/200µl, from 2 donors were 
either cultured alone or stimulated with PHA at 1µg/ml or 10µg/ml for 24 hours in order 
to establish how well the assay worked when using this cell type.  Results are shown in 
figure 3.9.  Mean absorbance increased over a range from 0 to 0.55, as cell density 
increased.  PBMC from donor 23 had a maximum absorbance of 0.55 when PBMC were 
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stimulated with 1µg/ml PHA and seeded at 5x106 cells/well, whereas PBMC from donor 
24 gave a maximum absorbance reading of 0.019 under the same experimental 
conditions.  Untreated PBMC from both donors (mean absorbance 0.53 and 0.16 for 
D23 and D24, respectively) proliferated as well as PBMC stimulated with 1µg/ml and 
10µg/ml PHA. 








D23 PBMC + 1µg/ml PHA
D24 PBMC + 1µg/ml PHA
D23 PBMC + 10µg/ml PHA












Figure 3.9: Mean absorbance of healthy control peripheral blood m nonuclear cells from donor 
23 (closed symbols) and 24 (open symbols).  Untreated (squares), stimulated with 1µg/ml PHA 
(triangles) or 10µg/ml PHA (circles) using MTT assay. 
 
The low level of proliferation observed for both donors, even when PBMC were 
stimulated with high concentrations of PHA, indicated that the assay was not sensitive 
enough.  The assay was to be used for the investigation of human CD4+CD25high T cell 
function and since these cells are found at low frequency in the peripheral blood, the 
insensitivity would be a problem and so an alternative proliferation assay was sought. 
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BrdU proliferation 
The BrdU proliferation assay works on the principle that BrdU (a synthetic thymidine 
analogue) is incorporated directly into the cell’s DNA, which is then recognised by an 
anti-BrdU antibody.  Similar to the MTT assay, a sub trate is added and coloured 
reaction is observed which can be read on a microplate reader.  Absorbance is 
proportional to cell proliferation (see Materials and Methods, section 2.12.2).  
 
The BrdU proliferation assay was tested on 2 establi hed LCL.  10-fold dilutions from 
1x105 to 1x102 cells/100µl well were set up and incubated for 24 hours prior to the 
addition of BrdU, whereupon the cells were incubated for a further 24 hours.  Results are 
shown in figure 3.10. 
 
Both LCL proliferated at 1x103 (mean absorbance 0.15 and 0.19 for LCL 48 and 117, 
respectively) and 1x104 cells/well (mean absorbance 1.86 and 0.97 for LCL 48 and 117, 
respectively) with maximum absorbance readings occurring when LCL were plated at 
1x105 cells/well (mean absorbance 2.02 and 1.54 for LCL 48 and 117, respectively).  
The maximum mean absorbance of 2.02 in the BrdU assay compared with 0.75 in the 
MTT assay, suggesting that the BrdU assay is the more sensitive of the two assays.  In 
addition, cells had to be plated at 5x106 cells/well in the MTT assay to give maximum 
proliferation whereas in the BrdU assay, the cells could be plated at the lower density of 
1x105 cells/well to give maximum proliferation. 
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Figure 3.10: Mean absorbance of LCL 48 (squares) and LCL 117 (triangles) at different 
densities using BrdU assay.  Bars indicate standard eviation. 
 
Next, PBMC were set up in doubling dilutions ranging from 2x105 to 1x104 cells/well.  
Each density of cells was stimulated with 1, 5 or 10µg/ml PHA or left untreated and 
incubated for 24, 48, 72, 96 or 120 hours.  Untreated PBMC provided a baseline mean 
absorbance and this was subtracted from the absorbance observed when PBMC were 
stimulated with PHA.  Figure 3.11 shows the results for this optimisation. 
 
No significant proliferation was observed when PBMC were treated with 1µg/ml PHA 
(figure 3.11A).  An increase of PHA concentration t 5µg/ml resulted in a slight increase 
in proliferation, with a peak mean absorbance of 0.33 when PBMC were plated at 5x104 
cells/well and incubated for 96 hours (figure 3.11B). 
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1µ g/ml PHA






































































Figure 3.11: Mean absorbance of PBMC stimulated for 24 (squares), 48 (up triangles), 72 
(down triangles), 96 (diamonds) or 120 (circles) hours of incubation with PHA at 1µg/ml (A), 
5µg/ml (B) or 10µg/ml (C).  Bars indicate standard deviation. 
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A further increase in PHA concentration to 10µg/ml resulted in a high level of 
proliferation for incubation periods of 72, 96 and 120 hours, with peak mean absorbance 
values of 0.64, 0.84 and 0.48, respectively.  Similar proliferation was observed when the 
incubation time was 24 or 48 hours with a peak mean absorbance of 0.09 when cells 
were plated at 2x105 cells/well.  The optimal conditions under which the ighest 
proliferation rate of 0.84 occurred when PBMC were plated at 1x105 cells/well and 
incubated for 96 hours (figure 3.11C).  This assay g ve better results when using lower 
cell numbers than the MTT assay and hence the BrdU assay was used for the remainder 
of the proliferation experiments. 
 
In order to examine the possibility that the FCS in culture medium could stimulate 
PBMC, another optimising experiment was set up. PBMC were either stimulated with 
PHA at 10µg/ml in TCM 10% or resuspended in TCM containing 5 or 10% FCS and 
proliferation was measured in triplicate wells at 48, 96 and 144 hours of incubation.  
Figure 3.12 shows results for this experiment. 
 
PBMC incubated for 48 hours proliferated only when stimulated with 10µg/ml PHA 
(figure 3.12A) with a maximum mean absorbance of 1.51 when cells were seeded at 
1x105 cells/well.  PBMC treated with 5% FCS and 10% FCS for 48 hours displayed low 
proliferative responses, with peak mean absorbance values of 0.105 and 0.103, 
respectively, occurring when cells were plated at 2x105 cells/well. 
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48 hours





























































Figure 3.12: Mean absorbance of PBMC treated with 5% FCS (closed squares), 10% FCS 
(closed triangles) or 10µg/ml PHA (open circles) for 48 (A), 96 (B) or 144 (C) hours of 
incubation.  Bars indicate standard error. 
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At 96 hours post-treatment, PBMC treated with 5% FCS demonstrated increased 
proliferation with a maximum mean absorbance of 0.401 when cells were seeded at 
2x105 cells/well.  Similarly, PBMC treated with 10% FCS increased proliferation with a 
peak absorbance of 0.619 under the same experimental co ditions.  PBMC treated with 
10µg/ml PHA demonstrated optimal proliferation at all cell densities, with a peak mean 
absorbance of 1.803 when cells were seeded at 1x105 cells/well.  This is an approximate 
4.5-fold increase compared to proliferation observed with either of the FCS treatments 
(figure 3.12B).  By 144 hours of stimulation, increas s in proliferation were observed 
when PBMC were treated with 5% FCS (mean absorbance 0.889) and 10% FCS (mean 
absorbance 1.004) when cells were plated at 1x105 cells/well.  Treatment of PBMC with 
PHA under the same experimental conditions resulted in a reduced level of proliferation 
in comparison to 48 and 96 hour incubation, with a pe k mean absorbance of 0.548 
(figure 3.12C). 
 
Having established the criteria for proliferation of PBMC stimulated with PHA and 
determined that FCS contributes to proliferation not before but only when incubated for 
120 hours, the next step was to optimise the conditi s for measuring proliferation when 
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72 hours

















































Figure 3.13: Mean absorbance of PBMC in response to stimulation with 5µg/ml (closed 
squares), 10µg/ml (up closed triangles) or 20µg/ml (down close triangles) plate-bound anti-CD3, 
10µg/ml PHA (open circles) or left untreated (close circles) for 72 (A) or 96 (B) hours of 
incubation. Bars indicate standard error. 
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PBMC were set up in doubling dilutions ranging from 2x105 to 1x104 cells/well and 
stimulated with plate-bound anti-CD3 at 5, 10 or 20µg/ml for 72 and 96 hours of 
incubation and proliferation measured in triplicate.  Stimulation of PBMC with 10µg/ml 
PHA was used as the positive control whereas untreated PBMC acted as the negative 
control.  Figure 3.13 shows the results of this experiment.  
 
At 72 hours of incubation, untreated PBMC proliferat d to a very low level at every cell 
density, with a maximum mean absorbance of 0.511 when plated at 2x105 cells/well.  
When stimulated with PHA at 10µg/ml for 72 hours, proliferation increased, in 
comparison to untreated PBMC, at every cell density w h a peak mean absorbance of 
1.399 when cells were plated at 1x105 cells/well.  PBMC stimulated with 5µg/ml anti-
CD3 for 72 hours proliferated at high levels, with the peak mean absorbance values of 
1.781 and 1.870 observed when cells were plated at 1x105 and 5x104 cells/well, 
respectively. This level of proliferation was also observed when the concentration of 
anti-CD3 was increased to 10µg/ml (mean absorbance 1.925 and 1.906, respectively) 
and 20µg/ml (mean absorbance 1.936 and 1.759, respectively) and the incubation period 
kept constant (figure 3.13A). 
 
Similarly, untreated PBMC proliferated to a very low level at every cell density when 
incubated for 96 hours with a peak mean absorbance of 0.49 when cells were plated at 
1x105 cells/well.  High levels of proliferation were observ d when PBMC were 
stimulated with PHA at 10µg/ml for 96 hours, peaking at 1.378 when cells were plated 
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at 1x105 cells/well.  PBMC proliferated equally well when stimulated with 5, 10 or 20 
µg/ml anti-CD3, with a maximum mean absorbencies of 2.183, 2.521 and 2.125, 
respectively, when plated at 5x104 cells/well (figure 3.13B). 
 
Since equal levels of proliferation were observed when anti-CD3 was used at 5, 10 and 
20µg/ml, a similar experiment was set up using lower concentrations of anti-CD3.  
Figure 3.14 shows results for PBMC proliferating in response to 0.5, 1 and 2µg/ml anti-
CD3, 10µg/ml PHA or left untreated, for incubation periods of 72, 96 and 144 hours. 
 
Unstimulated PBMC proliferated poorly when incubated for 48 or 96 hours, with mean 
absorbance values of 0.278 and 0.464, respectively, when plated at 2x105 cells/well 
(figure 3.14A and 3.14B).  Peak mean absorbance increased to 0.823 when untreated 
PBMC at 2x105 cells/well were incubated for 144 hours (figure 3.14C).  PBMC 
stimulated with 10µg/ml PHA proliferated well at 48, 96 and 144 hours of incubation 
with maximum mean absorbance values of 0.571, 1.689 and 1.154, respectively, when 
plated at 2x105 cells/well (figure 3.14B and 3.14C). 
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Figure 3.14: Mean absorbance of PBMC in response to stimulation with anti-CD3 at 2µg/ml 
(closed squares), 1µg/ml (up closed triangles) or 0.5µg/ml (down closed triangles) or 10µg/ml 
PHA (open circles) or untreated (closed circles) for 48 (A), 96 (B) or 144 (C) hours of 
incubation.  Bars indicate standard error. 
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PBMC stimulated with 0.5µg/ml anti-CD3 had a low maximum mean absorbance of 
0.202 at 48 hours post-stimulation when plated at 2x105 cells/well (figure 3.14A).  
However, this concentration of anti-CD3 did result in better proliferation with peak 
mean absorbance values of 2.195 and 2.038 when cells w re plated at 1x105 cells/well 
and the incubation period was extended to 96 and 144 hours, respectively (figures 3.14B 
and 3.14C).  An increase in anti-CD3 concentration o 1µg/ml resulted in an increased 
peak mean absorbance values of 1.673 with cells at 2x105 cells/well at the 48 hour point, 
2.449 at the 96 hour point and 2.346 when cells were at 1x105 cells/well and incubated 
for 144 hours.  Treatment of PBMC with anti-CD3 at 2µg/ml resulted in peak 
absorbencies of 2.254 (48 hours), 2.963 (96 hours) and 1.999 (144 hours) when cells 
were at 1x105 cells/well (figures 3.14A-C). 
 
These optimisation assays were carried out in order to stablish the ideal experimental 
conditions to measure the proliferative response of PBMC when stimulated with anti-
CD3.  The incubation period was chosen to be 96 hours with cells plated at 1x105 
cells/well.  The concentration of anti-CD3 was chosen to be 5µg/ml and, as a positive 
control, PHA would be used at 10µg/ml.  
Suppression Assay in 3 healthy controls 
In order to investigate whether cells isolated using the Treg enrichment procedure (see 
Materials and Methods, section 2.9) had regulatory function, a suppression assay was set 
up on 3 healthy seropositive controls.  Cells from these donors were separated into 
fractions; unseparated PBMC, CD4+CD25- T cells, CD4+CD25+ T cells and recombined 
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cocultures of CD4+CD25- T cells and CD4+CD25+ T cells.  These fractions were 
cultured at 1x105 cells per well in 200µl of TCM 10%, stimulated with either 5µg/ml 
plate-bound anti-CD3 or left untreated, for 5 days.  If cell numbers permitted, the same 
cell fractions were also stimulated with 10µg/ml PHA.  After 5 days of incubation, cell 
proliferation was measured using the BrdU assay and mean absorbance, proportional to 
cell proliferation, was established using triplicate values. 
 
Figure 3.15 shows the response of cell fractions from 3 seropositive donors to 5µg/ml 
anti-CD3 stimulation for the incubation period of 96 hours.  Unseparated PBMC 
proliferated to a high level, with a mean absorbance of 2.84.  The CD4+CD25- T cells 
demonstrated relatively high levels of proliferation with a mean absorbance of 1.24, 
albeit to a lesser extent than the PBMC fraction.  Proliferation of CD4+CD25+ T cells 
was reduced (mean absorbance 0.24) in comparison with PBMC and CD4+CD25- T 
cells.  Furthermore, the addition of CD4+CD25+ T cells to the CD4+CD25- T cells 
reduced their proliferative response, resulting in a mean absorbance of 0.43.  Statistical 
analysis was not possible since the numbers in each group were too small. 









































Figure 3.15: Proliferation of cell populations, from 3 seropositive donors (D27, D28 and D29) 
run in triplicate, in response to stimulation with 5µg/ml plate-bound anti-CD3 for an incubation 
period of 96 hours. Horizontal bars indicate mean. 
 
Conclusions 
The CD4+CD25+ T cells are poor at proliferation, even in the presence of anti-CD3 
antibodies.  Furthermore, coculture of CD4+CD25+ T cells with CD4+CD25- T cells 
results in reduced proliferation by the latter cell population.  Hence CD4+CD25+ T cells, 
enriched from healthy seropositive donors, are functio ally capable of suppressing 
proliferation of other cell populations.  Due to restrictions in cell number this experiment 
could not be carried out on cell fractions from IM patients. 




After establishing that CD4+CD25+ T cells, enriched from healthy seropositive controls, 
were capable of suppressing the proliferation of other cell fractions in culture, the next 
step was to see whether these cells were capable of affecting the response of PBMC to 
stimulation with EBV-specific antigens.  The IFN-γ ELISPOT measures IFN-γ released 
by cells, which is then bound by anti-IFN-γ antibody, visualised, and subsequently read 
using an ELISPOT plate reader.  This was the assay elected to evaluate whether PBMC 
responses to EBV antigens are altered by the addition or removal of CD4+CD25+ Treg 
(see Materials and Methods, section 2.9) 
Optimising the IFN-γ ELISPOT assay with LCL 
Initially LCL were chosen to stimulate PBMC since th y express all latent EBV antigens 
(Kieff & Rickinson, 2001).  In order to establish te experimental conditions required 
for a successful assay, PBMC and LCL were optimised for cell density and stimulation 
ratio. 
 
LCL and PBMC were cocultured for 48 hours in U-bottomed 96-well plates in volumes 
of 100µl in duplicate (at ratios and cell densities of PBMC shown in table 3.5) and the 
ELISPOT assay was carried out as previously described (Materials and Methods, 
section 2.10).  The experiment was carried out using healthy seropositive control PBMC 
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(D30) and PBMC from an IM patient (IM9).  LCL were established whilst PBMC were 
stored in liquid nitrogen. 
 
Table 3.5: Combinations of lymphoblastoid cells and peripheral blood mononuclear cells 
used to optimise the IFN-γ ELISPOT assay 
Peripheral blood mononuclear cell density/50µl lymphoblastoid 
cell lines 
density/50µl 1:1 1:2 1:5 1:10 1:20 
1x105 1x105 2x105 5x105 1x106 2x106 
1x104 1x104 2x104 5x104 1x105 2x105 
1x103 1x103 2x103 5x103 1x104 2x104 
 
 
Figure 3.16A shows results for the healthy seropositive control.  When LCL were used 
at a density of 1x105, mean SFC/million PBMC was 1845, 1468, 561, 184 and 52 as the 
ratio of PBMC:LCL increased from 1:1 to 20:1, respectively.  Overall range was 
between 0 and 1980 SFC/million PBMC.  Reducing the density of LCL to 1x104/well 
resulted in an increased mean SFC/million PBMC at each ratio, from 1:1 to 20:1 of 
2700, 1575, 920, 605 and 558, respectively and an increase in variation to a range of 
between 430 to 3640 SFC/million PBMC.  A further reduction in LCL density to 
1x103/well had different effects at each ratio, resulting in an increase in mean 
SFC/million PBMC at some ratios and a decrease in others: 3250, 3750, 720, 150 and 
325 (from 1:1 to 20:1, respectively).  The greatest variation in IFN-γ production 
occurred when LCL were used at 1x103/well, where the results ranged from 0 to 6660 
SFC/million PBMC. 
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Figure 3.16: IFN-γ ELISPOT results for healthy seropositive control D30 (A) and IM patient, 
IM9 (B).  PBMC stimulated with LCL at 1x105 (squares), 1x104 (upward triangles) or 1x103 
(downward triangles) per well.  Bars indicate standard error. 
 
The IFN-γ response seen in IM patients is shown in figure 3.16B   When LCL were used 
at a density of 1x105, mean SFC/million PBMC was 2615, 1338, 251, 69 and 0 as the 
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ratio increased from 1:1 to 20:1, respectively, showing a similar trend to the healthy 
seropositive control.  The range at this LCL density was between 0 and 2730 
SFC/million PBMC. 
 
When LCL were used at a density of 1x104 LCL, the mean SFC/million PBMC of 
11350, 5625, 4210, 1450 and 325 at each ratio was increased in comparison to the 
healthy control, as was the variation, with an increased range of between 935 and11500 
SFC/million PBMC.  At a density of 1x103 LCL, mean SFC/million PBMC at each ratio 
was 500, 1000, 300, 350 and 325, respectively.  These r sults are similar to the healthy 
control since there appears to be no particular trend.  Range was reduced in comparison 
to the control at this density of LCL, ranging from 0 to 1000 SFC/million PBMC. 
 
As a result of this experiment the conditions chosen for all future experiments were that 
LCL, at a density of 1x104/well, would be used to stimulate doubling dilutions of PBMC 
ranging from 1x105 to 1.25x104/well. 
 
Initially it was intended that PBMC from IM patients and healthy controls would be  in 
liquid nitrogen whilst LCL were developed. When the LCL had been grown up, the 
PBMC would be revived and separated into two portions; PBMC with CD4+CD25+ T 
cells and PBMC without CD4+CD25+ T cells.  Both cultures would then be stimulated 
with LCL and their response measured using the IFN-γ ELISPOT.  To this end, LCL 
were established for 10 IM patients and 10 healthy seropositive controls.  However, the 
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process of freezing samples from IM patients considerably reduced the number of viable 
PBMC revived.  It was therefore decided to use an alternative approach to assess the 
effect of CD4+CD25+ T cells on PBMC stimulated with EBV antigens that could be 
carried out on fresh IM samples. 
 
Figure 3.17: Flow cytometry staining 
for HLA A2 status on PBMC 
homozygous for HLA A2 (A), PBMC 
heterozygous for HLA A2 (B) and non-
HLA A2 PBMC (C), showing unstained 
PBMC (red), isotype control stained 
PBMC (green) and HLA A2 stained 
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The next option was to use EBV peptides to stimulate PBMC.  This required HLA 
typing of PBMC since the peptides are HLA restricted.  It was decided to use HLA A2 
positive donors since it occurs in 40-50% of the population worldwide (Mahdavi & 
Monk, 2005a;Botten et al, 2007b).  Figure 3.17 shows results for HLA A2 staining on an 
A2 homozygous PBMC, an A2 heterozygous PBMC and a non-A2 PBMC. 
 
Once this technique was established on PBMC with known HLA A2 expression, HLA 
staining was carried out on all IM samples and healt y controls.  The HLA A2 positive 
donors were used for further experiments. 
Optimising the IFN-γ ELISPOT assay with peptides 
PBMC from an EBV-positive HLA A2 heterozygous donor (D4) were set up at 2x105 
cells/well, 1x105 cells/well and 5x104 cells/well and treated with one of the following 
peptides; GLC, SVR or QAK at 5µg/ml and 10µg/ml, PHA at 1µg/ml or left untreated, 
and incubated for 48 hours (See Materials and Methods, section 2.10.3 for more details).  
The ELISPOT assay was then run and IFN-γ spots counted.  Figure 3.18 shows the 
results of this optimisation.   
 
The mean IFN-γ response by untreated PBMC peaked at 20 SFC/million PBMC when 
cells were plated at 1x105 cells/well.  The total range of SFC/million for all cell densities 
ranged from 0 to 50 SFC/million PBMC (figure 3.18A). 
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Figure 3.18: IFN-γ ELISPOT results for PBMC from a HLA A2 donor stimulated with peptides 
GLC (closed squares), SVR (closed up triangles) or QAK (closed down triangles), 1µg/ml PHA 
(open circles) or left untreated (closed circles).  Peptides were used at 5µg/ml (A) or 10µg/ml 
(B).  Bars indicate standard error. 
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A mean SFC/million PBMC of 13.3 was observed for PBMC treated with 5µg/ml of the 
non-A2 peptide, QAK, with a density of 5x105 cells/well (figure 3.18A).  The overall 
range for treatment with QAK was between 0 and 40 SFC/million PBMC.  When QAK 
was used at 10µg/ml an increased mean SFC/million PBMC of 55 was observed at a cell 
density of 2x105 cells/well (figure 3.18B).  Total range for all cell densities ranged 
between 0 to 95 SFC/million PBMC. 
 
Treatment with 1µg/ml PHA did not increase the IFN-γ release (peak mean SFC/million 
PBMC of 23.3 when cells were at a density of 1x105 cells/well) and since this was to act 
as the positive control, the higher concentration of 5µg/ml was used in future ELISPOT 
assays.  Overall, the results from PHA-treated PBMC ranged from 0 to 40 SFC/million 
PBMC, with higher responses observed at densities of 1x105 cells/well (mean 
SFC/million PBMC 23.3) in comparison with cell densities of 2x105 cells/well and 
5x105 cells/well, mean SFC/million PBMC 18 and 2, respectiv ly (figure 3.18A). 
 
A low level of IFN-γ was released in response to 5µg/ml SVR (mean SFC/million 
PBMC 13.3) at densities of 1x105 and 2x105 cells/well.  Very little response was 
observed when cell density was increased to 5x105 cells/well (mean SFC/million PBMC 
0.67).  Results ranged from 0 to 30 SFC/million PBMC for all cell densities (figure 
3.18A).  On increasing the SVR to 10µg/ml, the IFN-γ response was slightly increased, 
with peak mean SFC/million PBMC of 16.7 was observed when cells were at 1x105 
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cells/well.  However, the overall range of data remained similar to treatment with SVR 
at 5µg/ml, from 0 to 35 SFC/million PBMC (figure 3.18B). 
 
High levels of IFN-γ were released in response to 5µg/ml GLC at densitis of 1x105 and 
2x105 cells/well (mean SFC/million PBMC 43.3 and 41.7, resp ctively).  Some response 
was observed when cell density was increased to 5x105 cells/well (mean SFC/million 
PBMC 18) but not to the same extent as lower cell densities.  Results ranged from 0 to 
65 SFC/million PBMC for all cell densities (figure 3.18A).  Increasing the GLC 
concentration to 10µg/ml increased the response, with maximum mean SFC/million 
PBMC of 123.3, 103.3 and 48.7 being recorded when cells were at 1x105, 2x105 and 
5x105 cells/well, respectively.  The overall range also increased, ranging from 0 to 150 
SFC/million PBMC (figure 3.18B). 
 
Since GLC induced a high IFN-γ response, experimental conditions were established 
with regards to this peptide.  The higher concentration of 10µg/ml of peptide was opted 
for since it provoked a higher IFN-γ response to GLC (mean SFC/million PBMC 103.3).  
1µg/ml PHA did not induce an IFN-γ response so the concentration was increased to 
5µg/ml in all future experiments.  IFN-γ release reduced when PBMC density was 
increased from 2x105 to 5x105 (SFC/million PBMC 103.3 and 48.7, respectively) so the 
lower of the two cell densities was used. 
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ELISPOT results with & without Treg for 8 healthy controls 
HLA A2 positive healthy seropositive donors were used as controls for the IFN-γ 
ELISPOT assay and were provided by a frozen bank of PBMC already established in the 
research group.  Once revived, all donor PBMC were subjected to the Treg enrichment 
procedure.  The Treg-depleted PBMC were then separated into two samples and half of 
the enriched CD4+CD25+ T cells were added back to one sample.  The IFN-γ ELISPOT 
was then set up using the following fractions: Treg-depleted PBMC with CD4
+CD25+ T 
cells and PBMC without CD4+CD25+ T cells.  HLA information on each of the 8 donors 
is shown in table 3.6.  
 
Table 3.6: Information on healthy seropositive donors used as controls in the 
IFN-γ ELISPOT assays 




D8 A2- A11 
D9 A2- A3 
D10 A2-A28 
D11 A2- A11 
D12 A2- A2 
 
Figure 3.19 shows the IFN-γ response by all donor PBMC if left untreated (panel A) or 
in response to stimulation with QAK (panel B), PHA (panel C), SVR (panel D), LLD 
(panel E) or GLC (panel F).  PHA was used at 5µg/ml and all peptides were used at 
10µg/ml. 
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Figure 3.19: IFN-γ ELISPOT results for 8 healthy seropositive PBMC cultures in the presence 
(closed squares) or absence (closed triangles) of Treg, left untreated (A), QAK (B), 5µg/ml PHA 
(C), SVR (D), LLD (E) or GLC (F).  Horizontal bars indicate the median SFC/million PBMC. 
none
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Untreated PBMC released a low level of background IFN-γ, with a range of results 
between 0 and 56.7 SFC/million PBMC.  Comparing the pr sence of Treg (median 
SFC/million PBMC 13.4) to Treg absence (median SFC/million PBMC 15), no 
significant difference was observed (p=0.645).  PBMC stimulated with QAK, the non-
A2 peptide, had a range of 0 to 30 SFC/million PBMC.  The presence of Treg (median 
SFC/million PBMC 5) or absence of Treg (median SFC/million PBMC 5.8) did not 
significantly affect IFN-γ release (p=0.798).  PBMC treated with PHA resulted in the 
largest IFN-γ response with a result range between 148.3 to 2201.7 SFC/million PBMC.  
No significant difference was observed (p=0.798) betwe n PBMC with Treg (median 
SFC/million PBMC 793.4) and PBMC without Treg (median SFC/million PBMC 745.9). 
 
No significant difference was observed when PBMC were stimulated with SVR 
(p=0.798), with low levels of IFN-γ produced by both cultures containing Treg (median 
SFC/million PBMC 8.35) and lacking Treg (median SFC/million PBMC 9.2).  Results 
ranged from 0 to 41.7 SFC/million PBMC.  Stimulation with LLD resulted in a slight 
difference in IFN-γ response, albeit not significant (p=0.654), between cultures 
containing Treg (median SFC/million PBMC 25) and those lacking Treg (median 
SFC/million PBMC 13.3).  The results ranged between 0 a d 46.7 SFC/million PBMC. 
 
In the absence of Treg, PBMC released an increased level of IFN-γ in response to GLC 
when compared to cultures containing Treg (median SFC/million PBMC 45.85 and 
21.65, respectively) although this was not significant (p=0.699).  Results ranged between 
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0 and 146.7 SFC/million PBMC (figure 3.19).  A summary of the data displayed in 
figure 3.19 is shown in figure 3.21. 
ELISPOT results with & without Treg for 7 IM patients 
Figure 3.20 shows the IFN-γ response by PBMC from IM patients if left untreated 
(panel A) or in response to stimulation with QAK (panel B), PHA (panel C), SVR (panel 
D), LLD (panel E) or GLC (panel F).  PHA was used at 5µg/ml and all peptides were 
used at 10µg/ml.   
 
A low background level of IFN-γ was released by untreated PBMC, with a range of data 
between 1.7 and 48.3 SFC/million PBMC.  No significant difference was observed 
(p=0.710) when Treg presence (median SFC/million PBMC 13.3) was compared to Treg 
absence (median SFC/million PBMC 8.3).  Stimulation of PBMC with the non-A2 
peptide, QAK, also resulted in a low level of response with a result range of 0 to 42.5 
SFC/million PBMC.  IFN-γ production was not significantly affected (p=0.318) by the 
presence (median SFC/million PBMC 5) or absence of Treg (median SFC/million PBMC 
6.7).  PBMC treated with PHA resulted in the same high IFN-γ response from both 
culture with and without Treg (median SFC/million PBMC 66.7) with no significant 
difference (p=1).  The result range for this treatment was 16.7 to 881.7 SFC/million 
PBMC. 
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Figure 3.20: IFN-γ ELISPOT results for 7 IM patient PBMC cultures in the presence (closed 
squares) or absence (closed triangles) of Treg, left untreated (A), QAK (B), 5µg/ml PHA (C), 
SVR (D), LLD (E) or GLC (F).  Horizontal bars indicate the median SFC/million PBMC.   
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Equally low levels of IFN-γ were produced by PBMC with and without Treg (median 
SFC/million PBMC 5) when stimulated with SVR, with no significant difference 
observed (p=0.535).  The range of results was 0 to 65 SFC/million PBMC.  LLD 
stimulation of PBMC resulted in a low, non-significant response (p=0.383) by both 
cultures containing Treg (median SFC/million PBMC 5) and those lacking Treg (median 
SFC/million PBMC 6.7), with a result range of 0 to 33.3 SFC/million PBMC.  In 
response to GLC stimulation, an increased IFN-γ response was observed in PBMC 
lacking Treg when compared to cultures containing Treg (median SFC/million PBMC 
46.7 and 18.3, respectively) although this was not significant (p=0.805).  Results ranged 
between 0 and 168.3 SFC/million PBMC.  A summary of the data displayed in figure 




















































Figure 3.21: Combined IFN-γ ELISPOT results for 8 healthy seropositive PBMC cultures in the 
presence (light grey) or absence (dark grey) of Treg, left untreated or stimulated with 10µg/ml of 
peptide; QAK, SVR, LLD or GLC (A) or 5µg/ml PHA (B).  Bars represent standard error. 





















































Figure 3.22: Combined IFN-γ ELISPOT results for 7 IM patient PBMC cultures in the presence 
(light grey) or absence (dark grey) of Treg, left untreated or stimulated with 10µg/ml of peptide; 
QAK, SVR, LLD or GLC (A) or 5µg/ml PHA (B).  Bars represent standard error. 
 
Comparing the response of untreated PBMC in the presence of Treg from healthy 
seropositive controls and IM patients reveals a similar level of IFN-γ production 
(median SFC/million PBMC 13.4 and 13.3, respectively, p=0.78).  This was also 
observed in cultures lacking Treg (median SFC/million PBMC 15 and 8.3, respectively, 
p=0.28). 
 
IFN-γ production by PBMC with Treg stimulated with QAK did not vary between 
healthy controls and IM patients (median SFC/million PBMC 5 and 5, respectively, 
p=0.87) or in cultures lacking Treg (median SFC/million PBMC 5.8 and 6.7, respectively, 
p=0.46). 
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Stimulation of PBMC with PHA in the presence of Treg resulted in a significantly higher 
IFN-γ response in healthy seropositive controls (median SFC/million PBMC 793.4) than 
the same culture in IM patients (median SFC/million PBMC 66.7, p=0.009).  Similarly, 
PBMC stimulated with PHA in the absence of Treg resulted in a significantly higher 
production of IFN-γ in healthy seropositive controls (median SFC/million 745.9) than 
PBMC without Treg from IM patients (median SFC/million PBMC 66.7, p=0.009). 
 
Equally low levels of IFN-γ production were observed by PBMC from healthy 
seropositive controls and IM patients, with (median SFC/million PBMC 8.35 and 9.2, 
respectively) and without Treg (median SFC/million PBMC 5 and 5, respectively) in 
response to stimulation with SVR (with Treg p=0.19 and without Treg p= 0.87). 
 
Stimulation of PBMC with LLD in cultures containing Treg resulted in a significantly 
increased response (p=0.04) in healthy seropositive controls (median SFC/million 
PBMC 25) when compared with IM patients (median SFC/million PBMC 5).  No 
significant difference in IFN-γ production was observed in cultures lacking Treg from 
either sample group (median SFC/million PBMC in healthy seropositive controls 13.3 
and IM patients 6.7, p=0.78). 
 
Comparing IFN-γ production in cultures containing Treg between healthy seropositive 
controls and IM patients stimulated with GLC revealed no significant differences 
(median SFC/million PBMC 21.65 and 18.3, respectively, p=1).  Similar results were 
Chapter 3   Results: Role of Regulatory T cells 
 121 
observed in cultures lacking Treg (SFC/million PBMC 45.85 and 46.7, respectively, 
p=0.73). 
Conclusions 
The removal of CD4+CD25+ T cells from PBMC did not significantly alter the 
production of IFN-γ in response to stimulation with PHA or HLA A2-restric ed peptides 
derived from EBV antigens.  PHA and LLD responses were significantly lower in IM 
patients than healthy controls but were unaffected by the presence or absence of Treg. 
3.2.6 FOXP3 Staining 
Introduction 
To date one of the most specific markers for Treg is the expression of FOXP3, a 
transcriptional factor involved in the generation ad function of regulatory T cells 
(reviewed in Campbell & Ziegler, 2007a;Kim & Rudensky, 2006).  The expression of 
this marker was assessed to provide further evidence that the population of cells used in 
the experiments were conventional regulatory T cells.  
Optimisation of FOXP3 staining in Tonsil sections 
Published work on FOXP3 staining used tonsil sections as control material since Treg 
expressing this marker are almost always found in this lymphoid tissue (Roncador et al, 
2005).  Negative controls consisted of replacing the primary or a combination of primary 
and secondary antibody with PBS.  An antibody binding the B-cell membrane antigen 
(L26) was employed as the positive control. 
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Figure 3.23: FOXP3 staining in paraffin-embedded tonsil sections (C). Controls consisted of 
replacing primary and secondary antibodies with PBS (A) and L26 which binds B-cells (B). 
 
Figure 3.23 shows results for the staining procedur on tonsil sections.  No staining was 
seen in the negative control, whereas staining was idespread in the positive control.  
Nuclear-stained FOXP3 positive cells were apparent throughout the section.   
FOXP3 staining in PBMC from healthy controls 
Having established that the FOXP3 antibody could be used successfully in control tonsil 
sections, the next step was to look for FOXP3 in PBMC from healthy seropositive 
controls.  PBMC were separated into fractions; unseparated PBMC, CD4+-depleted 
cells, CD4+CD25- T cells and CD4+CD25+ T cells and cytospins were made from each 
cell population and stained with FOXP3 antibody.  The negative controls consisted of 
replacing primary only or primary and secondary antibody with PBS.  Staining with L26 
was used as the positive control.   
x20 
A B C 
x20 x20 x20 
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Figure 3.24 shows the results for staining on PBMC.  The negative control shows no 
staining. When PBS is used to replace the primary antibody alone, slight non-specific 
staining is observed although not in the cells themselves.  L26 provides a good positive 
control in this case since there will be B cells in the PBMC, the staining indicates that 















Figure 3.24: FOXP3 staining in PBMC cytospins (D).  Controls consisted of 
PBS replacing the primary and secondary antibodies (A), PBS replacing the 
primary antibody only (B) and L26 (C).  Magnification x40. 
 
 
Figure 3.25 shows results for staining on CD4-deplet d cells.  Similar to PBMC, no 
staining is seen when PBS is used to replace both the primary and secondary antibody. 
Non-specific staining is increased somewhat when PBS replaces only the primary 
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makes it difficult to see whether any cells are positive.  In addition, this fraction of cells 






















Figure 3.25: FOXP3 staining in CD4-depleted cytospins (D).  Controls 
consisted of PBS replacing the primary and secondary antibodies (A), PBS 




Figure 3.26 shows results for the CD4+CD25- T cell fraction.  No staining is observed in 
the negative or positive controls, or indeed with the FOXP3 antibody.  Of note is the 






































Figure 3.26: FOXP3 staining in CD4+CD25- cytospins (D).  Controls 
consisted of PBS replacing the primary and secondary antibodies (A), PBS 




Figure 3.27 shows results for the CD4+CD25+ T cell fraction.  Again, no staining is 
observed in any of the control slides, however, there are clearly positive cells when 











































Figure 3.27: FOXP3 staining in CD4+CD25+ cytospins (D).  Controls 
consisted of PBS replacing the primary and secondary antibodies (A), PBS 
replacing the primary antibody only (B) and L26 (C). 
 
This staining was carried out in order to investigate whether the CD4+CD25+ T cells 
enriched by the isolation procedure expressed FOXP3, one of the most specific markers 
for regulatory T cells.  Figures 3.24-3.27 show representative results for healthy control 
donor.  All three donors used for this staining procedure showed similar results.  
Limitations in cell number meant this procedure could not be carried out on IM patients.  
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FOXP3 staining of activated cells 
Although FOXP3-positive cells appeared to be at a higher frequency in the CD4+CD25+ 
T cell fraction, high levels of non-specific staining on unstimulated cell fractions meant 
interpretation of the results was difficult.  On advice from Dr Bridget Fox in Dr Alison 
Banham’s Oxford Laboratory, an adaptation was made to the protocol involving the 
stimulation of PBMC, CD4-depleted cells, CD4+CD25- T cells and CD4+CD25+ T cells 
with T cell expander beads and 500IU/ml rIL-2 for 3 days prior to making cytospins.  
FOXP3 staining was then carried out in order to determine which population of cells 
gave rise to the highest frequency of FOXP3-positive cells.   
 
Figure 3.28 shows results for staining on PBMC.  When PBS is used to replace both the 
primary and secondary antibodies no staining is observed.  Similarly, when PBS was 
used to replace the primary antibody no staining was observed.  The same level of 
staining was observed in each cell fraction using these negative controls so the figures 
below do not show all of these results.  L26 staining was strong and observed throughout 
the cell population, indicating the kit was working.  FOXP3 staining resulted in a few 
positive cells throughout the slide, accounting for 9.0% of the cells in any given view. 
 
Figure 3.29 shows results for staining on CD4-deplet d cells.  Similar to PBMC alone, 
no staining was observed when PBS was used to replace the primary alone, or primary 
and secondary antibodies (figures not shown).  L26 showed strong staining throughout 
the cells.  FOXP3-positive cells accounted for 7.9% of the cells, a slight decrease in 
comparison to PBMC. 




















Figure 3.28: Immunohistochemistry for PBMC cytospins with primary and 
secondary antibodies replaced with PBS (A), PBS replacing the primary 














Figure 3.29: Immunohistochemistry for CD4-depleted cytospins with the B-
cell antibody, L26 (A) and FOXP3 (B) 
 
Figure 3.30 shows results for staining on CD4+CD25- T cells.  No staining was observed 
with PBS replacing the primary and secondary (not sh wn) or with PBS replacing the 
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few B cells would be expected in this cell fraction.  FOXP3-positive cells occurred more 









Figure 3.30: Immunohistochemistry for CD4+CD25- T cell cytospins with 
PBS replacing the primary antibody alone (A) and FOXP3 (B). 
 
 
Figure 3.31 shows results for staining on CD4+CD25+ T cells.  No staining was observed 
with PBS replacing the primary and secondary (not sh wn) or with PBS replacing the 
primary antibody alone (figure 3.31A).  Again, L26 could not be used as a positive 
control since B cells would not be in this cell fraction.  Out of all the cell fractions, this 
cell population contained the highest frequency of FOXP3-positive cells, 63.8% of the 
cells stained for this protein. Figure 3.32 summarises the percentage of FOXP3-positive 






Figure 3.31: Immunohistochemistry for CD4+CD25+ T cell cytospins with 

























































Figure 3.32:  Percentage of FOXP3-positive cells in PBMC, CD4-deplet d, 
CD4+CD25- T cells and CD4+CD25+ T cells stimulated with T cell 
expansion anti-CD28/anti-CD3 beads and 500IU/ml human recombinant 
interleukin-2 for 3 days.  Bars indicate standard er or. 
 
Although when used in culture, the cell fractions were not stimulated in the same way, 
this experiment established that of all the cell fractions, CD4+CD25+ T cells contained 
the highest frequency of cells expressing FOXP3, providing further proof that the Treg 
isolation procedure did enrich CD4+CD25+FOXP3+ T cells with regulatory function as 
shown in suppression assays.  
FOXP3 staining in frozen lymph node and IM tonsil sections 
Having established that the enriched cells expressed FOXP3, and the staining procedure 
was successful, expression of this transcriptional regulator by cells in IM tonsils (kindly 
provided by A. Akbar) was investigated.  The IM tonsil sections available for staining 
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were frozen and as such required an alternative control to the previous staining of tonsil, 
which had been carried out on paraffin-embedded sections.  Frozen lymph node sections 
were chosen since they were also available. 
 
Negative controls consisted of PBS replacing either both primary and secondary 
antibodies or the primary alone.  L26 was again used as a positive control.  Figure 3.33 
shows that no staining was observed in the negative control (PBS used in place of the 
primary antibody, figure 3.33, panel A & B) or when FOXP3 antibody was used (figure 
3.33, panel C & D).  The tissue morphology of the lymph nodes suggests that these 
frozen blocks have deteriorated during storage. 
 
 
Figure 3.33: FOXP3 staining in healthy lymph node sections (C & D) with the 
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Figure 3.34 shows the staining results for IM59.  No staining was apparent in either of 
the negative controls (panels A and B).  The intact structure of the tonsil was clearly 
visible with a dense mass of cells in the follicular regions.  Upon staining with L26 these 
follicular regions are strongly stained (panel C).  FOXP3 positive cells were widespread 
and restricted to the extrafollicular areas of the tissue. 
 
Figure 3.34: FOXP3 staining in IM tonsil sections from IM59 (D).  Controls 
consisted of the primary and secondary antibodies replaced with PBS (A), PBS 
replacing the primary antibody only (B) and L26 (C). 
 
 
Figure 3.35 shows the staining results for IM60.  Again, the structure of the tonsil was 
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Figure 3.35: FOXP3 staining in IM tonsil sections from IM60 (C & D) with controls 
consisting of replacing the primary antibody with PBS (A & B). 
 
Conclusions 
FOXP3-positive cells are abundant scattered throught the extrafollicular tissue of the 
tonsils from two IM patients.  As a control, frozen lymph nodes were used although the 
tissue structure had degraded during storage.  FOXP3-positive cells appear to be less 
abundant in paraffin-embedded tonsil sections from healthy controls, implying that cells 
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3.3 Cytotoxic T lymphocyte (CTL) growth 
3.3.1 Introduction 
Members of the CMV laboratory have previously been involved in the generation of a 
bank of CTL, which were subsequently used to treat patients suffering Post-Transplant 
Lymphoproliferative disease (PTLD) (Haque et al, 2007a).  The growth of each of these 
cell lines was well documented and although the same procedure was used to develop 
each line, their ability to lyse target cells varied.  This prompted the suggestion that 
regulatory T cells may persist in some lines and affect their level of cytotoxicity.  To 
address this question, CTL lines were grown from 2 healthy seropositive donors (D35 
and D36).  Treg were initially depleted from all PBMC on day 0, half the cultures had 
half the Treg added back prior to stimulation, allowing the development of two cultures 
from each donor; CTL with Treg and CTL without Treg.    
 
The dynamics of growth were assessed for each of the CTL lines. Figure 3.36 shows the 
absolute number of CTL at day 0 and henceforth for each stimulation (panel A) and 
fold-increase in CTL (panel B).  All CTL increased in number until stimulation 7 or 8.  
Removal of Treg at the start of culture had no affect on CTL number for either cell line 
(figure 3.36, panel A).  Different numbers of PBMC were used to initiate cultures so 
fold-increase in cell numbers CTL was considered by dividing cell number at each 
stimulation by the starting number of PBMC (figure 3.36, panel B).  However, this 
revealed no difference in growth dynamics either.   
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3.3.2 Growth curves  













































Figure 3.36: Growth of CTL developed from two healthy donors D35 (squares) and D36 
(triangles) in the presence (closed symbols) or absence (open symbols) of Treg. Figure shows 
absolute number of CTL (A) and fold-increase in CTL (B). 
3.3.3 Regulatory T cell frequency 
The frequency of Treg was determined by flow cytometry at stimulation 4 and 8 for both 
CTL lines, in order to establish whether these regulatory cells had expanded in culture.   
Chapter 3:                  Results: Cytotoxic T lymphocyte growth 
 136 
Figure 3.37 shows results for Treg frequency in both CTL lines, with and without Treg, at 
stimulation 4 and 8, within the lymphocyte population (panel A) and within the CD4+ T 
cell population (panel B).  At stimulation 4, the fr quency of CD4+CD25+ T cells within 
the lymphocyte population is low within both Treg-depleted and Treg-repleted CTL lines 
for both donors (D35, 1.26% and 1.75%, respectively; D36, 0.14% and 0.17%, 
respectively).  At stimulation 8, Treg frequency is further reduced in both Treg-depleted 
and Treg-repleted CTL lines (D35, 0.15% and 0.01%, respectiv ly; D36, 0.03% and 
0.18%, respectively).  In the D35 CTL cultured with Treg, a moderately higher frequency 
of these cells is recorded at stimulation 4 (1.75%) although by stimulation 8, no 
CD4+CD25+ T cells can be found (0.01%).  The CD4+CD25+ T cells remain at a low 
level in D36 CTL, irrespective of culture type and stimulation number (panel A). 
 
Figure 3.37, panel B shows the equivalent Treg frequencies within the CD4
+ T cell 
population.  At stimulation 4, there is a high Treg frequency within the D35 CTL lines, 
irrespective of whether CD4+CD25+ T cells were removed from or reintroduced to the 
original culture (28.8% and 28.8%, respectively).  A reduced Treg frequency was found 
in D36 CTL (without Treg 5.3%; with Treg 6.4%) in comparison with D35 at stimulation 
4, again regardless of original culture status.  Atstimulation 8, a reduction in Treg 
frequency is observed in all cultures with no particular pattern emerging as to which 
cultures contain the most (D35, with Treg 0.3%, without Treg 4.3%; D36, with Treg 3.0%, 
without Treg 0.7%).  
 





















































































Figure 3.37: Frequency of CD4+CD25+ T cells shown in CTL developed from two healthy 
donors D35 and D36, in the presence (light grey) or absence (dark grey) of Treg, at week 4 (S4) 
and 8 (S8). Figure shows frequency of Treg within the lymphocyte population (A) and within the 
CD4+ T cell population (B). 
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Cytotoxicity 
Treg depletion did not affect growth of the CTL or CD4
+CD25+ T cells frequency.  To 
address their functional capacity, samples of CTL were taken at stimulations 4 and 8 and 
used in cytotoxicity assays against a panel of target cells: autologous LCL, mismatched 
LCL and K562, at ratios of 20:1, 10:1 and 5:1. 
 
Figure 3.38 shows results for all CTL lines at stimulation 4.  D35 CTL with Treg exhibit 
a low level of specificity demonstrated by the equally high specific lysis of both 
autologous (41.2% at a 20:1 ratio) and mismatched LCL (51.9% at a 20:1 ratio).  This is 
further evidenced by a particularly high level of killing when the targets were K562 cells 
(76.7% at a 20:1 ratio).  D35 CTL lacking Treg exhibit a similar level of killing for 
autologous LCL (48.5% at a 20:1 ratio), mismatched LCL (35.7% at a 20:1 ratio) and 
K562 (86.8% at a 20:1 ratio).  D36 CTL with Treg display high K562 killing (60.2% at a 
20:1 ratio) as do CTL without Treg (71.9% at a 20:1 ratio).  In the presence of Treg, CTL 
have high autologous LCL killing (47.7% at a 20:1 ratio) whereas absence of Treg results 
in no visible lysis of the same target.  Mismatched LCL killing is relatively low in both 
D36 CTL with Treg (6.1% at a 20:1 ratio) and CTL without Treg (8.5% at a 20:1 ratio). 
 
Figure 3.39 shows results for all CTL lines at stimulation 8.  A marginal increase in 
killing of autologous LCL (48.7% at a 20:1 ratio) was observed by D35 Treg-repleted 
CTL at stimulation 8 in comparison with stimulation 4 (41.2% at a 20:1 ratio) whereas a 
reduction in lysis of mismatched LCL and K562 (7.8% and 26.6%, respectively, at a 
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20:1 ratio) was observed compared to stimulation 4 (51.9% and 76.7%, respectively, at a 
20:1 ratio), highlighting the improvement in specificity by this line.   
 
D35 + T reg




















D35 - T reg




















D36 + T reg




















D36 - T reg





















Figure 3.38:  Cytotoxicity results for D35 (panels A & B) and D36 (panels C & D), in the 
presence (panels A & C) and absence (panels B & D) of Treg at stimulation 4. 
 
 
At stimulation 8, D35 Treg-depleted CTL no improvement in lysis of autologous LCL 
was observed (48.1% at a 20:1 ratio) in comparison with the same culture at stimulation 
4 (48.5% at a 20:1 ratio).  However, there were reductions in specific lysis of both 
mismatched LCL (13.4% from 35.7%, at a 20:1 ratio) and K562 (25.4% from 86.8%, at 
a 20:1 ratio). 
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Figure 3.39:  Cytotoxicity results for D35 (panels A & B) and D36 (panels C & D), in the 
presence (panels A & C) and absence (panels B & D) of Treg at stimulation 8.   
 
 
D36 Treg-repleted CTL exhibited reduced specificity, demonstrated by a decrease in 
killing of autologous LCL at stimulation 8 (8.2% at 20:1 ratio) in comparison with 
stimulation 4 (47.7% at a 20:1 ratio).  Specific lysis of mismatched LCL was reduced at 
stimulation 8 (0% from 6.1%, at a 20:1 ratio) as was the killing of K562 (26.4% from 
60.2%, at a 20:1 ratio).  D36 Treg-depleted CTL demonstrated slightly improved specific 
lysis of autologous LCL at stimulation 8 (3.0% at a 20:1 ratio) when compared to 
stimulation 4 (0%).  Reductions in specific lysis were observed at stimulation 8 against 
mismatched LCL (2.0% from 8.5%, at a 20:1 ratio) and K562 (38.8% from 71.9%, at a 
20:1 ratio).  
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3.3.4 Conclusions 
Four CTL were developed from 2 healthy seropositive controls, one culture from each 
containing Treg, the other depleted of these cells.  These results how that in preliminary 
experiments, Treg depletion has no effect on the development or functio  of CTL.  
3.4 In vivo Experiments 
3.4.1 Introduction 
In order to assess the ability of Treg to suppress EBV-driven proliferation i  vivo we used 
the SCID mouse model set up in the CMV laboratory where injected PBMC from 
healthy seropositive donors results in EBV-driven tumours developing in approximately 
50% of cases (Picchio et al, 1992b).  In this study, PBMC, Treg-depleted PBMC and Treg-
repleted PBMC were injected IP into SCID mice and tumour development and time to 
tumour were measured.  Results are shown in figure 3.40. 
3.4.2 Results 
At day 50 post-injection, all groups of mice had high survival rates (90%), regardless of 
whether they were injected with unmanipulated PBMC, Treg-depleted PBMC or Treg-
repleted PBMC.  By day 75, mice injected with unmanipulated PBMC had a much 
poorer survival rate (35%) in comparison to Treg-repleted mice (73%) and Treg-depleted 
mice (73%).  On day 100, the survival rate of mice inj cted with unmanipulated PBMC 
was further reduced at 27%, whereas the mice injected with Treg-repleted PBMC 
remained at 73% survival and the third group, mice treated with Treg-repleted PBMC 
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was slightly reduced with 62% survival, however, the differences observed did not 
significantly differ (p=0.213).  
 


















Figure 3.40: Survival curve for SCID mouse model where mice were inj cted with 
unmanipulated peripheral blood mononuclear cells (squares), peripheral blood 
mononuclear cells repleted with Treg (upward triangles) or peripheral blood mononuclear 




The removal of Treg from PBMC alters the time to tumour formation although not 
significantly, and to the equal extent of Treg-repleted PBMC.  This preliminary result 
probably indicates that the procedure by which the Treg are removed has an effect on 
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3.5 LMP experiments 
3.5.1 Introduction 
Published data have demonstrated that stimulation of PBMC from healthy seropositive 
donors with LMP peptides resulted in the release of IL-10 by CD4+ T cells.  In addition, 
PBMC stimulated in this way suppressed IFN-γ production by and proliferation of cells 
to non-EBV antigens (Marshall et al, 2003e).  Initially we set out to see if the 
experimental procedure resulted in similar results in our hands.  We also wanted to 
assess whether PBMC from IM patients would react similarly. 
3.5.2 Cytokine levels in healthy controls and IM patients  
PBMC from 8 healthy seropositive donors and 7 IM patients were plated out and 
stimulated with PRG peptide, PHA, PPD, or a combinatio  of PRG and PPD, for 5 days.  
The Mycobacterium tuberculosis antigen PPD was used because it should induce recall
T cell responses in PBMC in vitro since the majority of UK citizens have been 
immunized with bacillus Calmette-Guérin.  Samples were taken from triplicate wells 
and levels of IL-10 and IFN-γ were measured using an ELISA.  Levels of cytokines 
found in unstimulated PBMC were subtracted from other readings. 
 
IL-10 production 
Treatment of PBMC from healthy seropositive donors (figure 3.41) with PRG resulted in 
a low level of IL-10 production (median 0pg/ml) with a range of 0 to 600pg/ml.  
Stimulation of PBMC with PHA (median 2073.5pg/ml, range 1178.4 to 3082.4pg/ml) 
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resulted in a very significant increase in IL-10 production in comparison with PRG 
(p=0.0002).  PPD alone resulted in very low IL-10 production with a median of 
5.88pg/ml and a range of 0 to 273.3pg/ml.  Although marginally more IL-10 was 
produced by PBMC treated with PPD and PRG (median 41.8pg/ml, data range 0 to 
275.3pg/ml), this was not significant (p=0.442). 
 



















Figure 3.41: IL-10 concentration (pg/ml) produced by peripheral blood mononuclear cells from 
healthy seropositive donors in response to stimulation with PRG (squares), phytohaemagglutin 
(upward triangles), recall antigen PPD (downward triangles) and PRG + PPD (diamonds) for 5 
days.  Horizontal bars indicate median. 
 
 
PBMC from IM patients (figure 3.42) treated with PRG resulted in a low level of IL-10 
production in (median 0pg/ml) with a range of 0 to 415.7pg/ml.  PHA stimulation of IM 
PBMC resulted in an increased level of IL-10 production in comparison to stimulation 
with PRG (median 89.0pg/ml, range 0 to 452.9pg/ml) although this was not significant 
(p=0.208).  Treatment of IM PBMC with PPD alone resulted in low levels of IL-10 
(median 20.4pg/ml, range 0 to 147.1pg/ml).  The level of IL-10 was further reduced 
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when IM PBMC were treated with PPD and PRG (median 0pg/ml, data range 0 to 
37.3pg/ml), although this was not found to be signif cant (p=0.259). 
 

















Figure 3.42: IL-10 concentration (pg/ml) produced by peripheral blood mononuclear cells from 
IM patients in response to stimulation with PRG (squares), phytohaemagglutin (upward 
triangles), recall antigen PPD (downward triangles) and PRG + PPD (diamonds) for 5 days.  
Horizontal bars indicate median. 
 
On comparing the IL-10 response between healthy seropositive controls and IM patients, 
stimulation of PBMC with PRG resulted in a non-significant (p=0.955), equally low 
production of IL-10 (median 0pg/ml for both donor groups).  Stimulation of PBMC with 
PHA resulted in a highly significant difference (p=0.0003) in IL-10 production, with 
healthy seropositive donors producing more IL-10 (median 2073.5pg/ml) in comparison 
IM patients (median 89.02pg/ml).  PBMC from healthy seropositive donors produced 
lower levels of IL-10 (median 5.88pg/ml) in response to PPD stimulation than PBMC 
from IM patients (median 20.4pg/ml), although the difference was not significant 
(p=0.779).  Conversely, IM patients PBMC produced lss IL-10 (median 0pg/ml) in 
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response to treatment with PRG and PPD than healthy seropositive controls (median 
41.2pg/ml) with borderline significance (p=0.054). 
 
IFN-γ production 
Results for the IFN-γ ELISA are shown in figure 3.43 and figure 3.44.  PBMC from 
healthy seropositive donors stimulated with PRG result d in a very low level of IFN-γ 
production (median 0pg/ml) with a range of 0 to 11.2pg/ml.  Equally low levels of IFN-γ 
were produced by PBMC in response to PHA stimulation (median 0pg/ml, range 0 to 
12pg/ml) with no significant difference observed when compared to stimulation with 
PRG (p=0.959).  A high level of IFN-γ was produced by PBMC when stimulation with 
PPD alone with a median of 569.8pg/ml and a range of 0 t  1378.8pg/ml.  This was 
somewhat reduced when PBMC were stimulated with a combination of PRG and PPD 
(median 470.4pg/ml, range 34 to 1407.2pg/ml), although the difference was not 
significant (p=0.959). 
 
PRG stimulation of IM patient PBMC resulted in undetectable levels of IFN-γ (median 
0pg/ml).  Stimulation of PBMC with PHA, on the other hand, resulted in high levels of 
IFN-γ production (median 949.6pg/ml, range 0 to 1316.8pg/ml).  A high level of IFN-γ 
was also produced by PBMC in response to PPD stimulation (median 479.2pg/ml, data 
range 0 to 1309.6pg/ml).  This was significantly reduced (p=0.0262) when PBMC were 
stimulated with a combination of PRG and PPD (median 0pg/ml, range 0 to 
465.6pg/ml). 



















Figure 3.43: IFN-γ concentration (pg/ml) produced by peripheral blood mononuclear cells from 
healthy seropositive donors in response to stimulation with PRG (squares), phytohaemagglutin 
(upward triangles), recall antigen PPD (downward triangles) and PRG + PPD (diamonds) for 5 
days.  Horizontal bar indicates median. 















Figure 3.44: IFN-γ concentration (pg/ml) produced by peripheral blood mononuclear cells from 
patients with infectious mononucleosis in response to stimulation with PRG (squares), 
phytohaemagglutin (upward triangles), recall antigen PPD (downward triangles) and PRG + 
PPD (diamonds) for 5 days.  Horizontal bar indicates median. 
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Comparison of the PBMC response from healthy seropositive donors and IM patients to 
stimulation with PRG reveals similarly low levels of IFN-γ production, the median being 
0pg/ml for both groups.  In response to PHA stimulation, PBMC from IM patients 
produced significantly higher (p=0.0037) levels of IFN-γ (median 949.6pg/ml) in 
comparison to PBMC from healthy seropositive donors (median 0pg/ml).  Equally high 
levels (p=0.694) of IFN-γ were produced in response to PPD alone by PBMC from b th 
healthy seropositive donors (median 569.8pg/ml) and IM patients (479.2pg/ml).  When 
PPD and PRG were used in combination to stimulate PBMC, the IFN-γ response by 
healthy seropositive controls (median 470.4pg/ml) was significantly higher (p=0.006) 
than the response by IM patients (median 0pg/ml). 
3.5.3 Cell proliferation in healthy controls and IM patients 
PBMC from the same 8 healthy seropositive donors and 7 IM patients were plated out at 
a density of 1.25x106 cells/ml in 1ml aliquots in a 24 well plate.  PBMC were stimulated 
with 15µg/ml PRG, a LMP peptide, 10µg/ml PHA, 10µg/ml PPD, the recall antigen, or 
a combination of PRG and PPD, for 5 days.  Proliferation of the PBMC in response to 
stimulation was established using the BrdU proliferation assay.  Results for healthy 
seropositive controls and IM patients are shown in figure 3.45 and figure 3.46, 
respectively.   
 
The proliferative response of healthy seropositive control PBMC to stimulation with 
PRG was low with a median absorbance of 0.146 and a range between 0 and 0.38.  In 
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comparison, stimulation with PHA resulted in a significantly higher level (p=0.0499) of 
proliferation (median absorbance 1.34, range 0 to 2.6).   



















Figure 3.45: Proliferative response of PBMC from healthy seropositive controls to stimulation 
with 15µg/ml PRG, 10µg/ml PHA, 10µg/ml PPD or a combination of PRG and PPD.  Cells were 
incubated for 5 days.  Horizontal bars indicate median. 




















Figure 3.46: Proliferative response of PBMC from infectious mononucleosis patients to 
stimulation with 15µg/ml PRG, 10µg/ml PHA, 10µg/ml PPD or a combination of PRG and PPD.  
Cells were incubated for 5 days.  Horizontal bars indicate median. 
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A similarly high level of proliferation was observed when PBMC were treated with PPD 
(median absorbance 1.05, range 0 to 2.74).  Stimulation of PBMC with a combination of 
PPD and PRG slightly reduced the level of proliferation (median absorbance 1.01, range 
0 to 1.95), although this was not significant (p=0.5734).  
 
PBMC from IM patients proliferated poorly in response to stimulation with PRG 
(median absorbance 0.07, range 0 to 0.41).  Stimulation with PHA resulted in a very 
significant increase (p=0.0006) in proliferation (median absorbance 0.99, range 0.51 to 
2.76).  PPD treatment resulted in a reduced level of proliferation in comparison to PHA 
with a median absorbance of 0.68 and range of between 0.08 and 2.02, however, this 
was not statistically significantly (p=0.383).  A further reduction in proliferation was 
observed when PBMC were treated with a combination of PPD and PRG (median 
absorbance 0.48, range 0.03 to 2.12), although this was not significant (p=0.9015). 
 
PBMC from both healthy seropositive controls and IM patients responded with low 
levels of proliferation to stimulation with PRG (median absorbance 0.1 and 0.07, 
respectively), and this was not found to be significantly different (p=0.9551).  
Stimulation with PHA resulted in a higher proliferative response by PBMC from healthy 
seropositive controls (median absorbance 1.34) in comparison to PBMC from IM 
patients (median absorbance 0.99), although the difference was not significant 
(p=0.9551).  Treatment with PPD also induced higher levels of proliferation by PBMC 
from healthy seropositive controls (median absorbance 1.35) than IM patient PBMC 
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(median absorbance 0.68) but again, this observed difference was not significant 
(p=0.3969).  Similarly, a higher level of proliferation, although not significant 
(p=0.6943), was observed by PBMC from healthy seropositive controls (median 
absorbance 1.27) than PBMC from IM patients (median absorbance 0.48) in response to 
combined treatment with PPD and PRG. 
3.5.4 Conclusions 
Stimulation of PBMCs from healthy seropositive contr ls and IM patients with the recall 
antigen PPD and LMP peptide PRG did not significantly alter cell proliferation or IL-10 
production when compared to PPD stimulation alone.  However, in the same cultures 
IFN-γ production was significantly decreased in IM cases, and reduced, but not 
significantly so, in cultures from controls.  With t e exception of IFN-γ production from 
healthy controls, PHA significantly induced responses (IL-10 production and 
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4 Discussion 
4.1 Role of Regulatory T cells 
Regulatory T cell activity has been determined to affect the outcome of infection with a 
number of persistent viruses.  The role these suppressive cells play can be beneficial to 
the host.  Suvas et al were investigating the role of Treg in a mouse model of herpes 
simplex-induced stromal keratitis, an immunopathological disease mediated by CD4+ T 
cells.  Their results showed that the immunopathology was markedly increased in Treg-
depleted animals, with increased lesion severity and a lower dose of virus was required 
to cause disease (Suvas et al, 2004a).   However, Treg can also suppress T cell responses 
to viral antigens, as demonstrated by in vitro experiments with HCV antigens.  The 
coculture of CD4+CD25+ regulatory T cells with CD8+ T cells isolated from chronic 
HCV patients resulted in a reduced proliferative and IFN-γ response to HCV peptides as 
measured by flow cytometry.  Furthermore, depletion of Treg cells from PBMC increased 
the frequency of HCV-peptide tetramer binding, a result that was reversed by the 
addition of Treg at 1:2 and 1:10 ratios (Rushbrook et al, 2005f).  These two publications 
indicate that Treg activity influences viral immunopathology and persistence. 
 
The severity of primary EBV infection varies from subclinical seroconversion, with no 
apparent symptoms, to mild, severe or occasionally, fatal infectious mononucleosis 
(Wick et al, 2002b).  The symptoms of IM, including fever, lymphadenopathy, sore 
throat and fatigue, are thought to be caused by cytokines including TNF-α, TNF-β, IL-6 
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and IL-1β, produced by the over-whelming T cell response to EBV antigens (Callan et 
al, 1996;Foss et al, 1994c).  It is therefore possible that Treg are activated and play a role 
in the eventual subsidence of the CD8+ T cell response to EBV.  In this regard, a number 
of recent publications have investigated Treg responses to EBV antigens.  Stimulation of 
PBMC from healthy seropositive individuals in vitro with LMP-1 results in the 
suppression of IFN-γ production, and cell proliferation by a population of cells 
expressing CD4, via an IL-10 mediated mechanism (Marshall et al, 2003d).  In addition, 
Voo et al demonstrated the in vitro outgrowth of T cell clones with suppressive activity 
when PBMC were stimulated with an EBNA-1 peptide that carried out their regulatory 
activity via a cell-cell contact mediated route (Voo et al, 2005e).  To date one study has 
demonstrated Treg activity after IM in 4 subjects (Marshall et al, 2007).  We wanted to 
expand on this work in an attempt to elucidate what role Treg play in primary infection 
with EBV in this disease setting. 
 
The mechanisms by which Treg suppress cell responses is still the subject of intense 
scrutiny.  Currently two major regulatory T cell subgroups have been demonstrated that 
primarily mediate their activity via cytokine release; IL-10-producing Tr1 cells and Th3 
cells that secrete TGF-β1.  Hence the level of these cytokines was investigated in IM 
patient plasma to provide indirect proof for the prsence of either of these regulatory T 
cell populations. 
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IL-10 was found to be significantly elevated in patien s who had experienced IM 
symptoms for 1 week or less (median 71.8pg/ml) in comparison to healthy seropositive 
controls (median 11.3pg/ml).  When symptoms had persisted over a week, although 
marginally reduced (median 48.4pg/ml), IL-10 levels were still significantly higher than 
healthy seropositive controls.  TGF-β1 levels in patients who had suffered symptoms for 
a week or less (median 18ng/ml) were also significantly higher than healthy seropositive 
controls (median 9.3ng/ml) and this statistical signif cance increased further when 
symptoms had been endured for over a week (median 26.9 g/ml).   
 
The high levels of both IL-10 and TGF-β during the first week of symptoms imply, but 
do not prove, the presence of Treg.  Over a week of symptoms resulted in a reduction of 
IL-10, possibly indicating a reduced presence of IL-10-producing Treg, whereas the 
increased levels of TGF-β1 suggests cells secreting this cytokine, perhaps of the Th3 
regulatory lineage, become more abundant as disease progresses.  However, a number of 
different cell types are known to produce IL-10 and TGF-β1, including macrophages, 
monocytes and CD8+ T cells when activated.  Thus to provide firm proof f the cytokine 
origin, the identity of the cells producing these soluble mediators in IM must be 
established via intracellular staining and flow cytometry. 
 
Nevertheless, evidence supporting a link between th presence of IL-10 and TGF-β1 and 
Treg presence in persistent virus infections does exist.  Cabrera et al demonstrated in 
vitro IL-10 release by CD4+CD25+ Treg from in response to HCV antigens in chronically 
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infected patients (Cabrera et al, 2004d), Weiss et al demonstrated both IL-10 and TGF-
β1 release by CD4
+CD25+ Treg in response to the HIV antigen, p24, in HIV-infected 
patients undergoing HAART therapy (Weiss et al, 2004d) and Marshall et al identified 
IL-10-producing cells in response to stimulation with the EBV antigen, LMP-1, as CD4-
expressing T cells (Marshall et al, 2004c).  In addition, since it is known that EBV 
encodes a viral homologue of IL-10 (Hsu et al, 1990a), it is possible that this could 
induce Treg at the site of primary infection. 
 
Natural human Treg are identified as CD4
+CD25high T cells, hence investigating the role 
of Treg in IM was complicated by the high expression of CD25 on non-regulatory, 
activated CD4+ T cells as well as CD8+ T cells circulating during early infection 
(Tomkinson et al, 1987).  In an attempt to overcome this issue when investigating the 
frequency of Treg in the peripheral blood of IM patients, cells were gated using 
expression of CD4+ and very high levels of CD25, in the hope that thiswould represent 
the constitutively high CD25 expressers and thus Treg.   
 
CD4+CD25high T cell frequency in IM patients was investigated to establish if there was 
a difference in cell numbers when compared to healty virus carriers and to provide 
further proof that these regulatory cells might influence the outcome of primary 
infection with EBV.  By flow cytometry, CD4+CD25high T cells were found at low 
frequency (median 0.29%) in the lymphocyte population of healthy controls, similar to 
the previous studies (1-3%, Boettler et al, 2005c;Cabrera et al, 2004c;Baecher-Allan et 
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al, 2001b).  Slight differences in this frequency arelik ly to reflect differences in the 
gating strategy during flow cytometry.  However, since the same gating strategy was 
applied to both IM and healthy seropositive controls in this study, this was deemed a 
valid comparison.  The frequency of CD4+CD25high T cells within the lymphocyte 
population was significantly lower in IM patients (median 0.04%) when compared to 
healthy seropositive controls.  This is likely to have arisen because the total number of 
CD8+ T cells increases dramatically in acute IM (lymphocyte counts of up to 
15x109/litre) hence apparently reducing the CD4+ T cell count.  Thus the percentage of 
CD25high-expressing cells within the CD4+ T cell population was compared since this 
population of cells, although activated, do not expand in acute IM (Williams et al, 
2005).  The frequency of CD25high-expressing cells within the CD4+ T cells in IM 
patients (median 0.56%) was reduced in comparison to healthy seropositive controls 
(median 1.94%) with borderline significance (p=0.05); hence Treg are present but may be 
depleted in the blood of acute IM patients. 
 
Previous studies looking at roles for human Treg in persistent viral infections have found 
differences in the frequency of these regulatory cells in the peripheral blood of infected 
individuals when compared with healthy, uninfected controls.  The frequency of 
CD4+CD25+ Treg was found to be elevated in chronic HCV infection n comparison to 
recovered and normal controls (Cabrera t al, 2004b;Boettler et al, 2005b).  Similarly, 
Levy et al determined that CD4+CD25+ T cells were expanded in HIV patients 
undergoing HAART (Levy et al, 2003).  Weiss et al demonstrated these cells were 
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regulatory and suggested that persistence of HIV antige s might trigger their expansion 
(Weiss et al, 2004e).  Furthermore, Peng et al demonstrated higher frequencies of Treg in 
chronic HBV patients in comparison with healthy contr ls and acute HBV patients 
(Peng et al, 2000).  Our data is consistent with this, since we found a significantly higher 
frequency of CD4+CD25+ T cells in healthy EBV seropositive individuals (i.e. 
chronically infected subjects), in comparison acute IM patients.  However, it is 
important to note that these previous studies only investigated the presence of Treg in 
peripheral blood of patients, and the majority did not detect alterations in Treg frequency 
when healthy controls were compared with patients with acute infections. 
 
Since the majority of studies evaluating Treg frequency in persistent viral infections 
indicate that a higher frequency of this population of cells is associated with chronic 
disease, the investigation of Treg frequency in CAEBV could reveal that higher numbers 
of Treg are associated with disease duration and poor prognosis.  In order to determine 
this, a larger pool of IM patients would be required, with disease monitoring over a long 
period of time.  
 
The reduced number of Treg in IM patients may indicate a redistribution of these cells 
within the body, as shown in studies on patients with ovarian carcinoma (Curiel t al, 
2004c).  Using flow cytometry, Curiel at al found T cells expressing CD4 and CD25 at 
higher frequencies in malignant ascites of patients with untreated ovarian epithelial 
cancers, particularly at later stages of disease, in comparison to non-malignant ascites, 
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indicating the accumulation of cells was tumour-relat d.  This finding was confirmed by 
multicolour confocal microscopy.  In addition, they demonstrated high levels of FOXP3 
in ovarian tumour tissue but not in normal ovarian tissue.  Furthermore, on examining 
locally draining lymph nodes, fewer CD4+CD25+ T cells were found in ovarian cancer 
patients in comparison to normal controls, a fact the authors attributed to preferential 
recruitment of these cells to the tumour in the cancer patients, rather than the lymph 
node.  The functional activity of CD4+CD25+ T cells isolated from tumour ascites 
confirmed their regulatory activity by their ability o suppress cell proliferation of, and 
IFN-γ production by, CD3+CD25- T cells in coculture (Curiel et al, 2004b). 
 
Consistent with Curiel’s study, studies in our laborat ry indicated that FOXP3-positive 
cells appeared more abundant in IM tonsil (n=2) compared with healthy control sections, 
although care must be taken with this interpretation since normal control tonsil tissue 
was paraffin-embedded whereas the IM tonsil tissue were frozen sections.  In order to 
confirm these preliminary results, tissue sections should be subjected to the same 
procedure and FOXP3-positive cells counted.  However, this result does imply that 
FOXP3-positive cells may be recruited to the site of primary infection in acute IM 
patients.  In future additional markers, including LAG-3, CTLA-4 and GITR, could also 
be used to aid the identification of Treg.   
 
In human peripheral blood, CD4+CD25high T cells are found at low frequency (median 
0.29%), limiting the type of experiments that can be carried out.  These cells were 
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therefore enriched using a Treg enrichment kit.  The mean percentage purity of 
CD4+CD25high T cells isolated from 5 healthy seropositive donors was 79.18%, 
consistent with other published results (Rushbrook et al, 2005e;Boettler et al, 2005a).  
Thus the procedure used resulted in an enriched population of Treg rather then a totally 
pure population.  The purity of the Treg population could be improved with repeated 
washing and multiple column runs, however, this result d in fewer Treg with poor 
viability, reducing further experimentation.  Due to ethical restrictions in the size of 
blood samples obtained (20ml) Treg enrichment could not be carried out on blood from 
IM patients. 
 
In order to provide proof that the enriched CD4+CD25high T cells had regulatory activity, 
by virtue of their ability to suppress anti-CD3-induced proliferation of other T cells in 
coculture, suppression assays were set up.  The first method employed to measure cell 
proliferation was the MTT assay which was determined to be too insensitive (maximum 
mean absorbance 0.75 with LCL).  Subsequently the BrdU assay was attempted, 
resulting in an increased maximum mean absorbance of 2.0 with LCL, and this assay 
was chosen for all future proliferation assays.  Initially PHA stimulation was optimised, 
since this is a polyclonal activator of T cells and was used as a positive control.  10µg/ml 
resulted in the highest level of proliferation and as such this concentration was used in 
subsequent experiments. 
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Having established the conditions under which PHA induced maximum proliferation in 
PBMC, the next step was to establish the conditions u der which PBMC proliferated 
when treated with anti-CD3.  An incubation period of 96 hours and stimulation with 
5µg/ml anti-CD3 was chosen and suppression assays were set up using PBMC from 3 
healthy seropositive donors in order to determine if the Treg isolated using the 
enrichment procedure were functional.  PBMC from all 3 controls proliferated well in 
response to anti-CD3 stimulation (median absorbance 2.82) and in coculture, 
CD4+CD25+ T cells suppressed the proliferative response of CD4+ D25- T cells 
(median absorbance 0.41), indicating that the enriched Treg were functional.  However, it 
must be noted that the reduced proliferative respone of CD4+CD25- T cells in coculture 
could be due to the dilution of the cells themselves.  In order to establish if this is the 
case, CD4+CD25- T cells should be set up alone at densities equal to those that are added 
to the coculture. 
 
The results presented in this current study are consistent with previously published 
experiments used to provide proof of Treg activity in similar experimental set ups 
(Hoffmann et al, 2004;Dieckmann et al, 2002;Curiel et al, 2004a).  Baecher-Allan et al 
(2002) could not detect suppression in a similar assay although this may have been due 
to a reduced ratio of responder:regulatory cells (1:1/2) and a lower concentration of anti-
CD3 (2.5µg/ml).  In future, more samples would be us d so that statistical analysis could 
be carried out, and ideally this experiment should be carried out on PBMC from IM 
patients in order to establish that Treg are functional in these individuals. 
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The numbers of markers associated with Treg is still growing although an exclusive 
marker is yet to be found.  To date, the most specific marker remains FOXP3, a 
transcription factor essential for Treg development (reviewed in Campbell & Ziegler, 
2007c;Kim & Rudensky, 2006;Sakaguchi et al, 2006).  Hence to ensure that cells of this 
phenotype had been enriched in the CD4+CD25+ T cell enrichment procedure, staining 
for FOXP3 was carried out on cells from healthy seropositive donors.  
 
Staining for FOXP3 was optimised using paraffin-embdded tonsil sections in 
collaboration with Dr Alison Banham and Dr Bridget Fox.  FOXP3-positive cells were 
apparent scattered throughout the tissue sections with no obvious histological pattern 
(figure 3.23, panel C).  PBMC from 3 healthy seropositive controls were then separated 
into PBMC, CD4-depleted cells, CD4+CD25- T cells and CD4+CD25+ T cells and each 
population was stained for FOXP3.  Initially, high levels of non-specific staining made it 
difficult to identify FOXP3-positive cells.  This i likely to have been due to high levels 
of cell lysis and cell debris in the samples as a direct result of the long separation 
procedure using multiple centrifugation steps.  Non-specific staining may also have 
arisen from PBMC engulfing the CD25 microbeads, used for selecting the cells, and 
then binding by the anti-mouse secondary antibody. 
 
An alternative FOXP3 staining method was employed based on advice from Dr Bridget 
Fox, involving the use of T cell expander beads and high levels of IL-2, to which each of 
the populations of cells was subjected.  The aim of this procedure was to determine 
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which population of cells, when activated, contained the highest percentage of FOXP3-
expressing cells and this would imply which fraction contained the highest frequency of 
Treg upon activation. 
 
The results showed a low level of FOXP3-positive cells in unseparated PBMC (9%), 
which would be expected since Treg are known to be at low frequency in this population 
of cells.  This was enriched to >50% in the CD4+CD25+ T cell fraction.  However, a low 
level of FOXP3-positive cells was detected in CD4-depleted cells (7.9%) and a higher 
level was found in the CD4+CD25- T cell population (17.7%), indicating that either the 
sample was contaminated with remaining CD4+CD25+ T cells or the induction of 
FOXP3 in other cell subsets. 
 
The exclusivity of FOXP3 expression to the CD4+CD25+ T cell population has been a 
matter of debate and the results in this current study, consistent with previous 
publications  (Wang et al, 2007;Gavin et al, 2006b), suggest that other populations of 
cells can express FOXP3 under certain conditions.  CD8+ T cells have been shown to 
express FOXP3, possibly accounting for the results seen in the CD4-depleted cell 
fraction in this study (Gavin et al, 2006a).  Gavin et al demonstrated that FOXP3 
expression can be induced in CD4+CD25- T cells and CD8+ T cells after 3 days of 
stimulation with 5, 100 or 1000ng/ml anti-CD3 (Gavin et al, 2006c).  These results 
demonstrate that although the enrichment procedure on PBMC from healthy seropositive 
controls results in CD4+CD25+FOXP3+ T cells with regulatory activity, FOXP3 
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expression is not restricted to this population and can be induced in other cell 
populations, such as CD4+CD25- T cells and CD8+ T cells.  Whether this is directly due 
to the addition of T cell expander beads and IL-2 on PBMC or indirectly via the activity 
of any remaining CD4+CD25+ T cells on the surrounding cells leading to the induction 
of FOXP3 expression is unclear.  To establish if the latter event is responsible, the purity 
CD4+CD25+ T cell could be improved by repeating the enrichment procedure. 
 
Furthermore, the suppressive potential of the cell populations should be investigated by 
running suppression assays on cells activated by this procedure, which would also 
determine a link between FOXP3 expression and functio al capacity.  Apart from CD25, 
a variety of markers have been linked with human Treg, including GITR (Shimizu et al, 
2002b;McHugh et al, 2002c), CTLA-4 (Read et al, 2000a), and LAG-3 (Huang et al, 
2004a).  Staining for these markers in future experim nts would be of interest, especially 
since a role for Treg expressing LAG-3 but not FOXP3, has been demonstrated in the 
EBV-associated malignancy, Hodgkin’s Lymphoma (Gandhi et al, 2006b).  In future it 
would be advisable to use an alternative control to L26, the B cell antibody, to stain 
CD4+CD25- T cell and CD4+CD25+ T cell populations since these fractions should not 
contain B cells and hence L26 is not an ideal control antibody. 
 
To carry out functional assays on IM samples, the initial intention was to keep IM 
PBMC in liquid nitrogen whilst autologous LCL were grown, then PBMC would be 
revived and could be stimulated using the LCL.  However, poor revival of PBMC from 
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IM patients after freezing meant that too few cells were available to perform the 
experiment.  This cell death is a well established problem in IM, due to the highly 
activated state of IM CD8+ T cells resulting in rapid apoptosis in culture (Moss et al, 
1985;Uehara et al, 1992).  To overcome this problem, an experimental design based on 
peptide stimulation was chosen since this could be carried out immediately without the 
need for PBMC storage.  In order to determine whether Treg activity affected the T cell 
response to EBV in IM, PBMC from healthy seropositive controls and IM patients were 
separated into cultures containing CD4+CD25+ T cells and cultures lacking CD4+CD25+ 
T cells, stimulated with peptides, and the IFN-γ-secreting cells measured by ELISPOT.  
Peptides restricted to HLA A2 were selected since 40-50% of the population worldwide 
express this HLA type (Mahdavi & Monk, 2005b;Botten t al, 2007a).  HLA A2 
staining was carried out on cells from each individual IM patient and if found to be 
positive, the ELISPOT procedure was continued. 
 
Once the experimental conditions were established, PBMC populations, containing or 
lacking CD4+CD25+ T cells, were stimulated with 4 different peptides derived from 
EBV antigens; QAK, an EBNA-3A non-HLA A2 control petide, SVR, an EBNA-3A 
peptide, LLD, an EBNA-3C peptide and GLC, a BMFL1 (early lytic antigen) peptide.  
PHA was used as a positive control whereas untreated PBMC provided a background 
IFN-γ level.   
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In healthy seropositive donors, low IFN-γ responses were observed in cultures with and 
without Treg in response to the non-A2 peptide (median SFC/million PBMC 5 and 5.8, 
respectively) and no stimulation (median SFC/million PBMC 13.4 and 15, respectively), 
setting a low background level.  A strong IFN-γ response was observed when PBMC 
with and without Treg were treated with PHA (median SFC/million PBMC 793.4 and 
745.9, respectively).  A low IFN-γ response was also observed in cultures both with and 
without Treg in response stimulation to SVR (median SFC/million PBMC 8.35 and 9.2, 
respectively) and LLD (median SFC/million PBMC 25 and 13.3, respectively) whereas a 
high level of IFN-γ-secreting cells was recorded in response to GLC (median 
SFC/million PBMC with Treg; 45.85 and without Treg; 21.65). 
 
EBV in healthy virus-carriers is generally latent and hence, if these individuals did 
respond to peptide stimulation, they might be expected to react more strongly to the 
latent peptides, SVR and LLD, than the lytic peptide, GLC.  However, Rushbrook et al 
demonstrated a similar level of IFN-γ production in response to GLC in HCV-infected 
(EBV seropositive) individuals (Rushbrook et al, 2005d), as in the present experiments.  
In another similar study looking at the response of PBMC from healthy seropositive 
controls to GLC, the authors also demonstrated a response, with an average SFC/million 
PBMC of 276, although the range of data collected from 11 HLA A2 donors was broad; 
13 to 943 SFC/million PBMC (Yang et al, 2000). 
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One explanation for this response to a lytic peptide lies with the fact that EBV 
reactivates periodically, during which lytic antigens are expressed, hence the high level 
of IFN-γ produced in response to GLC maybe indicative of lytic viral activity in these 
individuals.  In support of this theory, Tan et al found high frequencies of CD8+ T cells 
in healthy virus carriers binding to lytic epitopes in comparison to latent peptides by 
tetramer analysis (Tan et al, 1999a).  Alternatively, the latent peptides used in our 
analysis were limited to one sequence from each of t e EBV antigens and it is plausible 
that individuals did not possess T cells specific for this particular sequence but may 
possess T cells specific for a different, as yet unknown epitope from the same antigen. 
 
Overall, no significant differences were observed when PBMC cultures with Treg and 
PBMC without Treg were compared.  There are several possible explanations for these 
results.  It may be that too few Treg were added to the cultures to have a measurable 
effect.  Alternatively, the separation procedure may not have been pure enough, hence 
some Treg would remain in the depleted cultures.  Rushbrook et al showed that a ratio of 
1 Treg to 10 PBMC resulted in a reduced expansion of CD8
+ T cells in HCV-infected 
patients in response to HCV peptides (Rushbrook et al, 2005c), in the current study the 
ratio was reduced (approximately 1:50-1:80).  It is also probable that Treg would have to 
be activated in order to mediate suppression, and perha s HLA class I-restricted peptides 
would not achieve this.  In order to investigate this, it would be interesting to carry out 
the same experiment using HLA class II-restricted peptides since the Treg under 
investigation in the current study express CD4+.  Rushbrook et al demonstrated no 
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difference in CD8+ T cell expansion in response to GLC when comparing cultures 
containing Treg and those lacking Treg in healthy controls via tetramer analysis.  These 
authors went on to use the same experimental design a  the current study and showed 
that removal of Treg from PBMC from chronic HCV patients did enhance IFN-γ release 
by CD8+ T cells in response to HCV antigens and GLC, indicating that MHC class II are 
not required to activate Treg (Rushbrook et al, 2005b).  Using HCV antigens, Cabrera t 
al showed elevated responses to HLA A2-restricted HCV peptides when Treg were 
depleted from PBMC and suppressed IFN-γ responses when additional Treg added to 
PBMC, also inferring that MHC class II restriction is not necessary (Cabrera et al, 
2004a). 
 
In similar experiments on blood from IM patients, low levels of IFN-γ were released in 
cultures with and without Treg in response to the non-A2 peptide, QAK (median 
SFC/million PBMC 5 and 6.7, respectively) and unstimulated cultures (median 
SFC/million PBMC 13.3 and 8.3, respectively).  There was some concern that high 
background levels of IFN-γ might arise in this group of patients since CD8+ T cell-
produced IFN-γ is partly responsible for the symptoms experienced by these patients 
(Biglino et al, 1996;Foss et al, 1994d).  However, the controls showed this was not the 
case.  PHA stimulation resulted in the same raised level of IFN-γ production in both 
cultures with Treg and cultures lacking Treg (median SFC/million PBMC 66.7).  
Stimulation with SVR resulted in a similar level of IFN-γ production by both cultures 
with and without Treg (median SFC/million PBMC 5).  Cultures with and without Treg 
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also responded similarly to LLD (median SFC/million PBMC 5 and 6.7, respectively).  
An increased response to GLC was observed in cultures lacking Treg (median 
SFC/million PBMC 46.7) in comparison to cultures containing Treg (median SFC/million 
PBMC 18.3) but this was not statistically significant (p=0.805). 
 
Similar levels of IFN-γ were released by PBMC from IM patients and control donors in 
response to SVR in cultures containing Treg (median SFC/million PBMC 8.35 and 5, 
respectively).  In IM patients, this result can be explained since during primary infection 
the major CD8+ T cell response is directed against lytic antigens, the response to latent 
antigen only gaining its majority after recovery from IM (Callan, 2004c).  In controls, a 
similar explanation can be applied as mentioned previously, that the donors in the small 
data set may not have possessed T cells specific for the particular peptide sequence. 
 
A significantly higher level of IFN-γ was produced by Treg-repleted PBMC from healthy 
seropositive donors than IM patients in response to LLD.  Again, this could be due to the 
fact that healthy seropositive donors would have more T cells capable of recognising 
latent peptides than IM patients.  However, a similar level of IFN-γ was released in 
response to GLC, the lytic antigen.  As mentioned previously, it was expected that T cell 
responses in IM patients would be targeted against lytic antigens early during the 
infection. 
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This current report demonstrates a significantly reduced (p=0.009) IFN-γ production by 
PBMC from IM patients (median SFC/million PBMC 66.7) compared to healthy 
seropositive controls (median SFC/million PBMC 793.4) in response to PHA.  
Previously published reports also demonstrate a reduced response to PHA stimulation in 
IM patients when compared to healthy seropositive controls, showing reduced RNA 
synthesis (Rubin, 1966) and cell proliferation (Sheldon et al, 1973), although a further 
study found no difference in response to PHA after 7 days of stimulation but 
lymphocytes were hyporesponsive in a mixed lymphocyte reaction (Twomey, 1974).  In 
conjunction with these previous studies, the present results indicate that 
immunosuppression of the T cell response occurs during early infection with EBV, and, 
although the present results suggest that Treg are not responsible, the actual mechanism 
of this remains to be elucidated. 
 
The present results failed to demonstrate significant Treg activity in IM or healthy 
seropositive donors, however, using a greater pool of peptides as well as HLA class II-
restricted peptides would allow for a better understanding of responses to EBV by both 
healthy virus-carriers as well as IM patients. 
 
The lack of any observed difference between Treg-depleted PBMC and Treg-repleted 
PBMC does not necessarily indicate that EBV-specific Treg are not active in IM.  This 
study investigated IM during the early stages of the disease.  It is plausible that 
continued antigen presence, in association with the production of viral IL-10, would 
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create an environment conducive to Treg induction.  This may occur at later stages during 
convalescence, causing the subsidence of the CD8+ T cell response.  In order to establish 
if this is the case, the same experiments could be carried out during later stages of 
disease.  Furthermore, since Treg activity has been demonstrated in chronic infection with 
HBV and HCV, and during the course of HIV infection, it is possible that Treg play a 
more active role in the rare cases of CAEBV, and this could also be investigated. 
 
It is also plausible that Treg play a role in silent seroconversion to EBV, rather than IM, 
where their activity may be responsible for early suppression of CD8+ T cell activity and 
therefore a reduction in the immunopathological sympto s of IM.  To investigate this is 
more difficult and would necessitate a long term study, requiring patients who are 
seronegative to be monitored until seroconversion occurs, taking blood samples at 
regular intervals. 
 
4.2 LMP experiments 
Most of the evidence suggesting that Treg activity features in EBV infection points 
towards a role for LMP-1 in the induction of regulatory T cells (Marshall et al, 
2003c;Marshall et al, 2007a).  In particular, Marshall et al stimulated PBMC from 20 
healthy EBV-positive donors and looked at responses to a range of peptides, spanning 
the entire length of the LMP-1 protein.  They found that a few selected peptides resulted 
in the production of IL-10, and suppression of the IFN-γ and proliferative responses to 
non-related antigen stimulation (Marshall et al, 2003b).  This study was carried out on 
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healthy seropositive donors and we have extended this work by repeating the experiment 
on 8 healthy seropositive donors, in order to compare our data with the published results, 
and on 7 IM patients, in order to determine if the same was detectable in this group of 
individuals.   
 
The results show that: 
• In healthy seropositive controls there was no significant difference in cell 
proliferation, IFN-γ or IL-10 production between cultures stimulated with PPD 
and PPD + PRG. 
• In IM subjects the addition of PRG to cultures contai ing PPD significantly 
reduced IFN-γ production (p=0.0262) but not cell proliferation or IL-10 
production. 
• PHA stimulation of IM PBMCs resulted in significantly less IL-10 production 
(p= 0.0003), significantly higher IFN-γ production (p=0.0037) but no difference 
in proliferation, when compared to healthy controls. 
 
The individual results are shown in figures 3.41-3.46 (see Results, pages 142 to 150) and 
figure 4.1 shows IL-10, IFN-γ and cell proliferation results for PBMC from both healthy 
seropositive controls and IM patients in response to stimulation with PRG, PPD and 
PPD in combination with PRG, in a format equivalent to hat of Marshall et al (2003a) 
for comparison. 
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Figure 4.1: IL-10 production (top panels), IFN-γ production (middle panels) and proliferative 
response (bottom panels) of peripheral blood mononuclear cells from healthy seropositive 
controls (left panels) and IM patients (right panels) in response to PRG peptide (light grey), 
recall antigen PPD (medium grey) or PRG in combinatio  with PPD (dark grey).  Bars indicate 
standard error. 
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We limited the stimulation to the LMP-1 peptide PRG shown by Marshall et al to induce 
IL-10 production, and suppression of both IFN-γ production and cell proliferation in the 
majority of healthy donors.  In our study, PBMC from 5 out of 8 healthy seropositive 
controls gave no measurable IL-10 production in respon e to PRG, and 3 out of 8 donors 
responded with high levels of IL-10 (median 409.8pg/ml).  Data published by Marshall 
et al showed that one representative individual responded to PRG with a high level of 
IL-10 (approximately 150pg/ml).  70% of the 20 seropositive donors responded 
positively to PRG by producing over double the leve of unstimulated controls.  In 
comparison, using these parameters in our study, 38% of donors responded positively. 
 
The IFN-γ response to PRG from all PBMC from the healthy seropositive controls in 
our study was undetectable.  Marshall et al detected approximately 15% of donors who 
responded positively, and since our study was smaller, these results may be regarded as 
consistent.  Cell proliferation in response to PRG the current study cannot be directly 
compared to findings published by Marshall et al, since different methods of measuring 
cell proliferation were used.  However, in the one representative individual shown in 
their paper, proliferation in response to PRG was not considered positive, and the 
combined results showed PBMC from fewer than 10% of the 20 seropositive donors 
responded with cell proliferation.  In our study, the proliferation was also low in 
response to PRG stimulation (median absorbance 0.146, figure 3.45, page 148). 
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Marshall et al’s treatment of seropositive PBMC with PPD alone resulted in very low 
IL-10 production from 3 individual donors, consistent with our study (median 
5.88pg/ml).  Treatment with PPD and PRG resulted in increased IL-10 production in all 
3 donors from Marshall’s study (approximately 800, 1 00 and 1000pg/ml, respectively).  
The results in our study demonstrated a moderate, non-significant increase in IL-10 
production with the same stimulus (median 41.8pg/ml) in all donors. 
 
Stimulation with PPD alone resulted in high levels of IFN-γ production from 3 
individual donors (20,000, 25,000 and 25,000pg/ml) in Marshall’s study, whereas in our 
study, there was less IFN-γ produced in response to PPD alone (median 569.8pg/ml).  
Marshall et al demonstrated a substantially reduced IFN-γ response from all 3 donor 
PBMC to treatment with PPD and PRG (almost undetectable) in comparison to PPD 
alone, whereas the results in this present study found no significant difference in IFN-γ 
response in 8 donors (median 470.4pg/ml). 
 
PBMC from all 3 donors proliferated to a high level ( ach approximately 20 mean 
counts per minute x10-3) in response to PPD alone, whereas the addition of PRG reduced 
this substantially (approximately 2.5, 7 and 7.5 mean counts per minute x10-3, 
respectively) in Marshall’s study.  In our study, a high level of proliferation was 
observed in response to PPD alone (median absorbance 1.05) and this was also reduced 
with the addition of PRG, although not significantly (median absorbance 1.01). 
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Overall our results agree with those of Marshall et al, and the differences between the 
studies may reflect differences in methodology and/or sample size.  In addition, we were 
only able to run single ELISA samples whereas Marshll et al ran samples in duplicate 
and cell proliferation samples in triplicate, providing a more accurate result.  In future, 
more donors would be recruited and samples would be run in duplicate or triplicate. 
 
Our experiments were also carried out on PBMC from IM patients (figure 4.1).  PBMC 
from 4 out of 7 IM patients did not responded to PRG whereas 3 out of 7 responded with 
high levels of IL-10 (median 162pg/ml).  Using the same method as Marshall et al to 
determine positive results, 43% of IM patients responded positively, similar to the 
healthy seropositive controls (38%).  The IFN-γ response to PRG from all IM patients’ 
PBMC was undetectable, again similar to results from healthy seropositive donors.  Cell 
proliferation by PBMC from IM patients was low (median absorbance 0.07) this was 
also found to be low in healthy seropositive controls (median absorbance 0.146).   
 
Treatment of IM patients’ PBMC with PPD alone resulted in very low IL-10 production 
(median 20.4pg/ml), increased in comparison to the lev l produced by PBMC from 
healthy seropositive controls (median 5.88pg/ml), although not significantly so.  
Treatment with PPD and PRG reduced IL-10 production to an undetectable level in IM 
patients whereas these stimuli caused an increased IL-10 production from healthy 
seropositive donor PBMC (median 41.8pg/ml). 
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Stimulation with PPD alone resulted in high levels of IFN-γ production from IM patients 
PBMC (median 479.2pg/ml), and the addition of PRG reduced IFN-γ in 6 out of 7 IM 
patients PBMC, in 5 cases to an undetectable level.  This is the only significant 
reduction in response to PPD induced by the addition of PRG in our study (p=0.026).  
This suggests Treg activity induced by PRG, again indicating a role for LMP in 
controlling the T cell immune response to EBV. 
4.3 CTL Growth 
The CMV laboratory has developed a bank of cytotoxic T lymphocyte (CTL) lines for 
use in the treatment of post-transplant lymphoproliferative disease (Wilkie t al, 2004).  
The growth of these CTL lines differs greatly in absolute number of CTL at the final 
stimulation and the frequency of CD4+ T cell and NK cell within the final population of 
cells, as does their ability to lyse specific EBV-positive target cells.  In order to establish 
if cell growth characteristics and the observed inability to lyse target cells was due to the 
presence of Treg, CTL from two donors were developed, one line from each being 
depleted of Treg and another line of Treg-repleted CTL.  
 
No difference in growth dynamics was observed from either of the lines, indicating that 
Treg presence or absence in the initial population did not affect the growth of CTL.  Treg 
frequency varied between the CTL although no trend being observed; one Treg-depleted 
CTL line had a higher frequency of Treg than the Treg-repleted line whereas the inverse 
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was true of the second set of lines.  Similarly, no trend was observed in specific lysis, 
with both lines having similar cytotoxic profiles at the end point of 8 weeks. 
 
One of the problems with using CD25high expression as a marker for Treg under these 
experimental conditions is that the CTL lines are restimulated once a week with 
autologous LCL, and IL-2 is added three times a week, r sulting in a highly activated 
population of cells.  In this case, FOXP3, GITR or CTLA-4 expression might be more 
appropriate as markers of Treg.  In addition, the method employed to isolate Treg results 
in approximately 80% purity, hence not all Treg were removed from the initial PBMC 
culture.  Repeating the enrichment procedure would increase the purity of Treg.  
However, this was a preliminary experiment only carried out on two donors.  For a more 
accurate representation, more donors would be required. 
4.4 In vivo experiments 
The current study could not find any in vitro evidence that removal of Treg from cultures 
affects the CD8+ T cell IFN-γ response to stimulation with a variety of EBV-deriv d 
peptides.  However, as has been the case in a number of previous studies, particularly 
looking at mechanisms by which Treg carry out their suppressive activity, results 
observed in vitro do not necessarily reflect in vivo observations (Read et al, 1998).  For 
example, Jonuleit et al demonstrated that anti-TGF-β did not alter the anergic state of 
human CD4+CD25+ Treg in vitro (Jonuleit et al, 2001) whereas data published on in vivo 
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studies revealed reduced suppressive activity when blocking anti-TGF-β antibodies were 
used (Powrie, 1995;Mason & Powrie, 1998;Fuss et al, 2002). 
 
Severe combined immunodeficient (SCID) mice lack functional B and T cells and have 
been used to study EBV-associated B-cell lymphoprolife ative disease (BLPD).  The 
introduction of PBMC from healthy EBV seropositive donors to SCID mice gives rise to 
EBV-positive BLPD, of human B-cell origin, in approximately 50% of SCID mice 
(Picchio et al, 1992a).  This model was used to investigate the effect of Treg activity on 
tumour outgrowth by injecting SCID mice with unmanipulated PBMC, Treg-depleted 
PBMC or Treg-repleted PBMC.  It was plausible that a lack of Treg would allow an 
unsuppressed T cell response to tumours and hence the group injected with Treg-depleted 
PBMC would develop tumours more slowly, or not at all. This theory was supported by 
the publication of a study, with the same experimental design, in which CD4-depleted 
PBMC significantly reduced tumour incidence (Johannessen et al, 2000) and a study by 
Shimizu et al, where Treg depletion resulted in a potent immune response to syngeneic 
tumours in mice and subsequent tumour eradication (Shimizu et al, 2002a). 
 
The results showed that mice injected with unmanipulated PBMC developed tumours at 
a faster rate than both the Treg-depleted PBMC group and the Treg-repleted PBMC group.  
PBMC with and without Treg caused similar levels of tumour development although 
tumours in both these groups took longer to develop than the unmanipulated control 
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cells.  Thus the manipulation of the cells resulted in reduced tumourgenicity, although 
the mechanism involved it is not clear. 
4.5 Working Model 
From the results presented in this thesis, we postulate that early during primary infection 
EBV-infected tonsillar B cells express viral IL-10 and LMP-1, creating an environment 
conducive to Treg activation at the primary site of infection.  This scenario would explain 
the high level of FOXP3+ cells in the tonsil of IM patients.  Whilst Treg induction occurs, 
the virus infects and becomes latent in B cells as they pass through the tonsil and enter 
the circulation.  In asymptomatic silent converters, these Treg would be responsible for 
suppressing T cell-mediated immunopathology by limiting the cytotoxic CD8+ T cell 
response to EBV during early infection.  In contrast, if the initial viral dose is high or the 
frequency of CD4+CD25+ T cells low then they may not be able to restrict he cytotoxic 
response to EBV, and acute IM would result.  In order to establish this hypothesis and 
elucidate the role of Treg in EBV infection, a long term study, with periodic blood 
sampling and larger donor recruitment would be requir d to carry out comparative 
experiments on acute IM, silent seroconverters, EBV-negative individuals and 
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